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Abstract 
 
Prostate Cancer Screening with PSA – A Study of Potential Negative Consequences 
 
Sigrid Carlsson, Department of Urology, Institute of Clinical Sciences,  
The Sahlgrenska Academy at Göteborg University, Sweden  
 
 
Aims: The Göteborg randomized population-based prostate cancer screening trial is a 
prospective study evaluating the efficacy of prostate-specific antigen (PSA)-based screening and 
its effect on prostate cancer mortality. The potential negative consequences in relation to benefits 
for men undergoing this screening are explored in this thesis. 
 
Methods: As of December 31, 1994, there were 32,298 men born between Jan 1, 1930 and Dec 1, 
1944 (ages 50-64, median 56 years) living in the city of Göteborg. Of these, 20,000 men were 
randomly allocated in a 1:1 ratio to either a screening group or to a control group. This 
population constitutes the basis for this thesis. The cumulative incidence of prostate cancer and 
prostate cancer mortality were calculated and analyses made by intention-to-screen. Anxiety 
levels were assessed in screen-positive men. Short-term overall mortality after prostate biopsy 
was studied. Perioperative mortality after radical prostatectomy was evaluated from registry 
linkage with the follow-up study of the National Prostate Cancer Register (NPCR) 1997-2002. 
Side-effects from radical prostatectomy were evaluated for men in the screening study who 
underwent radical prostatectomy at Sahlgrenska University Hospital between 2001-2008. 
 
Results: A PSA-based screening program reduced the relative risk of prostate cancer mortality 
by 44% over 14 years. Overall, 293 men needed to be invited for screening and 12 to be 
diagnosed to prevent one prostate cancer death. Attending a screening program for prostate 
cancer is seldom associated with severe negative psychological distress, even for men with 
persistently elevated PSA levels. The risk of excess fatal complications after biopsy of the 
prostate is low. Radical prostatectomy is a procedure with very low perioperative mortality 
throughout the whole of Sweden. With 14 years of screening, for each prostate cancer death 
averted, the surgically induced morbidity due to screen-detected prostate cancer will render 
four men impotent or sexually inactive, and less than one man incontinent. 
 
Conclusions: PSA screening significantly, and substantially, reduces prostate cancer mortality. 
This benefit compares favorably to other cancer screening programs. The potential negative 
consequences of such screening may be acceptable in the light of a disease-specific mortality 
reduction. The risks of severe consequences from the screening procedures and radical 
prostatectomy seem minor, but the risk of negatively influencing the sexual performance may be 
substantial. The outcome on a population level may differ from the benefit for the individual. 
 
Keywords: prostate cancer; screening; mortality; early detection; anxiety; 30-day mortality; 
prostatectomy; Prostate-Specific Antigen; prostate biopsy; impotence; urinary incontinence                                     
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SHORT OVERVIEW OF PAPERS 
 
 
Paper Population and design 
 
Endpoints Main findings 
I  The Göteborg randomized 
population-based prostate cancer 
screening trial  
 Randomized controlled trial 
 Population-based, prospective 
study 
 (1995-2008) 
 
n=10,000 screened 
n=10,000 controls 
 
 Prostate cancer incidence 
 Prostate cancer mortality 
 Number needed to screen 
 Number needed to treat 
A PSA-based screening program 
increases the detection of prostate 
cancer by 1.6 but lowers the risk of 
advanced disease. This program also 
reduces the relative risk of prostate 
cancer mortality by 44% over 14 years. 
     The number needed to screen to 
prevent one prostate cancer death is 
293 and the number needed to 
diagnose is 12. 
 
II  The Göteborg randomized 
population-based prostate cancer 
screening trial  
 Population-based, prospective 
and longitudinal study 
 (1995-2005) 
 
n=1,781 screen-positive men 
 
 Anxiety awaiting the result 
of PSA measurement 
 Anxiety associated with 
further clinical work-up 
including prostate biopsies 
Anxiety associated with prostate cancer 
screening in general is low to moderate, 
even in men with elevated PSA. 
     Severe anxiety affects a smaller 
group of susceptible men. 
 
III  Nationwide (Sweden)  
 NPCR – National Prostate 
Cancer Register (the follow-up 
study) 
 Localized prostate cancer 
(clinical stadium T1-2, Prostate-
specific antigen < 20 ng/ml, men 
≤70 years) 
 (1997-2002) 
 
n=3,700 
 
 Perioperative (30-day) 
mortality after radical 
prostatectomy 
Radical prostatectomy is a procedure 
with very low perioperative mortality 
throughout Sweden (0.11-0.13%), i.e. 
even when performed outside high-
volume centers. 
IV  Sub-study within the European 
Randomized Study of Screening 
for Prostate Cancer, ERSPC 
 Study centers: Finland, the 
Netherlands and Sweden 
 Prospective cohort study 
 (1993-2008) 
 
n=12,959 screening-positive men  
n=37,235 screening-negative men 
 
 30,60,90,120- and 365 day 
mortality after screening 
(~biopsy) 
Screening-positive men who are in fact 
biopsied have a lower short-term 
mortality as compared to screening-
negative men.  
     Prostate biopsy is not associated 
with excess mortality and fatal 
complications seem to be very rare in a 
screening setting. 
 
V  The Göteborg randomized  
population-based prostate cancer 
screening trial  
 Men who underwent radical 
prostatectomy at Sahlgrenska 
University Hospital (sub-study) 
 Population-based, prospective 
and longitudinal cohort study 
 (2001-2008) 
 
n=1,138 screened men with 
prostate cancer; 562 radical 
prostatectomies 
n= 711 controls with prostate 
cancer; 267 radical prostatectomies 
Questionnaires preoperatively 
and 18 months after surgery:   
 
   - International Index of   
     Erectile Function-5 
 
- Urinary incontinence 
 
n=205 screened men with 
complete questionnaires  
(72.4% of eligible men) 
n=89 controls with complete 
questionnaires  
(67.9% of eligible men) 
At 18 months post radical 
prostatectomy, the majority of 
preoperatively potent men are impotent 
or sexually inactive, whereas 14.3% of 
screened men and 20.5% of controls 
are incontinent. 
     However, at 14 years, the “cost” per 
prevented prostate cancer death is four 
men impotent and less than one man 
incontinent. 
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Abbreviations and glossary 
 
 
In alphabetical order and as they appear in the text: 
 
 
AS Active Surveillance 
AUA  American Urological Association 
BPH  Benign Prostatic Hyperplasia 
CT  Computed Tomography 
DHT  Dihydrotestosterone 
DRE  Digital Rectal Examination 
EAU  European Association of Urology 
ED  Erectile Dysfunction 
EPC  Early Prostate Cancer Trial 
ERSPC  European Randomized Study of Screening for Prostate Cancer 
F/T  Free to Total Ratio 
GnRH  Gonadotropin-releasing hormone 
HADS  Hospital Anxiety and Depression Scale 
IIEF  International Index of Erectile Dysfunction 
MRI  Magnetic resonance imaging 
NCI  National Cancer Institute 
NPCR  National Prostate Cancer Register 
PAP  Prostatic Acid Phosphatase 
PC  Prostate Cancer 
PCPT  Prostate Cancer Prevention Trial 
PDE5I  Prostaglandin 5 Inhibitors 
PIVOT  Prostate Cancer Intervention Versus Observation Trial 
PLCO  The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
ProtecT  Prostate testing for cancer and Treatment 
PSA  Prostate-Specific Antigen 
QoL  Quality of Life 
QALY  Quality-Adjusted Life Years 
RCT  Randomized Controlled Trial 
RP  Radical Prostatectomy 
SBU  Statens Beredning för medicinsk Utvärdering 
SEER  Surveillance, Epidemiology and End Results program 
SPCG  Scandinavian Prostate Cancer Group 
START  Standard Treatment Against Restricted Treatment  
TRUS  Trans-Rectal Ultra-Sound 
TURP  Trans-Urethral Resection of the Prostate 
UI  Urinary Incontinence 
USPSTF  United States Preventive Services Task Force 
WHO  World Health Organization 
WW  Watchful Waiting 
5ARI  5-alfa reductase inhibitors 
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1. INTRODUCTION 
The present thesis investigates potential negative consequences in relation to benefits of 
a population-based, randomized, controlled prostate cancer screening trial conducted 
between 1995-2008 in Göteborg. Screening was performed every second year with the 
blood test Prostate-Specific Antigen (PSA) as a screening tool.  
     The first study outlined in this thesis reports the acceptability and efficacy of this 
prostate cancer screening program. It contains the first evaluation of the main endpoint 
at 14 years of follow-up, i.e. differences in prostate cancer mortality between 10,000 men 
randomized to screening and 10,000 controls. In the second paper, screened men’s levels 
of anxiety associated with the screening procedures are assessed. The third paper 
explores the risk of excess mortality associated with prostate biopsy, the gold standard 
for the diagnosis. The fourth paper focuses on 30-day mortality after radical 
prostatectomy, the most common treatment option for early, screen-detected, localized 
prostate cancer. The fifth paper establishes the population-induced frequencies of 
erectile dysfunction and urinary incontinence after radical prostatectomy for men with 
screen-detected prostate cancers as compared to men with clinically diagnosed tumors. 
 
1.1. Prostate cancer – the scope of the problem and epidemiology 
Prostate cancer (hereafter referred to ‘PC’) is a worldwide health problem. It is one of 
the most prevalent cancer forms, especially in developed countries. The estimated 
incidence in the U.S. was 192,280 new cases in 20091 and 345,900 new cases in Europe in 
20062; accounting for 25% all newly diagnosed cancers in the U.S. and 20% in Europe. In 
Sweden, PC is the most common cancer in men; accounting for one third of new male 
cancer cases.3 It is now also the leading most common cancer, followed by breast cancer, 
cutaneous cancers and colorectal cancer.4 However, this has not always been the case. 
 
History 
Historically, the first genuine description of PC in the medical literature was given by 
Langstaff in the U.K. in 1817, based on the gross appearance at autopsy.5 The first PC 
case established by histological examination by an experienced microscopist was 
reported by Adams in 1853; stating that this was ‚a very rare disease‛.6 In the 1890’s, 
only 50 to 67 PC cases were reported in the literature.7 This may have three explanations. 
Firstly, the main explanation for this may be that in the 19th century, the average life 
expectancy at birth was less than 50 years. Before 1940, most men did not live long 
enough to acquire the disease. Secondly, at that time, the distinction between benign 
disease and cancer causing obstructive urinary symptoms was poorly defined. 
However, some early histological studies of enlarged prostates and prostatectomy 
specimens revealed a 10-15% prevalence of PC.7 Thirdly, dietary habits and exposure to 
environmental carcinogens may have altered. As there exist large geographical 
variations in PC mortality (see below), suggesting environmental factors of importance, 
it may well be that PC is a ‚modern‛ disease.  
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Incidence 
From being a barely recognized disease in the 19th century, the incidence of PC has 
increased dramatically during the last 100 years, with a rapid increase during the last 
two decades. A man’s lifetime risk of a PC diagnosis has more than doubled, from 8% in 
the early 1980’s to almost 18% today.8 This is due to a number of reasons. The 
introduction of the PSA (see below) is likely to explain most of this increase, reflected in 
the fact that the greatest increase in incidence constitutes of non-palpable tumors. Other 
reasons are believed to be an increased ageing male population with an increased life 
expectancy, an increased disease awareness (by men/patients and physicians), improved 
diagnostic techniques with more extended prostate biopsy schemes and also a true 
increase in incidence (due to dietary/ behavioral/ occupational effects).      
The average annual increase in PC incidence in Sweden has been 2.7% over the last 20 
years, with a decrease seen during the last years (2004 onwards).3 The incidence of PC in 
Sweden was around 2,500 new cases in 1970 increasing to around 6,500 in 1998, reaching 
a peak of nearly 10,000 new cases in 2004, now declining to around 8,700 in 2008.(Fig. 1)9  
 
 
 
Figure 1. Prostate cancer incidence. Annual numbers of new prostate cancer cases diagnosed in Sweden 1970-2008. 
Graphical illustration: S Carlsson. Courtesy to Socialstyrelsen (National Board of Health and Welfare).4 
 
Mortality 
PC is the leading cause of cancer related death among Swedish men, followed by lung 
cancer and colorectal cancer deaths. In 2007, a total of 2,470 men died from the disease, 
of whom 311 men deceased before reaching 70 years.10 In Europe, according to estimates 
for 2006, PC was estimated to be the cause of death in 87,400 men, accounting for 9% of 
cancer deaths in men2. The lifetime risk for a Swedish man today of dying from PC is 
around 5-6%; in 2007, 5.6% of 44,025 overall male deaths were due to PC, and 5.8% of 
42,350 men aged 45 years or older4. This can be compared with cardiovascular/ 
circulatory diseases that in 2007 accounted for 40.7% of male deaths (all ages).4 
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The age-standardized mortality from PC in Sweden has slightly increased during the 
last two decades and the absolute number of deaths has increased.4(Fig. 2) Looking at 
the absolute number of men diagnosed with PC and the number of men who die from 
the disease each year in Sweden, it is evident that it is definitely not harmless. 
 
 
Figure 2. Prostate cancer mortality. Annual numbers of deaths from prostate cancer in Sweden 1991-2007. 
Graphical illustration: S Carlsson. Courtesy to Socialstyrelsen (National Board of Health and Welfare).4 
 
Clinical presentation and natural history of the disease 
Some decades ago, 25-30% of men with PC presented with metastasized disease with 
concomitant significant morbidity and mortality. In the early 80’s, half the men with 
newly diagnosed PC had an incurable disease.11 Before the PSA era, approximately 40% 
with the diagnosis died from the disease. At that time, the only strategy against PC was 
a digital rectal examination (DRE). However, the DRE as a screening tool found many 
tumors incurable by the time they were palpable.8 There was a call for another test that 
could detect tumors earlier (see below). Five years already after the introduction of PSA 
testing, most men had a curable disease12. Today, we continue to see a decline in 
metastasized PC at diagnosis and the proportion of early tumors has increased.  
The discrepancy between the risk of a PC diagnosis and the risk of dying from PC 
shows that, although some PCs cause suffering and death, others are clinically less 
important, i.e. they would never cause symptoms within the life span of a typical man 
and/or would never pose a threat to this man’s life. This fact also highlights the 
importance of striving to develop new means of distinguishing those cancers that are 
destined to cause significant illness and premature death from those that are not.  
In Sweden, most men are diagnosed with PC between 65 and 69 years,9 while most 
men who die from the disease are over 79 years4. The mean age at death from PC 
exceeds the life expectancy for a Swedish male, which has increased from around 71 
years in 1960 to 79 years today13. This implies that many men will die from other co-
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morbid conditions rather than PC14, i.e. they will ‚die with it, rather than from it‛. But 
does this mean that ‚the old man’s disease‛ is not an important public health problem?  
The natural history of this disease is very heterogeneous. Frequently, the cancer 
progresses slowly and remains localized to the prostate gland. In other patients, tumor 
growth may be more rapid, resulting in cancer spreading beyond the confines of the 
prostate and long-term survival may be considerably diminished. Strategies for 
managing PC have therefore been aimed at detecting the tumors early. Patients who 
present with distant metastases in general have a poor prognosis with a median survival 
of 2.5 years, whereas men who have localized disease have a much better prognosis.15   
A recent study has indicated, that if current life expectancy trends continue, more 
than half the babies born today in wealthy nations will live to 100 years.16 Reaching this 
age may seem unrealistic, however, data from Statistics Sweden estimates that the life 
expectancy at birth for a Swedish male will increase to at least 85 years by 2060.13 With 
an ageing population, the public health burden from PC will most probably increase. 
 
1.2. Global incidence and mortality trends 
The global incidence and mortality trends for PC are more complicated than for other 
tumors, and different explanations for the rises and falls seen over time and the 
geographically diverse patterns have been proposed8.  
     The trends before and during the PSA era constitute a historical shift in the detection 
and treatment of PC around the world. After its commercial introduction in the mid 
80’s, the PSA test became widely used in the U.S. around 1990, both for diagnostic 
purposes in symptomatic men and as a screening test in asymptomatic men. PSA 
screening for men over 50 years was recommended by the American Cancer Society in 
1992.17 From then on, epidemiological studies on population-based data originating 
from the U.S. so-called SEER-database (Surveillance, Epidemiology and End Results 
program) showed markedly altered incidence and mortality patterns.  
 
Incidence trends 
Firstly, there was an initial rapid and dramatic PC incidence trend peak that coincided 
with the widespread implementation of the PSA test in the late 80’s (1985-1992), but 
since the early 1990’s (1993 onwards) PC incidence has been declining. The initial 
increase was interpreted as being due to the depletion of previously undiagnosed 
accumulated cases from the previous years’ pool18 (a ‚harvest effect‛).  The detection of 
a large number of prevalent cases has also been suggested as being the first indication of 
a successful screening program in detecting the disease. During the 80’s there was also 
an increase in the use of transurethral resection of the prostate (TURP) for benign 
prostatic hyperplasia (BPH). Because of an increase in the pathological examination of 
TURP-specimens there was also an increasing likelihood of PC diagnosis.8 
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Mortality trends 
The pattern of an initial increase followed by a decline was also seen in PC mortality 
from the early 90’s and onwards. After a surge in PC incidence in North America in the 
early 1990’s, diminishing rates of PC mortality became apparent in 1993.19-20 The age-
standardized mortality rates also declined in many countries worldwide21. In Tyrol in 
Austria where men, aged 45-74, have been offered PSA testing free of charge since 1993 
within the Tyrol Prostate Cancer Demonstration Project (a non-randomized study of the 
effect of screening in a natural experiment setting)8 the decline in PC mortality has been 
much greater than in the rest of Austria22-23. However, there are some inconsistencies in 
PC mortality trends and the uptake of PSA screening worldwide, and not everywhere is 
there a correlation between them.24 Similar trends are seen also in England and Wales, 
where national health policy has discouraged PSA screening, and where the use of 
radical treatment has been less common than in the U.S.24 However, the decline in PC 
mortality has been greater in the U.S., reflecting the different magnitude of the trends.25 
Collin et al reported that age-specific and age-adjusted PC mortality peaked in the early 
1990’s at almost identical rates in both the U.S. and the UK, but age-adjusted mortality in 
the U.S. declined after 1994 by -4.17%  each year, four-times the rate of decline in the UK 
after 1992 (-1.14%). The greater decline in PC mortality in the U.S. compared with the 
UK in 1994-2004 coincided with a much higher uptake of PSA screening in the U.S.25  
Mortality trends have been estimated in the five Nordic countries. Mean annual 
declines in PC mortality of 1.8-1.9% were observed from 1996-2004 in Finland and 
Norway. During the same period, mortality rates leveled off in Iceland and Sweden but 
continued to increase in Denmark. In all the Nordic countries, except Denmark, has PSA 
testing and curative treatment been more frequently practiced since the late 1980’s.26  
Consequently, many authors have interpreted the international trend patterns as 
indirect evidence for the efficacy of PSA-screening. Furthermore, after the introduction 
of PSA, the average age at diagnosis has fallen, the proportion of advanced stage tumors 
has declined and patterns of care have changed accordingly.19  
 
Why has prostate cancer mortality declined? 
Several explanations for the decline in PC mortality have been proposed. PSA screening 
was suggested to have lead to a harvesting of prevalent cases of patients with subclinical 
PC, thereby increasing the population of men whose death could potentially be 
attributed to this disease.8 Once the pool of prevalent latent cancers was reduced, the 
number of men who could have PC assigned as cause of death was also reduced. Even 
before the PSA era, there was an increased interest in early detection with DRE. This, 
together with increased radical prostatectomy rates as well as the availability of other 
improved treatment options might have contributed to the changes seen.19 Increases in 
PSA screening and better treatment of early-stage disease, possibly acting in 
combination, remain plausible hypotheses.21 The frequency of aggressive curative 
treatment for early-stage disease with surgery as primary treatment has increased and 
radiation therapies have evolved enormously since the late 1980’s.27-31 The pattern of 
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androgen-deprivation therapy usage has changed.32  Treatments previously reserved for 
metastasized disease are now being used as adjuvant or neo-adjuvant therapies for 
localized disease.8, 25-26 The increased use of hormonal therapy is, most probably, also 
contributing to the observed changes in mortality.32 Hormonal therapy can postpone PC 
death long enough for the patient to die from unrelated causes33.  
Some authors have claimed that the observed decrease in prostate-specific mortality 
within the first decade after the onset of PSA testing came too early, given the long 
natural history of the disease.19 The observations of improved PC survival have been 
suggested as having been caused by so-called ‚lead-time bias‛ (referring to the 
phenomenon that screening may appear to improve survival, when it only advances 
diagnosis).34 In a simulation model, Etzioni et al indicated that only short lead times (≤3 
years) could produce a decline in PC mortality, through PSA testing, of the magnitude 
that was observed in the U.S.35 Surveillance models suggest that PSA screening explains 
a significant fraction, but not all, of the drop in PC mortality seen.36  
One could also discuss lifestyle or health behavior, exposure and environmental 
changes. Other possible explanations include changes in co-morbidities and competing 
causes of deaths as well as changes in the risk of death from PC24. Obesity, for instance, 
has been associated with an increased risk of PC death.37 It has further been observed 
that the mortality from several malignancies, in general, has fallen.29 
The fact that the decline in PC mortality was preceded by an initial increase in both 
the incidence and mortality of PC could have introduced an artifact of its own. There 
might thus have been a bias related to the misattribution of cause of death, so-called 
attribution / classification bias. The likelihood of classifying PC as underlying cause of 
death for a non-PC death, could have been increased in PC patients because of the 
increased detection of PC.25,38 Such phenomena could have been reflected in the trends. 
To sum up, PSA screening has clearly affected PC incidence and mortality patterns 
around the world. However, these trends are complex products of several changes over 
time, including changes in diagnosis and treatment, and it is extremely challenging to 
determine the causal relationships. Whether PSA screening reduces mortality is difficult 
to establish in epidemiological (observational) studies, and it is being investigated and 
reported in randomized controlled screening trials (see below)39-40.  
 
1.3. The Prostate-Specific Antigen test, PSA  
The test used in screening for PC is called Prostate-Specific Antigen (PSA) and was first 
isolated and defined in the 1970’s41-43. It  is an androgen-regulated glycoprotein, a serine 
protease44 and a member of the tissue kallikrein family45. It is produced mainly by the 
prostate epithelium (with the majority of glandular tissue located in the peripheral 
zones of the prostate) and transported with seminal fluid. PSA is inactivated by forming 
complexes with protease inhibitors (‘complexed’ or ‘bound’ PSA), mainly alfa-1-
antichymotrypsin46  and to a lesser extent alfa-2-macroglobulin and alfa-1-antritrypsin. 
10-30% remains uncomplexed, but is inactivated by internal proteolytic cleavage (‘free’ 
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PSA). The biologic function is in regulating the degree of liquidity of the seminal 
coagulum by cleavage of semenogelins, hereby influencing the motility of the sperm47.  
In humans, the normal prostate glandular architecture consists of a single layer of 
secretory epithelial cells, surrounded by a basal layer and a basal membrane that 
separates the intra ductal PSA from the capillary and lymphatic drainage of the prostate. 
Normally, PSA leaks into the peripheral blood circulation in small proportions; the 
amount in serum is approximately one million fold lower than in prostatic fluid. Serum 
PSA normally increases with age48. PSA may be found in an increased amount in the 
peripheral blood of men who have prostatic disease or mechanical manipulation 
interfering with the natural barrier between the prostate and the capillaries.  
 
PSA as a marker for prostatic disease 
A characteristic early feature of PC is disruption of the basal cell layer and basal 
membrane, i.e. the normal architecture, allowing a greater fraction of the PSA produced 
to have access to the systemic circulation. This, together with a decrease in the luminal 
cleavage processing causes relative increases serum PSA.47 An increased cell turn-over 
or other mechanisms may play a role. Consequently, PSA is a marker for PC.49 However, 
PSA levels in serum may also be high in men who have a benign prostatic hyperplasia 
(BPH, an enlarged, but noncancerous prostate)50 or acute inflammation of the prostate 
(prostatitis). There is thus an overlap in total PSA levels between healthy men, BPH 
patients and PC patients. This may be due to the fact that the level of PSA expression on 
a per-cell basis is lower in PC cells than in normal prostate epithelium51-52. High PSA 
levels in men with advanced PC reflects the large number of tumor cells. A number of 
other factors can affect the PSA level, known to any urologist, such as urinary tract 
infections, indwelling catheters, rigid cystoscopy or 5-alfa-reductase-inhibitors. 
Historically, the utility of the PSA as an adjunctive tool in the diagnostic arsenal for 
PC was first proposed in 1980, when Kuriyama et al. found that men with PC (and BPH) 
had elevated PSA levels compared to both healthy men and healthy women and 
compared to both men and women with other (non prostatic) malignancies53. The PSA 
therefore came to replace the earlier prostatic acid phosphatase (PAP) because it was 
found by Stamey et al. to be more sensitive than PAP in the detection of PC49.  
PSA is neither specific to the prostate, nor cancer-specific. Although it is almost 
exclusively produced by the prostate epithelium, some tissues can also contain PSA. It 
has been found in breast tissue/tumors54-55, colon, liver, kidney, adrenal and parotid 
tumors56, in ovarian teratomas57, in skin tumors58 and in male salivary gland tumors59. It 
can also be found in male periurethral and male perianal glands60-62, however, these do 
not seem to have a clinically significant effect on serum PSA63. As there is no significant 
source of serum PSA outside of the prostate gland, serum PSA can be used to monitor 
the clinical course of PC, to monitor the efficacy of definitive local therapy, as an early 
indication of PC recurrence and to monitor response of hormonal therapy (androgen-
deprivation).47 Undoubtedly, no tumor marker has caused such a significant change in 
the approach to cancer detection, staging and monitoring following therapy as PSA8.  
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Specificity, sensitivity and positive predictive value 
‚Background noise‛ from BPH-related PSA elevation implies that the specificity of the 
PSA as a screening test for PC is not ideal.64 The PSA has been questioned as a screening 
tool for PC for possessing a low likelihood ratio (imperfect to ‚rule in disease‛)65. The 
sensitivity and specificity of the test depend on laboratory assay and method, PSA range 
in population studied, biopsy criteria and percentage biopsied. The specificity of the 
test, with a PSA cut-off of 3 ng/mL, is reported to be as high as 89%, (i.e. the proportion 
of the healthy population who have a negative test).66 The positive predictive value in 
the Göteborg screening study is reported to be approximately 24% (i.e. the proportion of 
men with a ‚positive‛ test result who actually have the disease), thus 76% are ‚false-
positives‛.66 The positive predictive value of a biopsy (measured as the number of 
cancers detected on screening divided by the number of biopsies expressed as a 
percentage) was on average 24% (range 18.6 – 29.6) in the European Randomized Study 
of Screening for Prostate Cancer, ERSPC (see below).39 This means that many men will 
undergo prostate biopsies to rule out cancer. The proportion of positive screening tests 
(mainly PSA > 3 ng/ml, but a cut-off of 4 ng/ml and DRE/transrectal ultrasound findings 
and free to total ratios were used in some centers) was 16.2% (with a range of 11.1 to 
22.3% among the centers). The average rate of compliance with biopsy 
recommendations was 85.8%.66  
  
A single PSA test as a screening tool 
To eliminate the effect of BPH-related PSA elevations and to find ways of improving PC 
detection, Lilja et al. conducted a case-control study in men aged ≤ 50 years, a group of 
men in which BPH was not yet high-prevalent. Between 1974 and 1986, 21,277 men 
enrolled in a cardiovascular study provided blood samples. They constituted a 
screening naïve population in Malmö, Sweden, as Swedish national guidelines have 
long advised against PSA screening.67 PCs were identified up to 25 years later from the 
Swedish cancer registry and most cases were clinical tumors (76% T2, T3 or T4). Men 
with PSA levels between 2-3 ng/mL had a 19-fold increase in odds for PC compared to 
controls. Of advanced detected tumors (T3, T4 or metastasized at diagnosis), 80% 
occurred among men with a PSA above the median already at age 44-50 years.68  
 
Other diagnostic tools or combinations of markers 
Other diagnostic tools to improve specificity have been proposed. Presumably because 
of disruption of the normal secretion of PSA into the excretory ducts in PC tissue, the 
proteolytic cleavages that occur in seminal fluid that make PSA inactive (‚free‛) are 
present at lower levels in PC tissue. Consequently, the ratio of free to total PSA 
(fPSA/tPSA, termed the PSA ratio) is lower in many patients with PC and seems to aid 
in the discrimination between BPH and PC, thus increasing the specificity of the test in 
men with slightly elevated PSA (3-4-10ng/mL)69, 70-72. Other ways to increase specificity 
have been suggested, such as PSA density (PSA/prostate gland volume)73 as higher PSA 
levels are seen in men with larger prostates74 and age-specific PSA cut-offs as PSA 
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increases with age48. The former has been criticized because the value is dependent on 
who performs the TRUS and the latter because there is a risk of excessive biopsy in 
younger men and under-diagnosis of advanced cancer in older men. The majority of 
PCs detected because of an elevated PSA are too small to be seen as hypo-echogenic 
lesions on TRUS. The value of ultrasound in itself is in measuring prostate volume and 
in improving the accuracy in the systematic sampling of biopsies.  
     Multiple kallikreins (total, free, intact PSA, and human kallikrein-related peptidase2) 
measured in blood has been shown to predict the result of biopsy in previously 
unscreened75 and screened76 men with elevated PSA and to reduce the number of men 
who have to undergo biopsies without missing many significant cancers. 
 The Prostate Health Index (phi) combines total PSA, free PSA and [-2]proPSA into one 
index that estimates a man's probability of having PC found on biopsy. Phi may add 
significant information regarding individual patient risk and may be used as an aid in 
patient management77.  PCA3 (Prostate CAncer gene 3) is a gene which messenger RNA 
(mRNA) is over-expressed in the majority of PCs78. An assay has been developed that 
detects this mRNA in urine to help make better biopsy decisions79. 
 
What is a ‘normal’ PSA? 
The optimal cut-off value in PSA screening has been discussed. A higher PSA threshold 
would minimize the number of negative biopsies (optimize specificity), but perhaps 
miss cancers (‘under diagnosis’), whereas a lower PSA threshold would maximize the 
number of cancers detected (optimize sensitivity) but perhaps diagnose too many 
indolent cancers (‘over-diagnosis’). For over two decades, a PSA-cut-off of 4 ng/mL was 
used as a screening tool in early detection of PC. The Prostate Cancer Prevention Trial 
(PCPT) in the U.S. changed this. In 2004, Thompson et al. reported outcomes for 2,950 
men with a PSA less than 4.0 ng/mL and who had an end-of-study biopsy after 7 years. 
Of these, PC was found in 15.2%. Of these, 15% had a Gleason score1* of 7 or higher (i.e. 
high grade disease). Of all tumors, 27% were detected in the PSA range between 3.1 and 
4.0 ng/mL, and every fourth tumor among these was high grade disease.80 Therefore, 
Thompson et al. could conclude that there was no lower limit of PSA at which PC could 
not be detected and that the PSA level should reflect a level of risk of PC and not be 
regarded as a dichotomous marker (‘positive’ or ‘negative’). This finding was a stunning 
revelation to the urologic and medical community; no longer was the PSA ‚normal‛ or 
‚elevated‛.8 Lodding et al. showed that lowering the PSA cut-off from 4 to 3 ng/mL in 
the Göteborg prostate screening trial increased PC detection by 30%, with most of these 
cancers clinically significant.81  
                                                 
1* Gleason score (GS) (after Donald F Gleason 1920-2008) is the pathological grading of prostate needle biopsies, TURP and 
radical prostatectomy specimen. It is based on the sum of the two most common morphological Gleason grades(GG)/patterns 
under the microscope, but after the 2005 ISUP Consensus Conference on Gleason Grading a modified GS  has been suggested so 
that needle biopsies includes tertiary patterns (i.e. GS = the dominant + worst pattern).  
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1.4. Screening 
Several definitions of screening have been proposed. The World Health Organization 
(WHO)82 states:  
 
‚The use of simple tests across a healthy population 
in order to identify individuals who have a disease 
but do not yet have symptoms.‛ 
 
The PSA is a simple, and inexpensive test and biomarker of PC49 that is used as a 
screening tool in detecting early PC among asymptomatic men83. The aim of general 
screening should be to diagnose and treat PC as early as possible, but at the same time, 
as ‚late‛ as possible to prevent a man from long-time suffering from the negative side-
effects of treatment. Hence the test should diagnose the disease with the aim of 
identifying men who would benefit from it, without being brought to harm. The 
diagnosis should, ideally, lead to reduced morbidity as well as reduced PC mortality.  
 
Diagnostic procedures 
To obtain the diagnosis of PC, the main tools in the diagnostic arsenal include digital 
rectal exam (DRE), PSA and transrectal ultrasonography (TRUS). Most PCs are located 
in the peripheral zone of the prostate and detectable by DRE when the volume is larger 
than 0.2 mL. A suspect DRE alone can detect PC in about 18%84.  A hypoechoic area on 
TRUS may be indicative of PC and biopsies targeted at this area may be useful. The only 
means of verifying the definite diagnosis is the presence of adenocarcinoma in prostate 
biopsies, or from specimens from transurethral resection, or radical prostatectomy. A 
transrectal approach is used for most prostate biopsies, but some urologists use a 
perineal approach. Sextant biopsies have long been the gold standard for sampling; 
however, 10-core biopsies are recommended today85. Saturation biopsies (average 24 
cores) detect PC in about 40%86. Ultrasound-guided peri-prostatic local anaestesia and 
antibiotic prophylaxis with quinolones are state-of-the-art. TRUS-guided transrectal core 
biopsies are favored over fine-needle aspiration biopsy because fewer pathologists are 
trained in cytology. Core biopsies also provide information on the histopathological 
grading (see Gleason score below) and the extent of the tumor. Complication rates after 
biopsy are low. Minor complications include macrohaematuria (15% > 1 day) and 
haematospermia (37%). Severe infections (fever, urosepsis) have been reported in < 1% 
of cases. Rectal bleeding occurs in about 2%.85 
 
History of prostate cancer screening 
The initial reports of PSA screening as compared to digital rectal exam (DRE) alone, 
those of Catalona et al., Wang et al., Cooner et al., Brawer et al. and Stamey et al.49, 83, 87-89, 
in populations that had never been examined with a screening test before, set the stage 
for a widespread adoption of the test that lead to an increased rate of PC detection as 
was seen across the U.S. between the late 1980’s to the early-mid 1990’s.8 Many medical 
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organizations agree today that appropriate candidates for screening include men older 
than 50 years of age and men over 40 years at increased risk (for example family history 
or race) for PC, but that screening is unlikely to benefit men who have a life expectancy 
of less than 10 years. These organizations include the American Academy of Family 
Physicians, the American Cancer Society, the American College of Physicians, the 
American Medical Association, and the American Urological Association.90 The latter 
recommend the age for obtaining a baseline PSA to be 40 years for all men.91 These 
organizations recommend that clinicians discuss with patients the potential benefits and 
possible harms of PSA screening, consider patient preferences, and individualize the 
decision to screen.  
 
Today’s national recommendations 
However, the U.S. National Cancer Institute (NCI) does not recommend general PSA 
screening and the U.S. preventive services task force (USPSTF) has concluded that the 
current evidence is insufficient to assess the balance of benefits and harms of PC 
screening in men younger than 75 years, and they recommend against screening for PC 
in men of 75 years or older.92 In Sweden, screening for PC is recommended to men who 
have two or more first-degree relatives with the disease. These men have an increased 
risk of a PC diagnosis before the age of 7093-94. In these men, screening (information, PSA, 
DRE) is recommended to start at 40-50 years.  
     In 1995, the Swedish Council on Technology Assessment in Health Care, 
internationally known by its Swedish acronym ‚SBU‛ (Statens Beredning för medicinsk 
Utvärdering) published a report on general screening for PC (‚Massundersökning för 
prostatacancer‛)95. It was concluded that screening for this disease could not be 
recommended, mainly due to the absence of convincing evidence from randomized 
trials on the benefits of early detection. More evidence has been published since the first 
SBU-report, but no change in current practice is predicted within the immediate future. 
The issue is discussed continuously in The National Board of Health and Welfare.  
 
1.5. Randomized controlled screening trials  
In a Cochrane review from 200796 on screening for PC, Ilic et al. identified 99 potentially 
relevant articles, of which two randomized controlled trials (RCT) met the inclusion 
criteria (i.e. screening versus no screening or routine care for PC); the Quebec trial that 
was commenced in 1988 by Labrie et al. (PSA and DRE, PSA > 3 ng/mL as cut-off, men 
aged 45 to 80 years, 2:1 randomization)97-98 and the Norrköping trial that was commenced 
in 1987 by Sandblom et al. (screening with DRE every three years in the first two 
screening rounds, 1987 and 1990, and DRE and PSA in 1993 and 1996, with DRE-
findings or a PSA > 4 ng/mL as biopsy triggers, men aged 50 to 69 years)99,100. Both trials 
had limitations in their study methodology.  
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The Quebec trial 
In the Quebec trial, firstly, only 23.6% were screened in the group invited (7,348 of 
31,133 men), and such a low adherence rate reduces the power of the study to detect a 
true difference that could be attributable to screening. In the control group, 7% were 
estimated as having been screened. Secondly, the data analysis presented was not 
performed according to the intention-to-screen principle. Instead, mortality from PC 
was analyzed for the number of men who actually underwent screening as compared to 
those that did not undergo screening, regardless of their initial group allocation.96 
 
The Norrköping trial 
The Norrköping study was smaller, encompassing 1,494 men randomized to screening 
and 9,026 controls (with every sixth man assigned to the screening group from a list of 
birth dates obtained from the national population register, described by Ilic et al. as 
‘quasi-randomized’). Further, information regarding the study was distributed through 
newspaper, radio and television broadcasting. This could have raised a potential for 
self-selection bias and contamination in the control group, with control participants also 
seeking screening.96 Furthermore, the Norrköping study was originally designed as a 
feasibility study to study the acceptability, organization and consequences of a screening 
program.99 Therefore, Ilic et al. concluded in the review that in order to make evidence-
based decisions, more studies were needed on firstly, the effect on PC mortality, and 
secondly, the impact on quality of life, economy and the harms of screening.  
 
The Stockholm trial 
Yet another screening study has been conducted in Stockholm, Sweden. Commencing in 
1988, a total of 2,400 men of 55-70 years were randomly selected and invited to a one-
time screening for PC. Of these, 1,782 (74%) attended. Participants were examined with 
DRE, TRUS and PSA. If they had abnormal findings on DRE and/or TRUS, they 
underwent randomized quadrant biopsies as did men with a PSA > 10 ng/mL. If the PSA 
was greater than 7 ng/mL, repeat TRUS was performed. Men with PC were offered the 
standard care of that time. With this protocol, a single intervention done in a previously 
screening naïve population revealed many PCs advanced at diagnosis (‘prevalent 
screen’). At a median of 12.9 years of follow-up, there was no effect seen on the risk of 
death from PC and other causes of death when all the men invited were compared with 
the source population of 27,204 men (incidence-rate ratios 1.10, 95% CI 0.83–1.46 and 
0.98, 95% CI 0.92–1.05, respectively).101 
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1.5.1. The ERSPC trial, The Göteborg trial and the PLCO trial 
To further evaluate the effectiveness of PC screening, two large-scale randomized 
population-based trials including men aged 55 – 74 years were initiated in the early 90’s: 
the European Randomized Study of Screening for Prostate Cancer (ERSPC, 
http://www.controlled-trials.com number ISRCTN49127736) in Europe and the Prostate, 
Lung, Colorectal and Ovarian cancer screening trial (PLCO, http://www.clinicaltrials.gov 
number, NCT00002540) of the National Cancer Institute (NCI) in the U.S.102 Hereafter, 
the acronym ‚PLCO‛ will refer in this thesis to the prostate section of the study only. 
 The studies are still ongoing. A few interim analyses have been made throughout the 
years and main end-point result reports have been published (see below). In the United 
Kingdom, another ongoing trial, the Comparison Arm for the Prostate Testing for 
Cancer and Treatment study, combines the assessment of screening and treatment. 
 
Background ERSPC 
After a series of pilot studies from 1991 to 1993, the final screening study of ERSPC was 
initiated in 1994 and includes eight European countries. The countries are: the 
Netherlands, Belgium, Sweden, Finland, Italy, Spain, Switzerland and France. The 
ERSPC is the world’s largest ever randomized study of screening for PC, in which 
nearly 73,000 men were randomized to screening and nearly 90,000 men were 
randomized to serve as controls, aged 50–74 years. In the first main outcome report (PC 
mortality) in 2009, results were reported for 162,387 men in the core age group of 55-69 
years in 7 of the 8 countries (excluding France)39. The participating countries and the size 
of the study sections of the ERSPC in this publication is illustrated in figure 3. 
 
  
 
 
 
 
 
 
 
  
 
 
 
Figure 3. Proportion of subjects per study center in the core age groups of the ERSPC trial  
in the 2009 New England Journal of Medicine publication (in which France was not included). 
Adapted from [Schröder FH et al. NEJM. 2009;360:1320-1328] 
http://www.erspc-media.org/ 
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The screening interval is 4 years, with the exception of Sweden where screening is 
biennial (every 2 years). Screening is PSA driven: a biopsy is indicated for men who 
have a PSA level of 3.0 ng/mL or higher (initially, in some centers, suspicious DRE or 
TRUS or a low ratio of F/T PSA < 16% in men with PSA 3.0 – 3.99 ng/ml were also 
indicators for biopsy). The Netherlands and the Göteborg sections of the ERSPC are, this 
far, the most extensively studied. The study and the related quality of life-research 
should result in evidence-based advice to governments around the world103. 
 
Background The Göteborg trial 
The Göteborg Randomized Prostate Cancer Screening Trial was approved by the ethical 
review committee of Göteborg University in 1994. Professor Jonas Hugosson at the 
department of urology at Sahlgrenska University Hospital is the principal investigator. 
As of Dec 31, 1994, the population register documented 32,298 men born between 1930 
and 1944 (age 50–64, median 56 years) living in the city of Göteborg, Sweden. By 
computer randomization 20,000 of these men were identified and allocated (1:1 ratio) to 
either the intervention arm (screening group) or to a control group. The study was 
planned independently from the ERSPC during 1993-94. After approval from the Ethical 
committee in 1994, the study started to invite men in January 1995. The power of the 
study was calculated upfront and it was not planned as a sub-study within the ERSPC. 
During the autumn 1995, the study board of the Göteborg trial was invited by the 
Principal Investigator of the ERSPC, Professor Fritz Schröder (the Netherlands), to the 
ERSPC meetings. The ERSPC accepted the Göteborg protocol without any changes and 
in 1996 the Göteborg (=Sweden) section agreed to join the ERSPC study with men in the 
core age group, which includes 11,852 men (59%) of all men randomized in the 
Göteborg trial. In the first main endpoint report from the ERSPC in 2009 the Göteborg 
section represents 11,852 of the 162,243 men (7.3%)39. 
 
Background PLCO 
The prostate component of the PLCO trial (figure 4) was initiated in the U.S. in the early 
90’s. The study randomly assigned 76,693 men (aged 55 – 74) to either screening or 
controls (usual care). Men who were assigned to the screening group were offered 
annual PSA testing for 6 years and annual digital rectal examination for 4 years. Men 
with a PSA value >4 ng/mL or suspicious findings on the DRE were advised to seek 
diagnostic evaluation, which in accordance with standard practice in the U.S. was at the 
discretion of the patient and his primary physcian.40 
 
 
 
       http://prevention.cancer.gov/plco 
              
 
Figure 4. The Prostate, Lung, Colorectal & Ovarian cancer screening trial 
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1.5.2. RCT’s – Results 
The major results of the world’s two largest randomized PC screening trials were 
awaited for several years. The first reports on the major end-points from these two trials 
were published in the same issue of the New England Journal of Medicine in early 2009. 
However, as Holmberg wrote in an editorial: ‚No one professionally involved in PC 
diagnosis and treatment would have expected the first analyses of the ERSPC and the 
PLCO to provide the final answers to all major questions in PC screening.‛104 A 
thorough report of the differences  between these two trials is presented by Schröder 
and Roobol in 2010.105 
 
 
ERSPC 
Earlier comparisons of the characteristics of PC detected in both arms of the ERSPC have 
given an indication of the immediate effects of screening on down-staging of the disease. 
An analysis in 2005 yielded the result that in the screening arm of the Netherlands’ 
section of the ERSPC the following characteristics were seen (as compared to the control 
arm): lower PSA at diagnosis, a favorable shift in Gleason score, lower stage, and a 
decrease in the diagnosis of metastatic disease106. Hence there was already confirmatory 
evidence that screening results in the identification of cancers with favorable 
characteristics.107 That PSA screening reduces the risk of being diagnosed with 
metastatic PC, the first prerequisite for achieving decreased PC mortality in younger 
men, has also been shown in the Göteborg trial.108  
These early findings of a favorable effect of PSA screening were confirmed when the 
first results on PC mortality from the ERSPC were published in 2009.39 Encompassing 7 
out of 8 countries in this analysis and 162,000 men in the core age group of men aged 55 
to 69 years, it showed that PSA driven, continuous, PC screening reduced PC mortality 
by 20% after a mean follow-up of 8.8 years (214 men out of 72,890, 0.29%, in the 
screening group died of PC compared to 326 men out of 89,353, 0.36%, in the control 
group, or RR 0.81, 95% CI 0.65 to 0.98, p=0.04 adjusted for alpha-spending). Adjustment 
for non-compliance resulted in an even greater effect of 27% among those screened39, 
and additional adjustment for contamination led to an estimated reduction of up to 
31%.109 There was a reduction in the incidence of advanced PC stage at diagnosis in the 
screening group. The proportions of men who had a Gleason score of 7 or more were 
27.8% in the screening group and 45.2% in the control group. Men in the screening arm 
were almost three times more likely than men in the control arm to undergo radical 
prostatectomy and twice as likely to receive radiation therapy110.  From the results of the 
ERSPC, it could be calculated that 1,410 men (or 1,068 men who actually underwent 
screening) are needed to be screened to have 48 PCs treated or managed, to prevent one 
man from dying from PC.  
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PLCO 
The PLCO could not corroborate the finding of the ERSPC. After 7 to 10 years of follow-
up, the rate of death from PC did not differ significantly between the two study groups. 
At 7 years, the rate ratio of PC mortality in the screening group as compared to the 
control group was 1.13 (95% CI, 0.75 to 1.70) and through year 10, with follow-up 
complete for 67% of the subjects, the rate ratio was 1.11 (95% CI, 0.83 to 1.50).40 There 
may be several explanations for this outcome:  
 
1. Sample size 
Firstly, the PLCO was smaller. Its sample size was only 77,000 individuals in total, 
which critically compromised the power of the study to detect any difference between 
the groups as regards PC mortality (see below, point 3).  
 
2. Dilution and contamination – screening in the control group 
Secondly, both the screened group and the control group in the PLCO consisted of 
around 30% of men who were already pre-screened (‘dilution’) with both DRE and PSA 
within the past three years before study start. Furthermore, the proportion of PSA-
screened men in the control arm was as much as 52% by the sixth year 
(‘contamination’).40 This could be compared with the compliance in the screening group, 
in which 85% had a PSA test. It could be questioned whether the narrow 33% difference 
in testing was sufficient to show an effect on PC mortality.  
 
3. Power calculation 
The power of the prostate section of the PLCO trial was calculated to amount to 91% 
and 98% to show a 25% and 30% PC mortality reduction respectively, by recruiting 
37,000 men to each trial arm. This was, however, under the assumption of a 100% 
compliance rate and one-sided hypothesis testing (p ≤ 0.05 considered statistically 
significant). From the original study protocol of the PLCO102, at least a 90% compliance 
and only a 20% contamination would have yielded a disease-specific mortality 
reduction of 27%. The reality instead was completely different. Screening was compared 
to men ‚following their usual medical care practice‛105. The study could therefore, even 
initially, be regarded as underpowered, as a study of that sample size and of the ages of 
60-74 years, with a compliance maximum of 50% and a contamination of at least 40% 
would have required – from the initial power calculations – an unrealistic disease-
specific mortality reduction of 90%. However, one can wonder why the substantial 
difference between the study investigators’ initial claims and the actual performed 
reality in the PLCO study was not communicated in the medical literature and to the 
media? (Recker F. personal communication)111 In the main endpoint publication of the 
PLCO40, no reference to the initial power calculation was given in the discussion. 
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4. Prostate cancer incidence  
As a result of the widespread PSA testing in the control group, there was only a modest 
increase in the excess numbers of PC detected in the screening group, compared to what 
one might have expected. At 7 years, screening was associated with a relative increase of 
22% in the rate of PC diagnosis, as compared with the control group (RR 1.22, or 2,820 
PCs in the screening group, as compared to 2,322 in the control group). In the ERSPC, 
there were instead about twice (1.71) as many cases of PC diagnosed in the screening 
group as in the control group in the ERSPC trial (5,990 PCs in the screening group or a 
cumulative incidence of 8.2% as compared to 4,307 PCs in the control group, or a 
cumulative incidence of 4.8%) indicating the lesser contamination in the ERSPC study 
(at least during the early years of the study, estimated at 3-6% to the range of 15%105) 
than in the PLCO study. When the ERSPC was initiated, in Europe, the perceptions of 
the value of early detection were different compared to those of the U.S. 
 
5. Follow-up of positive screening tests 
Contributing to the difference in incidence could have been the fact that in the PLCO, 
there was no systematic follow-up with clinical examination including TRUS and 
prostate biopsies for screen-positive subjects, as in the ERSPC. Instead, men with 
positive results of the PSA test or suspicious findings on the DRE were advised to seek 
diagnostic evaluation. In accordance with standard U.S. practice, diagnostic evaluation 
was instead decided by the patients and their primary physicians. In the ERSPC, the 
average rate of compliance with biopsy recommendations was 85.8%, as compared to 
the PLCO, in which only 40% of men had a biopsy. 
 
6. Low prostate cancer mortality rates 
The fact that approximately 44% of the men in each study group had undergone one or 
more PSA tests at baseline, could have eliminated some cancers detectable on screening 
from the randomized population, especially in health-conscious men (who tend to be 
screened more often). The authors reported that the cumulative death rate from PC after 
10 years in the two groups combined was 25% lower in those who had undergone two 
or more PSA tests at baseline than in those who had not been tested.40 
     At 7 to 10 years of follow-up in the PLCO, the rate of death from PC was low and did 
not differ significantly between the two study groups. Although the numbers were 
small, there were actually even more PC deaths in the screening group (50 or 0.13% of 
all screened men vs. 44 of 0.12% of all controls in year 7 and 92 out of 38,343 vs. 82 out of 
38,350 in year 10), however, this was non-significant (and the confidence intervals 
around the estimates were wide). The numbers of outcomes were somewhat modest. 
This limitation makes a statement about PC mortality difficult.  At 7 years of follow-up, 
the rate ratio of death attributed to PC was 1.13 (95% CI 0.75 to 1.70) and at 10 years the 
corresponding figure was 1.11 (95% CI 0.83 to 1.50).  
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7. Follow-up time 
Although the median duration of follow-up was 11.5 years (range, 7.2 to 14.8) in the 
PLCO, this is a comparatively short period for a disease such as PC, given its natural 
history. Follow-up was complete, i.e. vital status was known for 98% only at 7 years. 
After this period, the ERSPC did not reveal any mortality difference either. At 10 years, 
only 67% of subjects had a complete follow-up.  
 
8. Stage distribution 
Interestingly, despite more PCs being found in the screening group as compared to the 
control group (at 10 years 3452 versus 2974 PCs, rate ratio, 1.17), there was no difference 
in the stage distribution between the two trial arms of the PLCO40. A difference in the 
incidence of metastasized disease is a prerequisite for finding a mortality difference in 
younger men108. 
 
9. PSA cut-off 
Another possible explanation for the lack of PC mortality reduction in the PLCO study 
could have been the PSA cut-off level of 4 ng/ml as a biopsy indication, as compared to 3 
ng/mL in the ERSPC, where this reduction was seen. By using a higher criterion, one 
may miss some potential PCs and potentially some lethal ones. The screening algorithm 
was also different, in that in the PLCO, subjects who were assigned to the screening 
group were offered annual PSA testing for 6 years and annual digital rectal examination 
for 4 years.112 
 
10. Lead time 
Furthermore, by estimations from graphical comparisons of the cumulative PC 
incidence curves between the two arms, the lead time in PLCO was calculated to an 
average of only 2 years, as compared to 4.5 years in the ERSPC. Such a short lead time as 
2 years in the PLCO suggests a strong similarity between the screening arm and the 
control arm. Alternatively, a lead time of 4.5 years in the ERSPC shows the superior 
quality of the latter study.113  
 
11. Improvements in therapy 
Moreover, during the course of the PLCO trial, there were also improvements in early 
therapy for PC114, that could have resulted in fewer PC deaths in both study arms and 
hence may have blunted any potential benefits from screening.40 Aggressive radical 
treatment in both arms that concomitantly improved prognosis would make further 
improvements with a screening trial difficult.104 
 
12. Follow-up of abnormal screening tests 
Furthermore, yet another proposed reason why the PLCO failed to demonstrate a 
mortality benefit may have been the considerable delays in the follow-up of abnormal 
screening test results (median days between screening and first biopsy). In the PLCO, 
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the follow-up of abnormal screening results (when, how, by whom and which 
treatment) was at the discretion of the men’s physicians (the PLCO trial did not specify a 
diagnostic algorithm), and most men with abnormal screens were either not 
recommended, or chose not to undergo, immediate biopsy. The frequency of delayed 
biopsies resulted in that many cancers were diagnosed more than a year after an initial 
positive screening test.112 Men who died from PC also had a significantly greater delay 
in undergoing biopsy following abnormal test results, suggesting that this may be an 
important factor behind the negative findings of the PLCO trial.115 In a case-case analysis 
of men who died from PC compared to those who did not, disease-specific death was 
associated with a lower frequency of DRE and PSA testing.115 
In the ERSPC trial, the execution of prostate biopsies was performed within the 
screening centers, strictly following the defined biopsy indications. The difference in 
compliance with biopsy indications between the ERSPC and the PLCO resulted in 
dissimilar stage and grade distributions of the tumors detected.105  
 
1.5.3. RCT’s – Implications and over-diagnosis 
The first reports on PC mortality from the ERSPC and the PLCO were conflicting. Any 
final conclusion was difficult to draw, despite one first ‘level 1 evidence’ that PC 
screening reduces PC mortality. Fears still remain that the negative aspects of screening 
are substantial. While several publications on the potential benefits of screening are now 
reported, the degree of harm remains to be established.  
Some studies have indicated that most PCs detected via PSA are believed to be 
clinically important, based on the findings that the pathological features do not resemble 
those of autopsy cancers116-117. With the results from the ERSPC, we know that there is a 
window of opportunity where early treatment can affect the natural history of PC. 
However, this is not true for all PCs detected. Fears persist that a considerable 
percentage of screen-detected PCs are indolent and do not need to be detected at all (or 
can still be detected later at a curable stage).118  
 
Over-diagnosis 
One potential problem connected with early detection is the risk of so-called over-
diagnosis. By this we refer to cancers that are otherwise not diagnosed during a 
lifetime119-120, it can alternatively be defined as cancers that will not lead to death121.  
Although the Gleason score (histopathological grading of PC) is a good prognostic 
factor of PC-survival122-123, and a strong predictor of the natural history, to date, there are 
no prognostic parameters in biomaterials (urine, blood or prostatic tissue) that can 
predict the exact outcome of every PC. Prognostic models have been established by 
adding several features together. According to a prognostic nomogram, a man with the 
features of an organ-confined, less than 0.5 cubic centimeter and well-differentiated PC 
has a high chance of having an indolent tumor.124  
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In computerized simulation models, over-detection rates in PSA screening have been 
estimated to vary, depending on age span and screening algorithm, from around 15-40% 
(defined as the proportion detected through PSA screening, but who did not survive 
long enough to have their cancer clinically diagnosed, predicted by the simulation 
model, i.e. who were not estimated as dying of other causes during lead time)125 to up to 
50% (defined as the detection of irrelevant cancers, as the relative increase caused by 
screening, of the number of men with PC diagnosed during their lifetime).120  
     However, when trying to understand the potential implications for a man of being 
over-diagnosed, PC mortality has been suggested as being a more important end-point 
than disease incidence or symptoms of disease, especially when the benefit of early 
treatment in many men with screen-detected PC has not yet been clearly established.126 
Earlier work by McGregor et al. used PC mortality from the screening literature as an 
end-point for calculating over-diagnosis and estimated that 84% of screen-detected PCs 
might be over diagnosed.121 The proportion of screen-detected PCs today that will be 
potentially lethal within < 20 years will be an issue for further prospective research. 
 
Harms and benefits 
Even if screening has been demonstrated to be effective in reducing PC mortality, the 
major challenges are to minimize this potential over-diagnosis and frequent concomitant 
risk of over treatment, together with attempts to differentiate between potentially 
progressive and non-progressive disease.127 
    However, are the potential negative aspects from PC screening few enough and of 
such moderate magnitudes that screening can be justified – in the light of a reduced 
disease-specific mortality by 20% to up to 31% as now seen? Some authors have claimed 
that ‚even a modest 20% reduction in relative risk of suffering the atrocious 
consequences of metastatic disease and then dying from such a common cancer as PC is 
a worthwhile goal to consider‛.104  
    The debate surrounding PSA screening is still ongoing after the first reports. Studies 
with longer follow-up as well as more studies on the harms of screening are called for.  
 
1.6. Risk factors for prostate cancer 
Despite its being a common disease, the cause of PC is largely unknown. Several risk 
factors have been described128, of which the best documented are age129, ethnicity130,131 
and heredity93-94, 132. The incidence is 60% higher and the mortality rate is two-fold higher 
in black men compared to white men130. A man whose father was afflicted by PC has a 
higher risk of being diagnosed with PC than a man without heredity93. The risk is higher 
if a brother has the disease, and the younger the brother or the father was at diagnosis, 
the higher the risk94. Men with hereditary forms of PC are at increased risk of PC death, 
mainly because they are more likely to acquire the diagnosis before 70 years.  
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Sexually transmitted infections (STI) have been variably, but in prospective studies 
only borderline associated with the risk of PC.128 A retrovirus named XRMV, with a yet 
unclear route of transmission (blood or sexual transmission are plausible), has been 
linked to increased PC risk in genetically susceptible individuals.133  If PC is shown to 
be an infectious disease, targets for prevention could include information, physical 
barriers, vaccines, antiviral agents/antibiotics or other strategies. 
 
Geographic variability 
There are striking variations in the risk of PC and the risk of dying from PC by 
geographic area (Figure 5). The majority of PC cases are seen in developed countries and 
these differences are likely to be due to the combination of variations in diagnostic 
uptake, detection and registration as well as genetics, different dietary habits and 
different exposures to carcinogens. 
     Similar geographic variations apply to the mortality risk (Figure 6). Among 
developed countries, the age-adjusted mortality rate for PC is among the highest in 
Sweden (21.4 per 100,000 men, in year 2008)134, and among the lowest in Japan (5.0 per 
100,000 men. The U.S. age-adjusted mortality rate falls in between (9.7 per 100,000).  
     These differences, together with migrant studies, suggest that environment, lifestyle 
and dietary factors may play important roles in the development of clinically detectable 
PC. Studies of Japanese migrants to the U.S. show that the incidence increases with time 
spent in the migrant country (to an intermediate level between the original and the host 
population).135-136 Some of this change reflects diagnostic differences, but a proportion is 
certainly due to changes in environment and/or diet. Observational studies suggest that 
differences in dietary habits explain 30% of the variation in the risk of different cancer 
forms in the Western world, and that the most prevalent cancers; prostate, breast and 
colon cancer co-vary to a large extent.137      
     The international variations in incidence in men of similar ethnicity are compelling 
evidence that implies a potential for primary prevention. This, as compared to no 
prevention in a community, has been regarded as highly cost-effective by the National 
Board of Health and Welfare in Sweden9.  
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Figure 5. Prostate cancer incidence worldwide in 2008. Age-standardized incidence rates per 100,000. 
Dark colored areas have the highest incidence rates, with up to 173.7 per 100,000  
whereas the areas with the brightest color have the lowest incidence, less than 8.8 per 100,000. 
 
From Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:  
IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Prostate cancer mortality worldwide in 2008. Age-standardized incidence rates per 100.000. 
Dark colored areas have the highest incidence rates, with up to 61.7 per 100,000  
whereas the areas with the brightest color have the lowest incidence, less than 5.3 per 100,000. 
 
From Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:  
IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr 
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1.7. Primary prevention 
 
‚An ounce of prevention is worth a pound of cure.‛ 
Henry de Bracton, De Legibus (1240) 
 
This ancient and famous proverb was first recorded in Latin in 1240 and has been 
repeated ever since. PC is of great public health importance and its prevention would be 
a theoretically rational approach to diminish the patient-related, society- and health- 
related and economic impact of this disease. A couple of interesting primary prevention 
options have been suggested, however far they may be from being included in clinical 
practice today, 2010. A comprehensive review on the prevention of PC was published by 
Jayachandran et al. in 2008138.  
 
The androgen-prostate relationship 
It has long been suggested that androgens and androgen metabolites play a role in PC 
tumorigenesis and the relationship between androgens and the androgen receptor has 
been studied extensively139. Huggins was the first to study the androgen-prostate 
relationship. His pioneering work revolutionized the understanding of PC and heralded 
the era of drug therapy for PC, earning him the Nobel Prize in Physiology or Medicine 
in 1996140. In the original study from 1941141, Huggins and Hodges (his student) showed 
that PC was receptive to androgenic activity and that metastatic PC was inhibited by 
eliminating circulating androgens; either by orchidectomy or by means of 
administration of estrogens (the latter, however, soon used less frequently because of an 
observed increase in thromboembolic and cardiovascular events). There are few 
scientific articles that have had such an impact. Various antiandrogens and later the 
GnRH (Gonadotropin Releasing Hormone) agonists and antagonists were developed 
after this early work. However, more recent findings show that the cellular mechanisms 
are complex and some studies have shown no association between circulating levels of 
androgens and PC risk142-143 suggesting a more intricate effect on a receptor level. 
 
Chemo-preventives 
One primary prevention strategy on the androgen theme is based on the fact that 
inhibitors of the enzyme 5-alfa-reductase, 5ARI’s, that convert testosterone to the more 
potent androgen dihydrotestosterone, DHT, induce shrinkage of the prostate volume by 
approximately 30% in men with BPH. Studies of prostate biology support the concept 
that DHT is the principal androgen responsible for normal and hyperplastic growth of 
the prostate gland. The cancer transformation process involves cellular growth and 
division. Therefore, an altered endocrine state, such as the suppression of DHT activity, 
is hypothesized as having a preventive impact on prostate cells on the malignant 
transformation.144 Two 5-ARI’s have been investigated in randomized clinical trials145, 146. 
The Prostate Cancer Prevention Trial was initiated in the late 80’s in the U.S.  by the 
National Institute of Health147 in which a total of 18,000 healthy men > 55 years, with a 
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PSA ≤ 3 ng/mL and a normal DRE were randomized to either the 5ARI finasteride 
(5mg/day) or placebo (one matching tablet per day). After 7 years, a reduction in the 
period prevalence of end-of-study biopsy-proven PC of 25% was found, in favor of 
finasteride (the incidence of PC in the finasteride group was 18.4% as compared with 
24.4% in the placebo group).148  However, the initial enthusiasm for finasteride in 
preventing PC, was dampened by the finding of an increase in the proportion of high 
grade PCs (Gleason score ≥ 7, i.e. poorly differentiated PC, 37.0% in the finasteride 
group versus 22.2% in the placebo group, p <0.001). In the REDUCE study, focus was on 
high-risk men, 50-75 years old, with a PSA level between 2.5 – 10 ng/mL and with a 
previous negative prostate biopsy (6-12 cores).146 The study revealed a 23% reduced risk 
of incident biopsy-detected PC with dutasteride as compared to placebo over 4 years 
(95% confidence interval, 15.2 to 29.8, p<0.001). During the 4 years of the study, 659 of 
the 3,305 men in the dutasteride group (19.9%) and 858 of the 3,424 men in the placebo 
group (25.1%) received a PC diagnosis, corresponding to an absolute risk reduction with 
dutasteride of 5.1%. However, during year 3-4, there was a significant (p=0.003) increase 
in Gleason score 8-10 tumors (12 in the dutasteride arm versus 1 in the placebo arm).  
However, despite indications that 5-ARIs can reduce the incidence of PC, it is not yet 
known whether these drugs can affect PC mortality (or if they can only cause a delay in 
PC diagnosis).149 These medications can also adversely influence sexual function, which 
needs to be weighed against any potential benefits. The inhibition of the androgen 
receptors in BPH-cells and PC-cells differs and the biological impact is not fully clear. 
The impact on the risk of PC of introducing 5ARI’s to men who are being regularly 
screened is unclear. The effect of 5ARI’s in men who are already diagnosed with low-
risk, localized PC and are managed expectantly (see below) is being investigated.150  
 
Acetylsalicylic acid and vitamins 
Acetylsalicylic acid has been suggested as reducing the risk of being diagnosed with PC. 
Interests have also been raised in cyclooxygenase inhibitors, especially COX-2-
inhibitors. However, an observed increased risk in severe cardiovascular events resulted 
in that some of these were withdrawn from the market.151-153 
     There is some, as yet limited epidemiological evidence that sun exposure and vitamin 
D reduces the risk of PC.154-155 Epidemiologic evidence supports the hypothesis that 
tomatoes (lycopenes),156 selenium and vitamin E reduce the risk of PC. However, for the 
latter two, a phase III randomized placebo-controlled trial (SELECT) did not show any 
preventive effect of supplementation in a generally healthy population and was halted 
because of concerning trends of paradoxically increased risks of PC in the vitamin E 
group and type II diabetes mellitus in the selenium group (albeit statistically non-
significant).157 In the Physician’s Health Study II, neither vitamin E nor C 
supplementation reduced the risk of PC158. Overconsumption of multivitamins may be 
harmful, increasing the risk of advanced and fatal PC 159. 
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Diet, physical activity and lifestyle 
Some studies indicate that epidemiologic and pathologic links exist between BPH and 
PC. Recent publications support the hypothesis that both diseases may be part of the 
metabolic syndrome (a cluster of metabolic disturbances including glucose intolerance/ 
type 2 diabetes, dyslipidaemia, hypertension and central adiposity). Furthermore, 
inflammation of the prostate is also emerging as contributory to the development of 
both.160-161 Patients with clinical PC may have the same metabolic abnormality, of a 
defective insulin-stimulated glucose uptake, and hyperinsulinaemia as patients with the 
metabolic syndrome.162 The theory behind this is that hyperinsuliaemia leads to a 
decreased synthesis of IGFBP-1 in the liver and elevated concentrations of free IGF-1, 
which can be a potent mitogen of the prostate epithelium. High circulating IGF-I 
concentrations have been associated with an increased risk of PC in several studies163. 
Hyperinsulinaemia also contributes to higher levels of leptin, and higher serum levels 
have been associated with the later development of PC164. Hammarsten et al. have 
shown that men who died from PC had higher insulin levels than men who were still 
alive with clinical PC at follow-up. The insulin level has therefore been suggested for 
use as a marker of PC prognosis and tumor aggressiveness, regardless of the patient's 
PC stage, cancer grade and PSA level.165 A diet based on carbohydrates with low 
glycemic index (GI) and low glycemic load (GL) has been suggested as valuable in the 
primary prevention of PC since this diet keeps the insulin levels normal; the higher the 
GI and GL the higher the risk of PC.166 
     A high level of physical activity has also been suggested as being associated with a 
decreased risk of PC167; however, the epidemiologic evidence is inconsistent168-169 and the 
magnitude of the risk reduction observed is small.170 Smoking is also a suggested risk 
factor171, although studies diverge. 
     In a 2009 systematic review of the effect of diet in PC prevention and treatment, the 
recommended diet is one that is low in fat, high in vegetables and fruits, and avoiding 
high energy intake, excessive meat, and high dairy products and calcium.172 In the 2007 
report from the World Cancer Research Fund / American Institute for Cancer Research, 
the panel judged that foods containing lycopene and selenium are probably protective 
against PC whereas processed meat, milk and dairy products and foods containing 
calcium are thought to increase the risk. It is unlikely that beta-carotene has an effect on 
the risk. There is limited evidence suggesting that legumes including soya, foods 
containing vitamin E, and alpha-tocopherol supplements are protective.173  
It could be argued that a lifestyle that ensures overall well-being, that is also 
protective against cardiovascular diseases, overweight, hypertension and diabetes could 
be advised in the meantime, in the absence of evidence on the true benefits or harms of 
chemo-preventives and dietary/lifestyle modifications. A Paleolithic diet, i.e. one 
corresponding to foods that may have been consumed during the Paleolithic Period 
(‘Old Stone Age’, between 2,600,000 and 10,000 years ago), has been suggested as being 
protective against many of the diseases affecting the Western world.174 
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1.8. Secondary prevention - possibilities and problems 
 
Since knowledge about the etiology of PC is scarce, there is no given basis for primary 
prevention. Instead, in theory, the highest chance of successful cure today is through 
early detection (secondary prevention).  
 
Clinical presentation of prostate cancer 
Before the PSA era, PC was usually diagnosed when symptoms of locally advanced, 
regionally advanced or metastatic disease occurred, or when patients were investigated 
or treated for what was presumed to be benign disease175. PC most often grows in the 
peripheral zone of the prostate, whereas BPH grows in the transitional zone that is 
adjacent to the urethra, and thus gives lower urinary tract symptoms when the prostate 
becomes enlarged. Urinary symptoms such as hesitancy, poor stream, nocturia, 
frequency and urgency result from mechanical obstruction to the bladder outflow. 
About 80% of prostate tumors originate from the peripheral zone, which is distant from 
the urethra, and only 15-20% from the peri-urethral, transitional zone176. Early stage PC 
is therefore often a silent disease and bladder outflow obstruction a late event. Only 13% 
of patients with acute urinary retention have underlying PC177. As the disease 
progresses, some men can have symptoms such as urinary frequency or poor stream 
(lower urinary tract symptoms). Advanced PC can invade the urinary bladder, seminal 
vesicles and rectum and give rise to symptoms such as haematuria, haematospermia, 
perineal pain and rectal bleeding. Unexpected malaise or unrelenting bone pain in 
elderly men may suggest signs of metastatic disease.  
     Metastasized disease is often associated with severe morbidity and can be extremely 
painful when spread to the bones. Skeletal metastasis may, in the worst case, affect the 
spinal cord with compression resulting in paralysis of the legs and/or the urinary 
bladder, which is a feared condition that requires acute intervention. While historically, 
spinal cord compression was sometimes the first presentation of metastatic malignancy, 
early detection has made this rare. Today, PC is most often diagnosed early in the course 
of its natural history, many years before progression to skeletal metastases. The use of 
PSA has altered the presentation of PC, both of the initial disease state and of recurrent 
disease after treatment by earlier identification of failure through PSA monitoring.178 
 
Screening can alter the natural history 
Since the window for curative treatment is limited, screening for PC seems intuitively to 
be beneficial since it provides a way of finding the disease before the cancer cells have 
reached outside the prostate capsule and started to invade the surrounding tissues or 
have spread to the lymph nodes or already metastasized.  
     In its early stage, PC is a silent disease. By the time symptoms become present, the 
disease is generally more advanced and often the disease is too advanced to cure. This 
underlines a theoretical importance of screening, since it provides the only way to 
identify asymptomatic men with PCs that are completely curable. The fact that PC is 
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possible to treat and cure at an early stage, but impossible to cure when more advanced 
(although treatment in advanced stages of the disease can also affect prognosis, see 
below) makes a strong argument for screening. The metastatic staus at time of diagnosis 
has a profound impact on disease-specific survival; men with distant metastases at 
diagnosis have in general a poor prognosis with a median survival of 2.5 years.15 
     Early detection through screening provides an opportunity for curative treatment. 
The window of curability for PC is markedly decreased when the tumor is already 
greater than 1.5 cubic centimeter and even a significant level of small volume cancers 
exhibit extraprostatic extension179. Results of cancer control ten years after radical 
prostatectomy provide evidence that disease confined to the prostate is curable180. PC-
specific survival in organ-confined disease has been reported as being 94-98% at 10 
years85,181, 82%-90% at 15 years182-183 and 76% at 30 years.184 
 
High prevalence on autopsy 
The prevalence of latent PC is high. We know from autopsy studies that many men, 
dying from other causes, have cancer cells in their prostate glands. The earliest study 
from Johns Hopkins Hospital in the U.S., was published by Rich et al. in 1935185. In 292 
consecutive autopsies on males older than 50 years dying from a wide variety of causes, 
PC was found in 41 cases (14%). In 66% of these cases, the tumors were reported as not 
having been clinically recognized, but on autopsy, most often found near the outer 
margins of the prostate gland, and even when only a few millimeters in size, showed a 
tendency to invade the prostate capsule. Latent PC on post mortem examination has 
been shown to increase with age and also to vary with geography, with for example a 
low prevalence in China and a high prevalence in Sweden.186 More recent studies show a 
PC occurrence on autopsy of approximately 30-50% in males between 50-70 years129 (i.e. 
those subjected to screening in today’s trials). A recent study of incidental PC diagnosed 
in organ donors found PC in one in three men aged 60-69, and this increased to 46% in 
men over the age of 70187.  
 
What cancers are detected by screening? 
The high prevalence of latent PC on autopsy and the comparatively ‚low‛ incidence of 
clinical PC pose a risk of over-diagnosis with screening. A screening program risks 
detecting some PCs that might not be life-threatening, whose carrier would not benefit 
from treatment, but only suffer from side-effects. With screening, there is also a small 
risk (although much lower compared to the risk of detecting indolent cancers) of 
detecting aggressive, previously undetected tumors for which local treatment would be 
ineffective and curative treatment impossible.  
      Catalona et al. showed early, in 1993, that PSA screening identifies an increased 
proportion of organ-confined tumors (clinically localized) as compared to the evaluation 
for abnormal DREs. The PCs detected with PSA were of intermediate histological grade 
of tumor differentiation.12  
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Advanced disease is associated with high morbidity 
The risk of relapse after initial treatment with curative intent for locally advanced PC188, 
together with the morbidity and hospital care costs associated with advanced or 
metastasized diseases are other incentives for trying to detect PC at an early stage. The 
morbidity from advanced PC can be devastating for a man. Patients who fail deferred 
treatment consume a fair amount of health care resources (hospital care and palliative 
therapy) before they succumb from PC.189 We know today that PC screening can 
significantly reduce the absolute risk of being diagnosed with metastatic PC after 10 
years of follow-up108. We also know today that PC is a potentially hazardous disease, 
and even small tumors will eventually progress to metastatic disease if the patient lives 
long enough190. PSA screening can reduce these risks. 
 
1.9. Treatments for prostate cancer 
Various treatments for PC are available, either with curative intent or in palliative care 
depending on PSA level, tumor stage, Gleason score (the pathological grading), patient 
age, co-morbidities, remaining life-expectancy, symptoms, and other patient factors such 
as sexual function, anxiety et cetera.  
The assessment of the extension of the tumor (staging) is made by DRE, PSA, 
operative lymphadenectomy and bone scan, with the aid of computed tomography (CT) 
or magnetic resonance imaging (MRI) and chest X-ray in some situations. The clinical 
stage of the extent of the cancer spread is described by the TNM-classification;191 T – 
tumor, N – lymph nodes, M – metastases (table 1). Treatments differ for localized 
tumors (T1-T2, N0, M0), locally advanced tumors (T3-4, NX-N0, MX-M0), metastasized 
disease (T1-4, N1 or M1) and castration-resistant tumors.  
 
Table 1. TNM classification of prostate cancer stage85 
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Management and curative treatment options include radical prostatectomy (open 
retropubic, laparoscopic or robot-assisted as well as perineal), radiotherapy (dose-
escalated external beam radiotherapy or external beam therapy combined with either 
high-dose rate brachytherapy or radioactive seeds implantation), watchful waiting (with 
delayed palliative therapy), or active surveillance (with delayed treatment with curative 
intent). Early endocrine therapy can be an option for certain patients. Endocrine therapy 
(in different administrations and combinations with other treatment modalities) is 
reserved for patients with locally advanced tumors, at recurrence after surgery or 
radiotherapy and for primary metastasized disease. Postoperative endocrine treatment 
or radiotherapy can be administered adjuvant to surgery for tumors with positive 
margins or PSA recurrence. Palliative treatment also includes radiotherapy targeted at 
skeletal metastases and chemotherapy.85  
  
Two different forms of expectant management 
PC is almost unique among solid tumors in that a substantial proportion of patients may 
not need immediate treatment178. Two forms of management of PC exist that both entail 
expectation: watchful waiting (WW) and active surveillance (AS). Watchful waiting is a 
strategy for administering hormonal treatment when local or systemic symptomatic 
progression occurs, whereas the concept of active surveillance is fundamentally 
different in that it is a strategy for delivering curative treatment when pre-defined signs 
of progression occur (i.e. a short PSA doubling time or deterioration of Gleason score at 
repeat biopsy). Watchful waiting is also known as ‘deferred treatment’ or ‘symptom-
guided treatment’. This strategy emerged in the pre-PSA screening era (before 1990); at 
the time symptoms occurred, the patient would be treated with palliation including 
TURP or similar for urinary tract obstruction and hormonal therapy or radiotherapy for 
the palliation of metastatic lesions. Active surveillance is also known as ‘active 
monitoring’. It is a newer term developed in the past decade and includes an active 
decision to postpone immediate treatment and closely monitor the patient for signs of 
progression.85 Active surveillance candidates are often healthy and potentially fit for 
curative treatment while men under watchful waiting are often elderly men or men with 
co-morbidities and limited life-expectancy. The rationale behind watchful waiting was 
the observations that PC can progress slowly, and is diagnosed in older men in whom 
there is a high incidence of co-morbidity and related high competing mortality.85 
 
Watchful waiting 
Observation emerged as a therapeutic alternative in men with PC and a low risk of 
disease progression, based on the findings of Chodak et al.192 and Albertsen et al. (the 
latter reporting outcomes for men diagnosed in 1971-1984)193 that men with favorable PC 
face a low risk of death from PC within 15 years of follow-up. In the pooled analysis by 
Chodak et al. of 828 case records from six non-randomized studies (published between 
1985-1992) of men treated conservatively (with observation and delayed hormone 
therapy but no radical surgery or irradiation) for clinically localized PC, the disease-
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specific ten year survival was 87% for low grade tumors, but only 34% for grade III 
(high grade) tumors. The corresponding figures for metastasis-free survival were 81%, 
58% and 26% for grade I (low), II (intermediate) and III (high grade) tumors, 
respectively. These findings correlate with the register study by Lu-Yao et al. from the 
U.S. Surveillance, Epidemiology and End Results (SEER) database of the National 
Cancer Institute. The 10-year disease-specific survival was 92%, 76% and 43% for grade 
I, II and III tumors, respectively.194 Early cohort studies by Johansson et al. and 
Adolfsson et al., with patients diagnosed in the 70’s and 80’s, indicated a fairly good ten-
year natural history of initially untreated early-stage PC (watchful waiting), but with a 
high risk of death for patients with poorly differentiated tumors.34, 195  
The earliest natural history studies for PCs following conservative management by 
Chodak et al., Albertsen et al., Johansson et al. and Lu-Yao et al. demonstrated 10-year 
disease-specific survival estimates varying between 48-93% for moderately and well-
differentiated tumors whereas the corresponding figure for poorly differentiated tumors 
is reported to be 23-45%.192-194,196 Further follow-up (for initially untreated tumors), 
between 15-20 years, demonstrated a high risk of dying from the disease for GS 8-10197 
and for all tumors a disease-specific survival decreasing from 78.7% to 54.4% with 
time.198 The Albertsen studies show that GS 7-10 tumors carry a continuously increasing 
risk of ending the patients’ lives for up to 15-20 years after conservative management,85, 
193, 197 even when diagnosed at 74 years of age.193 
PC is a complex disease with an extraordinarily variable clinical outcome, with a 
natural history best predicted today by the histological Gleason scoring system, clinical 
stage and PSA-level at diagnosis. However, given sufficient time, PC is highly likely to 
progress to systemic disease and death unless there are competing causes of death. 
Patients with a life expectancy exceeding 10 years have been shown to have a higher 
mortality rate from PC (localized at diagnosis) when left without curative treatment190, 
199-200. In a population-based prospective Swedish study, Aus et al. found a 56% 
cumulative risk of dying from PC after 15 years of follow-up (in a setting where active 
screening was not advocated).199 
 
Active surveillance 
The approach using active surveillance was first proposed by Klotz in 2005201, as many 
‚good risk patients‛ were believed to be over treated. Active surveillance can be suitable 
for men with low risk disease: localized tumors T1c-T2a, Gleason score ≤6 and PSA <10 
ng/ml202. Since there seems to be a window of curability for patients with favorable risk 
disease, radical treatment can be initially withheld, but is still an option over time with 
this strategy (as opposed to watchful waiting). Patients with clinically low-risk PC under 
an active surveillance program are, as the name implies, monitored closely under a strict 
follow-up protocol with repeated PSA measurements and prostate biopsies. They are 
offered delayed curative treatment when the PC is reclassified as a high-risk tumor over 
time, based on biochemical or pathologic progression of the disease. 
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     Active surveillance is evolving as a therapeutic strategy with the aim of decreasing 
the burden of therapy in patients with indolent disease, while providing definitive 
therapy for those with biologically active disease.203 The expectations behind active 
surveillance are to minimize the risk of over treatment of indolent tumors (as with early 
invasive treatment) and minimize the risk of under treatment of advanced tumors (as 
with watchful waiting). 
      Screening for a cancer without offering an active intervention may seem to be a 
contradiction and to involve an ethical dilemma. However, expectant management with 
active surveillance is becoming a more commonly used option today. This concept is 
now being tested in large-scale trials, but this far, only < 10 year data are available.  
One of the first large prospective trials was initiated in 1995 by Klotz et al. In a recent 
report of this cohort of 450 patients, with a median follow-up of 6.8 years (range 1–13 
years) overall survival was 78.6% and the 10-year PC actuarial survival was 97.2%. 
Overall, 30% of patients were reclassified as being at higher risk and were offered 
definitive therapy. Of 117 patients treated radically, the PSA failure rate was high at 
50%.204 This reinforces the importance of close monitoring and of definitive treatment for 
those in whom disease is reclassified as higher risk over time205.  
Results from the ERSPC trial on 616 men diagnosed between 1994 and 2007 (PSA ≤ 10 
ng/ml, PSA-density ≤ 0.2 ng/ml per ml, stage T1c/T2, GS ≤ 3+3 = 6, and ≤ 2 positive 
biopsy cores) have shown a calculated 10-year PC-specific survival for men on active 
surveillance of 100% (median follow-up 3.9 years). The calculated treatment-free 
survival was low at 43%.206  
     Receiving a screen-detected PC diagnosis and not electing to have definitive 
treatment, can be a choice, according to Klotz, based on five postulates207: 1) Screen-
detected PC may be clinically insignificant (will not pose a threat to the man’s health), 2) 
Patients selected to active surveillance can be identified with reasonable accuracy, 3) No 
treatment lacks side-effects, 4) Patients with low risk reclassified as high risk over time 
can be radically cured in most cases, 5) The psychological burden of living with 
untreated PC may have less impact on quality of life than early therapy.     
     Fears have been raised that anxiety will result from a cancer diagnosis and that some 
men cannot be dissuaded from immediate treatment. However, recent work from North 
America and the Netherlands suggest that this need not be the case. Burnet et al. 
concluded that active surveillance for managing localized PC was not associated with 
greater psychological distress than more immediate treatment.208 van den Bergh et al. 
showed that men on active surveillance report even favorable levels of anxiety and 
distress as compared to men who underwent other treatments for localized PC209. 
Another study suggests no difference in anxiety between active surveillance and 
radiotherapy208. The ongoing randomized trials worldwide will provide further 
knowledge on effective treatment options for PC. 
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Expectant management of PSA-detected tumors 
The natural history of today’s PCs that are more often PSA-detected is not fully 
understood. Lead-time bias refers to the time interval by which PC is detected by 
screening as compared to the clinical detection. It may seem that screening prolongs life, 
when, in some cases, only the observation time is prolonged. Therefore, comparing 
survival between screen-detected tumors and clinically detected tumors can be difficult.  
     In a recent observational study, the National Prostate Cancer Register (NPCR) of 
Sweden follow-up study, including men aged ≤ 70 at diagnosis, local tumor stage T1-2, 
NX or N0, MX or M0, and PSA < 20 ng/mL, Stattin et al. reported a cumulative 10-year 
PC–specific mortality for men with low-risk PC of 2.4% (95% CI = 1.2% to 4.1%) among 
1,085 patients on conservative treatment and 0.7% (95% CI = 0.3% to 1.4%) among 1,601 
patients who received treatment with curative intent. The 10-year risk of dying from 
competing causes was 19.2% in the surveillance group and 10.2% in the curative intent 
group, indicating that patients with a short life expectancy were more often selected for 
surveillance than for surgery or radiation therapy. Conservative treatment (coded as 
‚expectancy‛ in NPCR) included both active surveillance and watchful waiting. 
Another limitation of the study was the median follow-up time of 8.2 years. Many 
patients currently diagnosed with localized PC at age 60–70 have a life expectancy of 
more than 15 years. A low 10-year disease-specific mortality of only 3% for surveillance 
makes this regimen suitable for many men with low-risk disease; however, longer 
follow-up is awaited.210 
 
Radical prostatectomy 
The approach of treating PC by means of surgery was first applied by Billroth who 
performed the first perineal prostatectomy in the 1860’s211 and later by Young in the 
beginning of the 20th century212. Initially, radical prostatectomy (RP) was performed 
primarily for palliation. In 1931, transurethral prostatic resection became available and 
was adopted as a palliation for obstructive PC.7 The first prostatectomy with a radical 
retropubic approach was performed by Millin in 1945. However, the procedure was 
associated with high mortality and morbidity; severe urinary incontinence, erectile 
dysfunction and stricture of the vesicourethral anastomosis. Many of the tumors were 
detected at a late stage.213 With the discovery of the PSA, this was dramatically changed 
when prostatectomy could be regarded as a means of successfully treating PC detected 
at an early stage. During the 1970’s, efforts were initiated to decrease the per- and 
postoperative complications. In 1982, Walsh described the detailed anatomy of the 
prostate gland, the dorsal venous complex and the existence and function of the neuro-
vascular bundles214. These pioneering efforts helped in modifying the radical retropubic 
surgical dissection of the prostate215 and led to improvements in postoperative 
continence and potency as well as reducing perioperative mortality. Further 
modifications and improvements in surgery, anesthesia and pre- and postoperative care 
have been made throughout the years, with a concomitant decrease in complication 
rates216. RP is the gold standard of treatment for localized PC; however it is not clear 
  
43 
 
which technique is superior in terms of oncological and functional results and cost-
effectiveness85. RP can be performed either as open retropubic surgery, laparoscopic or 
robotic-assisted laparoscopic surgery as well as perineal. Observational studies have 
compared the outcomes of these modalities217, but no RCT exists to date. 
    Consistent with increased diagnostic activity, especially testing with PSA, the 
incidence of PC in Sweden has risen rapidly today, as have rates of treatment with 
curative intent.218 In 2006, more than 2,000 radical prostatectomies were performed219. 
 
The VACURG study 
Early treatment with radical prostatectomy has been evaluated in both RCT’s and 
observational studies. In 1995, Iversen et al. reported on the 23 year follow-up from the 
Veterans Administration Cooperative Urological Research Group (VACURG), an RCT 
comparing radical prostatectomy with watchful waiting between 1967 and 1975 in the 
U.S. However, this study was relatively small (underpowered to detect treatment 
differences) and vital status was assessable for only 111 of the 142 men. The tumors were 
classified as clinical stage I or II (clinically localized or locally advanced); however, 
staging was simplified which could also have affected the outcome. This study could not 
demonstrate any difference in overall survival.220  
 
The SPCG-4 study 
A decade later, a larger RCT was able to report on the benefits of early treatment. This 
Scandinavian study (SPCG-4) conducted by Holmberg et al., randomized (in 1989-99) 
695 men with clinical stage T1-2 tumors; 348 men to watchful waiting and 347 men to 
radical prostatectomy. Men in the watchful waiting group received no immediate 
treatment, but underwent transurethral resection if sign of obstructive symptoms 
occurred. Both groups received hormonal therapy if metastases were confirmed. The 
hormonal therapies used were mainly orchiectomy or gonadotropin-releasing hormone 
analogs as lifelong therapy. During a median of 10.8 years of follow-up, radical 
prostatectomy significantly reduced the risk of local progression (RR = 0.36, 95% CI  0.27 
- 0.47; P < .001), the risks of metastasized disease (RR 0.65, 95% CI 0.47 - 0.88; P = .006) 
and disease-specific mortality (RR 0.65, 95% CI = 0.45 - 0.94; p = 0.03).114 At a median of 
8.2 years of follow-up the difference between the two arms in overall mortality rates was 
statistically significant221, but not at 10.8 years for all ages – however it was significant 
for men < 65 years (RR 0.59, 95% CI 0.41 - 0.85, p=0.004)114. The results from this 
landmark study showed that, at 12 years, the absolute reduction in the risk of PC death 
was somewhat small, 5.4% (12.5% in the surgery group vs. 17.9% in the watchful 
waiting group had died of PC), however, the reductions in risks of local tumor 
progression and metastases were larger (19.3% of men in the surgery group vs. 26% of 
men in the watchful waiting group had been diagnosed with distant metastases).114 The 
number needed to treat, NNT, to ‚cure‛ a single case of PC with radical prostatectomy 
compared to watchful waiting was calculated at 10-19.  
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Observational studies 
In 2001, Barry et al. reported 10-year survival outcomes in a retrospective cohort study 
including 2,311 men aged 55-74 diagnosed with non-metastasized PC between 1971-
1984 and who were managed with either radical prostatectomy, external beam therapy 
or observation. Kaplan-Meier estimates for disease-specific and overall survival were in 
favor of radical prostatectomy (86% for disease-specific mortality, 95% CI, 84-88% and 
69% for overall survival, 95% CI, 67-71%) and lowest for men who underwent 
observation.222  
In 2006, Wong et al. reported overall and cause-specific mortality results from an 
observational cohort study (in more than 44,000 men) using data from the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program and 
Medicare that compared initial treatment (radiation therapy or radical prostatectomy) 
with observation in men aged 65–80 with low and intermediate risk localized PC. At 12 
years of follow-up, men who received active treatment had statistically significant 
improvements in overall and PC specific mortality versus men who underwent 
observation (37% vs. 24% deaths).223 However, non-randomized studies should be 
interpreted with caution, since they can be subjected to selection bias in that men who 
select these alternative management strategies have different characteristics. 
 
Radiotherapy 
Radiation therapy (RT) has been used since the 1960’s for the treatment of PC. 
Modifications throughout the years have been focused on concentrating the radiation 
energy to the prostate and minimizing the toxicity to the surrounding organs (urinary 
tract and bowel toxicity).224 A number of different radiation techniques are available 
today, including external beam radiation therapy or brachytherapy (high-dose rate 
brachytherapy or seeds implants). A combination of external beam radiotherapy and 
high-dose rate brachytherapy seems to provide favorable results as regards biochemical 
control as compared to external beam radiotherapy alone225 or in combination with 
radioactive seed implantation.226  
     According to the National Institutes of Health (NIH) consensus, external beam 
radiotherapy offers similar long-term survival as surgery and equal quality of life.85,227  
     In 2009, Widmark et al. reported the results from the SPCG-7-study, a randomized 
trial comparing endocrine therapy with and without local radiotherapy, followed by 
castration on progression. For men with locally advanced or high-risk local PC (T3; 78%; 
PSA < 70 ng/ml; N0; M0), the addition of local radiotherapy to endocrine treatment 
(three months of total androgen blockade followed by continuous endocrine treatment 
with flutamide) halved the 10-year PC-specific mortality and decreased overall 
mortality with an acceptable risk of side-effects compared with endocrine treatment 
alone. The cumulative 10 year prostate-cancer-specific mortality was 23.9% in the 
endocrine alone group and 11.9% in the endocrine plus radiotherapy group (difference 
12.0%, 95% CI 4.9-19.1%).228 
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     In a meta-analysis of randomized trials, Bria et al. concluded that hormone treatment 
added to radiotherapy significantly decreases biochemical failure and clinical 
progression-free survival for men with locally advanced PC.229  
 
Endocrine therapy 
Endocrine therapy is mainly used in patients with advanced PC, incurable disease, in 
delaying clinical progression and in reducing symptoms in men with metastasized 
disease. The principle behind this is that the elimination of androgens from the testes 
has inhibitory effects on PC cells. This elimination can be achieved by means of 
surgically removing the testes, by inhibiting the gonadotropin secretion from the 
pituitary gland that normally stimulates the testes (GnRH-agonists or antagonists), or by 
estrogens reducing the secretion of GnRH from the hypothalamus. Antiandrogens block 
the effect on the receptor level.  
In recent years, early hormonal treatment has been shown to have benefits even at 
some of the earlier stages of the disease. Messing et al. have shown that immediate 
antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy 
improves survival and reduces the risk of recurrence in patients with node-positive 
PC.230 For men with locally advanced PC, the study by Bolla et al. in 2002 showed that 
immediate (early) androgen suppression with a GnRH analogue given during and for 3 
years after external beam radiation improves disease-free and overall survival.231  
     The antiandrogen bicalutamide can be used either as monotherapy or adjuvant to 
standard therapy. A large randomized trial (SPCG-6) within the Early Prostate Cancer 
(EPC) program evaluated endocrine therapy with bicalutamide (150 mg/day) in addition 
to standard care (radiotherapy, radical prostatectomy or watchful waiting; the majority 
were followed conservatively).232 For men with locally advanced disease, the study 
showed that endocrine therapy in addition to standard care improved overall survival, a 
significant reduction in the risk of death of 35% (HR 0.65; 95% CI 0.50 – 0.85; p = 0.001) 
relative to standard care alone, as well as progression-free survival, a reduction in the 
risk of progression by 53% (HR 0.65; 95% CI 0.55 – 0.76; p < 0.001) compared with 
standard care alone, after a median of 7.1 years of follow-up.. PC mortality was lower in 
the bicalutamide plus standard care group (25.5% as opposed to 34.8% in the standard 
care alone group). This was reflected in the overall survival. However, these benefits 
were not seen in men with localized disease. Instead, primary antiandrogen therapy for 
localized PC may result in worse outcomes for these patients.  
Lu-Yao et al. have reported that patients with localized PC (T1-T2) have a lower 10-
year PC-specific survival with primary androgen deprivation therapy compared with 
conservative management. However, a subgroup of men with poorly differentiated 
cancer had improved PC-specific survival with the same treatment (but no effect on 
overall survival).233  
It thus seems that endocrine therapy should mainly be withheld until there is proof of 
disease activity, but whether to deliver it before the patient develops metastatic disease 
is yet uncertain85. 
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Side-effects from treatment 
All treatments for PC at different stages have side-effects. Major improvements in 
curative therapy have been made during the past three decades and the risk of side-
effects has fallen. Early invasive therapies with curative intent seem to offer equivalent 
tumor control, but the spectrum of acute and late side-effects differs178. Today, radical 
prostatectomy is a less invasive procedure with lower morbidity, providing good 
control of clinically localized PC and with a 10-year PC-specific survival rate of 95%.181 
The main side-effects include erectile dysfunction, urinary incontinence and a lesser risk 
of stricture of the vesico-urethral anastomosis234. However, some men can have erections 
with medications such as oral PDE5-inhibitors or intra cavernosal, or intra urethral 
injections. Men reporting severe incontinence are few, but complete urinary leakage can 
adversely and tremendously affect a patient’s quality of life.  In the most severe cases, 
this condition needs surgical implantation of an artificial sphincter or other strategies.  
Side-effects from radiotherapy include erectile dysfunction, increased frequency of 
micturition, urge urinary incontinence, strictures and bowel disturbances (diarrhea, 
rectal bleeding or fistulae). Long-term side-effects include secondary cancers (bladder 
and rectal), hip fractures as well as proctitis and post-radiation hemorrhagic cystitis 
which may have a huge negative impact on the patient’s quality of life. 
     The most bothersome permanent side-effects after radical prostatectomy are urinary 
incontinence and erectile dysfunction235. In reviews, the incidence of post-prostatectomy 
potency rates has varied between 11%-87%236-237 and post-prostatectomy incontinence 
between 0%-87%236-240. At 52 months after radical prostatectomy, 88% have been reported 
to suffer from erectile dysfunction and 31% from urinary leakage, while the 
corresponding figures for external beam radiotherapy is 64% and 13%, respectively, and 
in the latter group there is also a marked effect on bowel function and bowel bother 
scores.241 Long-term PC survivors have reported even better health-related quality of life 
(HRQL) scores compared with a control group of men without cancer (radical 
prostatectomy patients had the highest HRQL, followed by watchful waiting, 
radiotherapy and with the lowest scores for patients receiving hormonal treatment).242   
     Adjuvant hormone therapy is reported to be associated with worse outcomes across 
multiple quality of life domains among patients receiving brachy- or radiotherapy.243 For 
hormone therapy, there are, unfortunately, many side-effects. GnRH agonists are 
associated with loss of potency and libido, nausea and vomiting, hot flushes, weight 
gain, osteoporosis, energy loss and mental disturbances. GnRH agonist treatment is 
preceded by a couple of weeks of antiandrogens to avoid the initial ‚flare up‛, an 
increase in testosterone levels and risk of deterioration of the disease. In patients with 
advanced disease, the surge in testosterone can lead to flare-up of tumor growth that 
can cause urethral obstruction, bone pain and spinal cord compression. Antiandrogens 
can be combined with GnRH agonists (total androgen blockade) or orchiectomy, or can 
be given as monotherapy. The main side-effects associated with antiandrogens are the 
risk of gynecomastia (breast development) and breast tenderness or pain. A single dose 
prophylactic radiotherapy of the breast can decrease these risks.244  
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1.10. The WHO-criteria for introducing screening 
In 1968, ten criteria were set up by Wilson and Jungner, on behalf of the WHO, that need 
to be met to justify population-based screening for any disease, in general:245-246  
 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognizable disease. 
3. Facilities for treatment and diagnosis should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared disease,   
should be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed)                     
should be economically balanced in relation to possible expenditure on medical care as a whole. 
10. Case-finding should be a continuing process and not a ‚once and for all‛ project. 
 
Notably, evidence from randomized screening studies was not part of these criteria. Nor 
were ethical issues such as over-diagnosis and over treatment discussed. A review 
exploring these ten criteria was published by Postma and Schröder in 2005.107 
 
1.10.1. Criterion 1 – An important health problem 
 
‚The condition sought should be an important health problem.‛ 
 
In Sweden, PC is the most common cancer form in men and also the most common 
cause of cancer-related death in men10. Approximately 5-6% of all men who die each 
year in Sweden succumb to PC. Every year, 2,500 men die of the disease in Sweden (as 
compared to 1,500 women dying from breast cancer and 500 people dying in traffic 
accidents). There is no doubt about the importance of this disease. Advanced PC is 
associated with low quality of life and expensive health care, even among elderly men. 
The fact that PC is a major health problem, associated with significant morbidity and 
mortality satisfies the first criterion for mass screening. 
 
1.10.2. Criterion 2 – Treatment and side-effects  
 
‚There should be an accepted treatment for patients with recognizable disease.‛ 
 
As illustrated in the previous section (see 1.9.), the summary of evidence clearly 
indicates the advantages of early treatment in all stages of the disease: for localized, 
locally advanced, and metastasized disease. Complications from the various treatments 
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are also dependent on the stage of the disease. The SPCG-4 study demonstrated a 
significant effect on overall mortality at 10.8 years for men < 65 years with localized PC 
in favor of radical prostatectomy.114 Although this study was very well carried out, it is 
unclear whether these results can apply to today’s Western male populations, who are 
diagnosed more often by PSA testing contrary to the population in this study (in which 
only 5.2% were screen-detected tumors and 74-78% of tumors were T2, i.e. palpable).  
The effect on screen-detected tumors remains to be established from ongoing trials. 
An RCT began in 1994 and is addressed at comparing radical prostatectomy with 
watchful waiting for clinically localized PC (stage T1-2), as in SPCG-4, but of which 75% 
were detected by PSA elevation or rise: the U.S. Prostatectomy Intervention Versus 
Observation Trial.247 The Prostate Testing for Cancer and Treatment began in 2001 and is 
a 3 arm RCT in the U.K. comparing radical prostatectomy with external beam 
radiotherapy or active surveillance for clinically localized PC detected through PSA 
testing.248 The Standard Treatment Against Restricted Treatment (START), lead by the 
National Cancer Institute of Canada, enrolls men in Canada, the U.S. and the U.K., and 
will compare early interventions, determined by patient or provider preference to active 
surveillance with delayed intervention.202 SPCG-4 was the first RCT that assessed long-
term outcomes of modern PC care. PIVOT will soon contribute information in men with 
PC detected early in the PSA era. ProtecT and START will increase this knowledge for 
men diagnosed later in the PSA era and investigate active surveillance regimens. Or as 
expressed by Wilt in 2008: ‚The SPCG-4 provided a needed START to PIVOTal data to 
promote and ProtecT evidence-based PC care.‛249 
     Studies assessing the side-effects from treating screen-detected as opposed to 
clinically diagnosed tumors are also called for.  
 
1.10.3. Criterion 3 – Facilities 
 
‚Facilities for treatment and diagnosis should be available.‛ 
 
At present, resources for general screening (‚screening clinics‛ including the complete 
‚urological arsenal‛) are not available in Sweden, not even in the major cities. Whether 
enough facilities for treatment/management of men with screen-detected PCs in a 
situation in which more men undergo screening is already available (pathologists, 
urologists, oncologists, nurses et cetera) is difficult to estimate today.  
 
1.10.4. Criterion 4 – Latency  
 
‚There should be a recognizable latent or early asymptomatic stage.‛ 
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From autopsy studies, we know that there is no doubt about the existence of a latent 
stage (see above). Almost 30-50% of men in the 5th to 7th decade harbor cancer cells in 
their prostate glands129. PC most often has a long preclinical stage; a prerequisite that 
optimizes the detection of the cancer long before signs of symptoms. The potential of 
finding PCs at an early stage, while they are still curable, has proved to be highly 
efficient with PC screening250. Results from the Göteborg randomized population-based 
PC screening trial show that with 10 years of follow-up, the risk of being diagnosed with 
metastatic PC is reduced by 48.9% (decreasing from 47 cases in the control group to 24 
cases in the group randomized to screening).108 However, the fact that PC can have a 
long latent stage is also associated with a risk of over-diagnosis, which in turn can entail 
a risk of over-treatment.251  
     
1.10.5. Criterion 5 – Test  
 
‚There should be a suitable test or examination.‛ 
 
The ideal screening test should be available, acceptable, minimally-invasive, accurate 
and affect the outcome of the disease8. However, no such diagnostic test exists today.  
     The ability to find a cancer through a simple blood test is a remarkable achievement, 
in itself, and the PSA test is probably one of the most accurate screening tools that exists 
today. Today, PSA is one of the best and most frequently used tumor markers. PSA in 
combination with digital rectal examination, i.e. palpation of the prostate and trans-
rectal ultrasound (TRUS) with prostate needle biopsies, give a high number of detected 
PCs. Although the specificity and sensitivity of the modalities are good, but not ideal 
(see above), repeat screening with PSA is sufficient to find most early cancers while they 
are still curable250. TRUS guided prostate biopsy is nowadays the gold standard for the 
diagnosis of PC. The suspicion of PC is usually raised in connection with an elevated 
PSA or an abnormal digital rectal examination, which both have a rather low 
specificity.88 The positive predictive value in the ERSPC study is reported to be 24% (i.e. 
the proportion of men with a ‘positive’ test result who actually have the disease).39, 66 The 
PSA test is a simple and inexpensive diagnostic test. It also has the sensitivity to 
diagnose PC (with repeated testing) before symptoms with almost 99%.250, 252  
 
1.10.6. Criterion 6 – Acceptability  
 
‚The test should be acceptable to the population.‛ 
 
PSA is a simple and safe blood-test, acceptable to almost any man. The PSA test and the 
DRE take only a few minutes to perform, and involve minimal discomfort. In the PLCO 
study, DRE was rarely associated with pain or bleeding (0.3 per 10,000 screened). The 
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PSA blood test was associated with dizziness, bruising and hematoma in 26 per 10,000 
screened and fainting in 3 per 10,000 screened. Although the TRUS-guided prostate 
biopsy procedure itself is considered unpleasant by some men, the majority of screened 
men with a positive screening test regard it as acceptable253 and are willing to undergo a 
repeated biopsy if needed254. In the PLCO, complications from prostate biopsies 
included infection, bleeding, clot formation and urinary difficulties in 68 per 10,000 
diagnostic evaluations.40  
 
 
1.10.7. Criterion 7 – Natural course  
 
‚The natural history of the condition, including development from latent to declared disease, 
should be adequately understood.‛ 
 
As indicated in the previous section (1.9.) current knowledge of the natural history of PC 
is limited to clinically diagnosed cases, whilst little is known about the natural history of 
screen-detected PCs. We do not yet know how many screen-detected PCs might have 
caused death if left undiagnosed and untreated. In a recent observational study, Stattin 
et al. reported a cumulative 10-year PC–specific mortality of 2.4% for men with low-risk 
PC (local stage T1a, b, or c and GS 2-6 or World Health Organization grade I-II and a 
PSA level <10 ng/mL) on expectant management (as compared to 0.7% for men with 
low-risk PC treated with radical prostatectomy or radiotherapy).210 
 
1.10.8. Criterion 8 – Whom to treat 
 
‚There should be an agreed policy on whom to treat as patients.‛ 
 
There are various forms of treatment for PC depending on a number of patient-related 
and tumor-related factors, including patient age and tumor characteristics (see above). 
Level 1 evidence exists for some strategies, although outcomes for screen-detected 
tumors are fewer. Active surveillance for favorable-risk tumors is being evaluated. It is 
hoped that major randomized trials (apart from the ERSPC and PLCO) will provide 
more evidence on treatment options for screen-detected PC (see above). There is no 
consensus on whether there is a group with very small lesions that do not need at least 
immediate treatment. The optimal time for when men with early screen-detected PC 
should be treated to provide a balance between curability and overtreatment is not 
established. 
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1.10.9. Criterion 9 – Costs 
 
‚The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole.‛ 
 
Results from Norrköping and Göteborg show acceptable costs for a screening program 
for PC. Sennfält calculated that the economic consequences of implementing a 
nationwide PC screening program in Sweden would mean additional costs (added to 
the health care costs for PC) of approximately 30%. Sennfält also calculated that a PC 
screening program could be regarded as cost-effective if potentially curable PC patients 
would gain at least one year of survival in good health.255 Cost-benefit and cost-
effectiveness calculations are under way within the ERSPC. 
 
1.10.10. Criterion 10 – Case-finding 
 
‚Case-finding should be a continuing process and not a ‘once and for all’ project.‛ 
 
After a mean follow-up of 8.8 years, the ERSPC trial showed a 20% reduction in PC 
mortality in the core age group of men aged 55 to 6939.  Repeated PC screening (‘a 
continuing process’) is currently favored over a once-only screening (‘once and for all’). 
However, the optimal screening algorithm and screening interval remain to be decided. 
There is also a lack of knowledge about which age to start and which age to stop. 
 
1.10.11. Conclusions on the ten WHO-criteria 
To sum up, when examining the ten criteria put forward by Wilson and Jungner, we can 
conclude that the majority of the requirements are fulfilled today. The sum of evidence 
for introducing screening for PC is not weaker than the evidence for screening for breast 
cancer with mammography. 
 
 There is no doubt that PC is an important major public health problem (criterion 1).  
 Effective treatments are available (criterion 2) and early treatment seems more 
beneficial than delayed treatment at all stages of the disease; however, none are 
free of side-effects.  
 Resources for a nationwide screening are unavailable today (criterion 3).  
 There is undoubtedly a latent stage of the disease (criterion 4). Although PC 
screening introduces a beneficial stage migration, it may also increase the incidence 
of non-significant tumors. 
 The PSA test is a suitable screening test for PC (criterion 5). Although it has a non-
optimal specificity, it is probably the most accurate PC screening test currently 
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available. The ideal test would be such that it could distinguish between significant 
and non-significant PC107.  
 The screening procedures, with DRE, the PSA test and TRUS-guided prostate 
biopsies in screen-positive subjects, are acceptable to the general male population. 
Complications connected with the procedures are limited (criterion 6).  
 The understanding of the natural history of screen-detected PC is not fully known 
today (criterion 7).  
 There is a policy, albeit somewhat controversial, of whom to treat as patients. 
Research is being continuously conducted on this issue, especially on early, screen-
detected PCs (criterion 8).  
 The costs of a screening program could be acceptable (criterion 9); however, cost-
effectiveness calculations are under way.  
 Current evidence suggests that case-finding should be a continuing process rather 
than a ‘once and for all’/’one single screening’ project. Repeated PC screening is 
currently favored (criterion 10), however the optimal interval/algorithm remains to 
be established. 
 
However, although these criteria are still regarded as ‘classics’, they may not be fully 
applicable to today’s health care256. However, Wilson and Jungner never expected their 
criteria to remain unchanged over time: ‚If anywhere we have appeared dogmatic, we 
hope this may serve to stimulate discussion, since, in the end, real development depends 
on an exchange of views.‛256 
     In 2008, Andermann et al. made a synthesis of emerging screening criteria proposed 
over the past 40 years that resulted in the following ten criteria: 
 
1. The screening program should respond to a recognized need. 
2. The objectives of screening should be defined at the outset. 
3. There should be a defined target population. 
4. There should be scientific evidence of screening-program effectiveness. 
5. The program should integrate education, testing, clinical services and program management. 
6. There should be quality assurance, with mechanisms to minimize potential risks of screening. 
7. The program should ensure informed choice, confidentiality and respect for autonomy. 
8. The program should promote equity and access to screening for the entire target population. 
9. Program evaluation should be planned from the outset. 
10. The overall benefits of screening should outweigh the harm. 
 
     These modern criteria for early detection thus focus more on positive health 
outcomes balanced against side-effects and potential negative aspects, as well as taking 
into account equality issues, informed choice and the respect of each individual’s 
autonomy and freedom to make choices about participation. Using these newer criteria, 
it is still unknown whether the overall benefits outweigh the harms. Cost-benefit and 
cost-effectiveness analyses are under way. The potential negative and ethical aspects of 
PC screening need to be taken into consideration. 
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1.11. Other cancer screening programs  
Cervical cancer screening 
Globally, cervical cancer is a common disease and a common cause of cancer-related 
death among females. In the 1950’s, cervical cancer was a common female cancer also in 
Sweden, but with the introduction of an organized, nationwide cytological 
Papanicolaou (Pap) smear257 screening program in the 1960’s, the incidence rate of 
invasive cervical cancer declined, as did disease-specific mortality. Between 1965- 1982, 
cervical cancer mortality fell by 34%.258 Today, although never examined in a 
randomized controlled trial but based on solid evidence from observational studies, 
regular screening with the Pap test markedly reduces mortality from cervical cancer by 
80%.259 However, this screening is also associated with harms, false-positives, additional 
diagnostic procedures and treatment for low-grade squamous intraepithelial lesions 
(LSIL), which in turn can have long-term consequences for fertility, pregnancy and 
sexual quality of life. Two vaccines against the most common human papilloma virus 
strains (that cause the majority of cervical cancer cases) have recently (in 2006 and 2007) 
been developed for primary prevention, targeted at young girls (10-12 years) and 
subsidized by the Swedish government. 259 
 
Breast cancer screening 
Breast cancer today is the most common cancer form among Swedish women and the 
second leading cause of cancer-related death among Swedish women after lung cancer4. 
Each year, approximately 7,000 women get the diagnosis and 1,500 die from the disease 
in Sweden10. To date, a variety of estimates of the benefits and harms of mammography 
screening for breast cancer around the world have been published. The most reliable 
results come from RCT’s, many of which have been carried out in Sweden.  
     In 1977, a trial to investigate the efficacy of mass screening with single-view 
mammography was established, the so-called WE-study (‚Östergötland/Kopparbergs-
studien‛). The study included over 130,000 women aged 40-74. With a follow-up to the 
end of 1984, it showed a 31% reduction in breast cancer mortality and a reduction in 
more advanced breast cancers in the screening group.260 Therefore, in early 1985 when 
these results were published, the National Board of Health and Welfare in Sweden drew 
up guidelines for general screening with mammography. At that time, a few other 
studies existed indicating a benefit from mammography screening.261-263 A survey of five 
of the early randomized mammography screening trials in Sweden was presented in 
1993 by Nyström et al., including over 270,000 women in total. The estimated reduction 
of breast cancer related mortality was 24% among those invited to mammography 
screening. The largest reduction in breast-cancer mortality (29%) was seen in the age 
group between 50-69 at randomization, whereas among women in the oldest age group 
between 70-74 screening seemed to have only a marginal impact.264  
     The scientific basis for the decision-making at that time was not stronger than the 
evidence is for PC screening today. Gradually, screening was established throughout 
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Sweden and became nationwide in 1997. Later, the reduction in breast cancer mortality 
seen in the W-E trial has been shown to remain consistent over long-term follow-up265.  
     In a review of eight randomized trials of mammography screening conducted up to 
2004, Smith et al. concluded that the trials provided conclusive evidence that the policy 
of offering screening was associated with a significant and substantial reduction in 
breast cancer mortality266. With thirty years of experience of mammography screening, 
Tabar et al. reported that randomized controlled mammography screening trials have 
unequivocally demonstrated prevented death from the disease.267 Duffy et al. have also 
demonstrated that the majority of breast cancer mortality reduction is due to 
screening268. However, other authors are somewhat skeptical. In a Cochrane review from 
2009, exploring the past two decades of RCTs comparing mammography screening with 
no screening, Gøtzsche et al. concluded that mammography screening does reduce 
breast cancer mortality (the RR for seven of the trials combined was 0.81,  95% CI 0.74 to 
0.87)269; however, the authors considered that the question whether screening does more 
good than harm could still be discussed and that the reduction in disease-specific 
mortality might be small. The main disagreements were due to study-design issues and 
negative side-effects such as false positives, over-diagnosis (estimated at approximately 
30%) and over treatment with effects on quality of life. In earlier publications, Gøtzsche 
and Olsen criticized mammography screening270-271. However, in an extensive review by 
Freedman et al. it was claimed that positive studies on mammography were excluded by 
the authors simply through misreading of the data and the literature.272 
     The benefits of any cancer screening need to be weighed against the potential 
negative aspects. For breast cancer screening, pain during the procedures is common but 
brief and not a barrier to screening. Anxiety, distress and other psychosocial effects have 
been reported as being transient in systematic reviews273-274. False-positive results are 
common; younger women have more false-positive mammography results, but rates of 
biopsy are lower. Rates of over-diagnosis are estimated at 1-10% (in the Cochrane 
review to 30%). Evidence supports a relationship between radiation exposure and breast 
cancer with much higher doses of radiation than obtained through screening.275  
A systematic review of mammography screening from 2007 by Armstrong et al. 
demonstrated a reduction in breast cancer mortality, an increased risk of mastectomy 
but a decreased risk for adjuvant chemotherapy and hormone therapy, and only a small 
effect on psychological health due to false-positive results. However, this meta-analysis 
also indicated that among women of 40-49 the risks of mammography screening may 
overweigh the benefits. While screening may decrease a woman’s risk of death due to 
breast cancer, it will, at the same time increase her risks of undergoing unnecessary 
procedures, breast cancer–related anxiety, discomfort at the time of screening, and 
exposure to low-dose radiation. The incidence of breast cancer and the effectiveness of 
mammography may be lower in women in their 40’s. This results in less absolute benefit 
and greater absolute risk than for an older woman. The authors therefore concluded that 
a woman of 40-49 who has a lower-than-average risk of breast cancer and higher-than-
average concerns about false-positive results might reasonably delay screening.276 
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 In comparison to the feared risk of over-diagnosis of indolent PCs with screening 
based on autopsy studies where microscopic lesions are highly prevalent, the prevalence 
of breast cancer (and ductal carcinoma in situ) on autopsy has been reported as very 
similar to those of PC; 39% of women aged 20-54.277 
 
Comparisons of number needed to screen and diagnose in other cancer screening programs 
Instead of evaluating relative risks or absolute risks from screening trials for various 
cancer diseases, more interpretable measures such as the number needed to screen 
(NNS) and the number needed to treat (NNT) to prevent one disease-specific death can 
be calculated. The NNT, as developed by Cook and Sackett in 1995, can be expressed as 
the reciprocal of the absolute risk reduction, ARR (from the intention-to-treat 
analysis)278. As reported by Rembold in 1998, the NNS is calculated in the same way 
(1/ARR)279 and corresponds to number needed to invite to the screening arm. The NNT is 
then derived from the excess disease incidence detected by screening. In PC screening, 
many men with the disease are, in fact, not treated, but rather managed. The NNT 
therefore rather represents the number needed to diagnose.   
     With 9 years of PC screening in the ERSPC, the relative risk reduction in PC mortality 
was 20%, corresponding to a NNS to prevent one PC death of 1408 (or 1410) and a NNT 
of 48.39 These results can be compared with those of screening for breast and colorectal 
cancer. The relative risk reduction among eight randomized trials of mammography has 
varied from -2% to 42%,280-287 and in the Cochrane review, it was calculated as 19%.269 In 
the 2009 Cochrane review, Gotzsche et al. estimated the summarized relative risk 
reduction in breast cancer mortality as being 19%, but assumed that the true reduction 
would only be 15%. Under this assumption, the death rate in the control group was 
applied to a study group of the same size to estimate the NNS. The NNT was based on 
the assumption of a 30% level of overdiagnosis.269 In this review, encompassing seven 
out of eight randomized trials of mammography, the NNS was 2,000 and the NNT was 
10 throughout 10 years.269,280-287 In a meta-analysis from 2002 including eight randomized 
breast cancer screening trials with  mammography, the summary relative risk reduction 
was 16% for women aged 39-74, equivalent to a number needed to invite to screening to 
prevent one breast cancer death of 1,224 (credible interval 665 – 2,654) an average of 14 
years after study entry.288 In a recent update of this evidence, the number needed to 
invite to screening ranged between 377 (CrI, 230 – 1050) for women aged 60-69 and 1,904 
(CrI, 929 – 6378) for women aged 39-49 years. The relative risk reduction was estimated 
as ranging between 15% and 32% for women aged 39-69.275 
For colorectal cancer screening by fecal occult blood test, the relative risk reduction 
has varied between 13 and 33% among four randomized trials289-292 and was 16% overall 
in a 2008 Cochrane review293 (after 11.7 to 18 years) and in a meta-analysis (after 7.8 to 13 
years).294 The NNS after 10 years was estimated as 1,173 (95% CI 741 to 2807). NNT is not 
estimable since screening may reduce the incidence of colorectal cancer (by means of 
removing precursors to cancers, i.e. colorectal polyps).295 No subgroup analyses of 
NNS/NNT per age groups have been reported. 
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2. ETHICAL ANALYSIS  
 
Screening for PC leaves many dimensions unexplored and available for ethical 
reasoning. Even though we are provided with evidence that mortality from the disease is 
reduced with screening39, the ethical discussion is quite essential.     
     When considering a population-based voluntary screening for healthy men, there is 
an ethical obligation to ensure that it must not cause more harm than good.296 Firstly, the 
screening programs must take into account the participants’ tolerance of the methods 
used and limit the various risks of morbidity and even mortality that might follow 
adherence. Secondly, the risks of over-diagnosis and the associated aspects of quality of 
life (QoL) need further quantifications and interpretations. Thirdly, when there is an 
increased detection of early PC with screening, there is also an urgent need to evaluate 
the potentially negative side-effects following treatment. Minimization of postoperative 
morbidity is of great importance. Fourthly, cost-effectiveness analyses together with 
considerations on implementation into clinical routine practice must be evaluated.  
     The ethical issues in PC screening are manifold and some are explored in the papers 
outlined in this thesis. It is important to understand these issues in order to maximize 
benefits and minimize harm to the enormous group of men worldwide at risk of this 
common disease.8 
 
2.1. Frameworks for ethical analysis 
In medicine and public health, there are many methods for ethical analysis; however, no 
matter what personal philosophy, politics, religion or moral philosophies one relies on, 
some principles are often applicable to almost any moral issue.297 In this part of the 
thesis, two frameworks are presented that will constitute the basis for an ethical 
analysis. A synthesis of these two is made (independently by S. Carlsson, spring, 2010), 
very similar to that proposed by Nilstun (Professor in Medical Ethics, University of 
Lund) et al. in 2009.298  
     The first framework is a cluster of four moral principles, namely ‚principlism‛ or 
‚the four-principle approach‛, and was presented by Beauchamp and Childress at the 
Appleton Consensus Conference in 1988299. These are: (1) respect for autonomy, (2) non-
maleficence, (3) beneficence and (4) justice. Although this approach is not aimed at 
providing a definitive answer or the solution to a moral issue, it is a helpful means of 
structuring an ethical analysis. Most classical ethical theories include these principles in 
some form, and they have long played a central role in medical ethics. PC screening has 
previously been evaluated by means of these four principles, by Krantz et al. in 2005300. 
However, the analysis made in this thesis is different. 
     The second framework was set up by Roberts and Reich in The Lancet in 2002 and 
distinguishes three philosophical views that may be used as tools in analyzing ethical 
dilemmas in public health:301 (1) utilitarianism, a position based on outcomes, i.e. 
decisions should be judged by their consequences, in particular by their effect on the 
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sum total of individual wellbeing, (2) liberalism, a position focused on rights and 
opportunities and (3), communitarianism (not to be confused with ‘communism’), a 
position that emphasizes the balance between individual rights and interests with that 
of the community.  In discussing the launching of a screening program for PC, the type 
of ethical choice will vary depending on the framework motivating the decision.  
    If we link these two frameworks, we find that respect for autonomy, liberalism and justice 
are closely related. Likewise, beneficence together with non-maleficence is connected to 
utilitarianism (‚the greatest happiness of the greatest number‛). Communitarianism is 
presented separately. 
 
2.1.1. Autonomy, liberalism and justice 
The philosophical concept of autonomy is associated with the philosopher Immanuel 
Kant (1724-1804), who is also associated with the moral philosophy of liberalism, a 19th 
century doctrine rooted in the Enlightenment. The concept refers to the right of an 
individual to make an informed, un-coerced decision (the right to self-determination in 
moral choices). All humans are believed to have an ethical obligation to respect each 
others’ right to self-determination, as long as it does not trespass on others’ rights to self-
determination.298 The most recent American philosopher associated with this doctrine is 
John Rawls (1921-2002). Liberalism prioritizes individual rights and the right to choose. 
Along these lines, individuals should have positive rights to health, which may include 
screening for diseases. Liberals who see health as a state-guaranteed right would move 
to ‚aggressive‛ efforts to control certain diseases to improve health outcomes.  
     With the evidence available today, 2010, an ethical dilemma arises when a man 
consults his doctor about the PSA test. On the one hand, he should have a right to make 
his own decisions, provided he receives relevant information. But, how will he be able to 
judge between pros and cons, when evidence or knowledge is (still somewhat) 
deficient?300  
     Although the ERPSC has provided evidence that mortality from PC is reduced39, 
general PSA screening, either voluntary or ‚mandatory‛ (here: strongly recommended or 
encouraged), has not yet been regarded as justified in order to protect the public health 
since the final conclusive reports on harms and costs are still awaited. These are ongoing 
within the ERSPC. 
     From an autonomy point of view, men’s right to self-determination might be 
regarded as being put aside when general PSA testing is not offered. On the other hand, 
men’s right to self-determination might also be regarded as being put aside if PSA 
testing were being implemented as ‚mandatory‛ (here: strongly recommended or 
encouraged) by a government (or similar). Voluntary universal screening rests on 
encouragement rather than coercion. Such a screening regimen would therefore not 
violate any moral rights to privacy or autonomy. It is highly unlikely that any 
government would force a man to take his PSA, but a screening program introduced by 
a government (or similar) would probably function, at least to some extent, in that 
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direction. If a man receives a brown envelope with an appointment for screening, like 
the one women get for breast cancer and cervical cancer screening, many men would 
probably interpret this as that something good is being done for them. However, the 
potential negative consequences that might arise from what at first could be regarded as 
a simple PSA test may not be in the individual man’s best interest. 
     In Sweden, there is now a compromise situation in the medical community that any 
man requesting the PSA test should be fully informed of its consequences. Fully informed 
men should be free to exercise their personal preferences regarding the test. In April 
2007, the National Board of Health and Welfare published National guidelines on PC 
care and provided a patient brochure9 (which was up-dated in April 2010). Before a man 
takes the PSA test, it is recommended that he reads this written information on the 
potential consequences the different outcomes of the test might have. The brochure is 
distributed mainly to primary care or private health care. Discussion with a doctor is 
thought to be a necessary complement to the brochure.302 From these guidelines, it is 
concluded that a man may have the PSA test as soon as he is acquainted with the 
contents of this information about it. Hence the interpretation of these guidelines is that 
today, no man in Sweden – after receiving information – can be denied the test. In fact, 
the pattern of PSA use has changed in recent years. Bratt et al. have recently estimated, 
in a population-based study, that about one third of all Swedish men aged 50 to 75 had a 
PSA test between 2000 and 2007303. 
     The guidelines from the National Board of Health and Welfare thus emphasize the 
importance of information to men who ask for PSA testing. The American Cancer 
Society (ACS) and American Urological Association (AUA) write: ‚Information should 
be provided to men about the benefits and limitations of testing so that an informed 
decision about testing can be made with the clinician’s assistance.‛  However, as the 
situation is today, without screening, there is a risk that only (well-) educated, well-
informed men ask for the PSA test. Is this ethically justifiable? Or could this even be 
regarded as an expression of social bias? 
     In A theory of justice (1971) Rawls presented a general concept of justice on how a 
just/fair society should be built up: ‚All social primary goods – liberty and opportunity, 
income and wealth, and the bases of self-respect – are to be distributed equally, unless 
an unequal distribution of any of all of these goods is to the advantage of the least 
favored (from a lifetime perspective)‛.  In line with this theory, one could argue that all 
men, not only the well-informed, should be given the opportunity to choose freely 
whether to be screened or not. 
     Allowing men to choose freely is in complete harmony with the principle of 
autonomy. For these men, voluntary screening (or offering of screening) is preferable. 
However, while an autonomous choice means the right to choose, it does not have to 
mean a duty to choose, as some individuals prefer paternalism (‚The doctors know what 
is best for me‛). For these men, either no screening or voluntary screening/offering of 
screening would be preferable.  
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     Kant argued that individuals ought to be treated with respect, as ends in themselves, 
and not as means to other individuals’ ends. This view directly opposes utilitarianism’s 
(see below) willingness to treat some people as means to others’ ends to maximize utility 
and produce the greatest good for the greatest number. If the number needed to screen 
and treat to prevent one PC related death is high, the standpoint of liberalism would be 
critical to implementing nationwide population-based screening programs. Therefore, if 
screening is beneficial only for a few, other men are treated as means to those men’s 
ends who benefit from screening, which would be in conflict with liberalism.  
     In Sweden, priorities in health care are often made from the principles of social 
solidarity and needs. Resources should be spent where needs are highest and with 
priority for those with severe diseases and poor quality of life. Priorities should also take 
account of those who are worst-off (solidarity) assuming that all individuals are equal.   
On the public health level, resources should be used fairly and rationally for all 
diseases. Hence screening could be regarded as a priority-setting dilemma in the context 
of the distribution of scarce resources. Budget constraints often determine the provision 
of health care services. In its advanced stages, PC is associated with tremendous 
morbidity, with loss of quality of life and large consumption of health care resources. In 
health care, the benefits, risks and costs need to be distributed fairly (distributive 
justice). Would it be fair to bestow resources on Swedish men between 50 and 70 years 
for PC screening, while other important diagnoses are not allocated money because of 
restricted health care resources? Would it even be a signal of social bias? Health-care 
economists would argue that working years lost and contributions to society are more 
important factors in these calculations than extending life or minimizing morbidity for 
elderly men. And what would be the cost for management/treatment of early detected 
disease as opposed to palliative care? Or should the public health burden of PC be 
regarded as so substantial that a screening program would be justifiable? 
     Liberalism views the right to health from a lifetime perspective. Would this rather 
indicate distributing health care resources not on men between 50-70 years but on the 
younger part of the population? The right to a minimum level of health is mainly 
regarded as necessary for people in order to have a range of opportunity when they 
make life choices. Some have therefore argued that the health care system should place 
priority on averting premature deaths and spend less time on extending the life of the 
elderly, who have already had a chance to develop and implement their life plans.301 But 
is elderly men’s health not important?  
     In Sweden, women are regularly screened for two major cancer forms, breast cancer 
and cervical cancer. Despite the fact that more men die from PC than women from 
breast and cervical cancer together each year4 (Figure 7), is PC screening not 
recommended. Although the diseases are biologically different, affect individuals of 
different ages, are associated with different morbidity and mortality at various stages of 
the disease and following treatments – one could argue that the total burden of PC 
should be regarded as being at least as important and one could indeed discuss the 
matter from a gender perspective. 
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Figure 7. Number of cervical cancer deaths, breast cancer deaths (women only) 
and prostate cancer deaths per age span, in Sweden, in 2007. 
Graphical illustration: S Carlsson. Courtesy to Socialstyrelsen (National Board of Health and Welfare).4 
 
To screen or not to screen? 
One difficulty in interpreting results from population-based data, is how they should be 
translated to the individual level. This is often an impossible challenge. While a reduced 
disease-specific mortality may be seen for a population, the individual man may not 
derive any advantages from screening, but only suffer from side-effects (see also below).       
Imagine a situation where a man can choose whether to know or not to know about 
his disease, or to paraphrase Shakespeare’s line in Hamlet, ‚to screen or not to screen‛; 
see also front cover of this thesis. Would this man’s quality of life be better if he was 
unaware of the diagnosis? He would continue to lead his life unaware that a tumor was 
slowly growing in his prostate gland (one day giving rise to symptoms and even death, 
or perhaps without him ever experiencing any symptoms during his remaining 
lifetime). Or could early detection through screening, with concomitant early treatment 
at a curative stage, have prevented the same man from dying too early from the disease? 
Denying examination and treatment to men who actually have cancers that will be 
lethal, is to judge an unpredictable group of men to an early, and sometimes severe 
death. Who decides over humanity, one’s right to live?  
     Anxiety and worry about PC is a common reason for a man to seek a urologist. A 
normal PSA value might reduce distress. Some men feel that ‚knowing is better than not 
knowing‛. Having the test can provide a man with a certain amount of reassurance – 
either he doesn’t have PC, or he does have it and can have it successfully cured. A 
psychological benefit is suggested by the fact that PC screening has some reassurance 
value for 97% of men.304 Some men have a philosophy of life that makes them grasp any 
opportunity to avoid a serious cancer disease later in life. Other men value their current 
quality of life higher, especially if they are afraid of side-effects from early treatment 
with curative intent (impotence, urinary incontinence and bowel disturbances) and a 
lowering of the quality of life that an eventual diagnosis would lead to.  
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2.1.2. Beneficence, non-maleficence and utilitarianism 
All doctors learn the Hippocrates’ oath: ‚Primum non nocere‛ (lat.) – first do no harm. 
Any potential benefits derived from screening for PC need to be weighed against any 
potential negative aspects and the potential harms of screening, including the diagnostic 
procedures, the treatments for PC and the morbidity and mortality aspects. Almost all 
treatments for PC have side-effects, for early stage tumors as well as for advanced 
disease. With PC screening, would it be ethically justifiable to cause side-effects/harms 
to ‛innocent subjects‛ to achieve benefits for others? However, for some men, early 
treatment in itself can be valuable. In a randomized Swedish study, men reported 
similar (or indicated even better) quality of life after 15 months to two years after radical 
prostatectomy compared to men assigned to watchful waiting235. Adjusted for several 
confounders, another study showed better mental health scores for men who had 
undergone radical prostatectomy as compared to radiotherapy and men on watchful 
waiting305. There are also indications that men selected to active surveillance report 
favorable anxiety levels compared to reference values in the literature of men 
undergoing other PC treatments.209 
    At present, screening offers a possibility to diagnose early PCs that can be successfully 
cured. At the same time, screening may also detect indolent cancers that do not form a 
threat to the patient’s life. With screening, there is a risk of over-diagnosis and over 
treatment120,251. A screening program ought to provide benefits and to balance them 
against risks. The potential benefits of PC screening on a population-level are reductions 
in PC-specific mortality and morbidity, but how can these benefits be interpreted on an 
individual level? An illustration of some examples is given in table 2: 
 
Table 2 Examples of different outcomes of screening as well as in the absence of screening 
 
 SCREENED  UNSCREENE D  
 Man A Man B Man C Man D Man E Man F Man G 
OUTCOMES: Early 
detection,  
cured on time,  
PC mortality 
reduced 
 
Labeled 
“patient” for 
many years,  
suffers from 
side-effects of 
treatment  
but is saved 
from PC 
death. 
 
Early 
detection, 
early 
treatment,  
less morbidity 
than the 
diagnosis at 
an advanced 
stage in a 
clinical setting;  
 
saved from 
needless 
suffering 
Early 
detection  
of low risk 
tumor;  
 
the man feels 
safe and 
secure under 
an active 
surveillance 
program 
“Over-
diagnosed”,  
latent PC,  
clinically 
insignificant 
cancer that 
will never 
cause 
symptoms or 
pose a threat 
to the man’s 
life;  
he is 
unnecessarily 
“labeled” 
patient for 
many years  
and perhaps 
also 
immediately 
(or later on) 
treated 
unnecessarily 
and suffers 
from the side-
effects of 
treatment.  
Unaware of 
the diagnosis 
until its clinical 
presentation;  
the cancer is 
found too late; 
he suffers 
tremendously 
from the 
morbidity of 
the disease 
and from the 
treatment if 
that affects his 
quality of life.  
 
Later, he dies, 
either from the 
disease itself  
or from an 
event 
associated 
with the 
treatment or 
from inter- 
current death. 
Unaware of 
the diagnosis;  
latent indolent 
cancer that 
will never give 
any symptoms 
or pose a 
threat to the 
man’s life. 
Initially 
unaware of 
the diagnosis;  
is not labeled 
cancer patient, 
does not 
suffer from 
side-effects 
from 
unnecessary 
treatment 
 
Later, the 
cancer 
surfaces 
clinically, the 
patient is 
treated with 
hormonal 
therapy that 
affects his 
quality of life, 
but dies of a 
heart attack or 
other 
competing 
mortality. 
 
“Ethical profit” + + +   + + 
“Ethical loss” -   - -  - 
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Whether the sum of all ‚ethical profit‛ and all ‚ethical loss‛ is beneficial for the group of 
men that undergo screening as compared to the same calculation for men who do not is 
not known today. Some authors, in favor of screening, claim: ‚It would make sense to 
try to minimize the psychological and medical effects of a diagnosis of low-risk PC 
rather than to deprive some men of an effective means of detecting and treating a high-
risk cancer just because we are afraid of adversely affecting a whole lot of other men.‛306 
Other authors claim that the number of men who will not benefit from screening will 
exceed the number of men who will. The number needed to screen and to treat to 
prevent one PC death that should be regarded as acceptable is an issue for debate.  
We know that screening with PSA reduces PC mortality (‚man A‛ as compared to the 
situation for ‚man E‛)39 and PC morbidity (‚man B‛)108.  However, we also know that 
PC screening with PSA is associated with over-diagnosis (‚man D‛)39 and that many 
men have asymptomatic PC without ever knowing it during their life time (‚man F‛)129, 
as clearly shown by autopsy studies of men dying from other causes129. 
     As a result of screening, many men will have to live several years as cancer patients, 
without experiencing the benefits of early detection because their disease will not 
progress to cause symptoms or death. Some have estimated the number of over-
diagnosed men to be high since the introduction of the PSA test in the U.S.307 Receiving a 
cancer diagnosis is always a turning point in an individual’s life, not necessarily 
negatively, but often markedly. Both localized and advanced PC have an influence on 
men’s daily lives. However, many men find a way to live in balance in their new 
situation and sometimes even with positive changes in their lives.308 
 
Utilitarianism 
     Because public health policy decision-makers are mainly population oriented, they 
often determine priorities with the help of the utilitarian approach. It is an ethical theory 
founded by Jeremy Bentham, James Mill and John Stuart Mill in England in the 19th 
century. The theory claims that ‚that action is best that produces the greatest good for 
the greatest number‛.309 Bentham (1748-1832) believed that the moral rightness (or 
wrongness) of an action can be found by adding up the amount of pleasure or pain that 
it produced, the so-called ‚hedonic calculus‛. The doctrine of utilitarianism sees 
maximization of utility (for example, given a benefit) and minimization of disutility (not 
given a benefit) as moral criteria for the organization of a society. The morally best act is 
thus the one that maximizes human welfare, giving equal weight to each person’s 
welfare, ‚the greatest good for the greatest number, regardless of who receives it‛. The 
right choice is the one that produces the greatest reduction in the total burden of the 
disease. Utilitarianism therefore permits calculations of QALY’s (quality-adjusted life 
years) and DALY’s (disability-adjusted life years) as well as cost-effectiveness analyses. 
     The decision on PC screening could be based on a utilitarian rationale under the 
assumption that the main goal is to create the greatest utility for the society as a whole, 
with utility measured according to the health benefits directly resulting from PC 
screening. The morally right choice would then be the one that produces ‚the largest 
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reduction in the burden of disease‛, for example in terms of more deaths averted and 
life-years gained with or without screening. The decision-makers might be regarded as 
objective utilitarians, ‚a group of experts which define an index that embodies the 
rationally knowable components of well-being‛301. Their choice would rely upon 
numerical indicators of health benefits, instead of personal assessments of health gains.  
     The goal of offering early diagnosis must be to decrease the burden of suffering and 
potential death from PC. If treatment is very efficacious, the cost-effectiveness of 
screening may be reasonable; if treatment is less efficacious, the results may be net harm 
and high costs130. With limited resources, investing in early-detection services for PC 
requires an understanding of all the resource costs (for instance, physician’s time, 
laboratory tests, patient’s time away from work)310 together with the costs associated 
with follow-ups, treatments, hospital care et cetera. 
 
Cost-effectiveness analyses 
De Koning et al., from the Netherland’s branch of the ERSPC provided a way to 
calculate preliminary estimates on the benefits and harms of PC screening based on the 
current evidence from ERSPC and the literature (personal communication)311. These 
calculations may be regarded as built upon utilitarian beliefs. The estimates can be 
informatory in a cost-effectiveness analysis that can be combined with a quality of life 
(QoL) analysis. Cost-effectiveness analyses will estimate the ratio of resources used 
(costs) and the health benefits achieved (effects) with PSA screening compared to a 
situation without screening. Cost-utility analyses will consider added life years and the 
benefits achieved, together with QoL. The benefits of screening could be calculated from 
PC specific mortality reduction, life years gained and reduction in advanced disease. 
The harms could be calculated from estimates of over-diagnosis, over-treatment and 
lead time years. Utilities could be expressed in terms of values of QoL for a man who 
dies from PC compared to a man in full health, taking into account the QoL from 
different treatment options. The duration of time with loss in utility is corrected for. 
These types of calculations will be of the utmost importance in the nearest future.  
     The basis for discussing population-based PC screening in several countries 
throughout the world will greatly depend on the outcome of QoL- and cost-effectiveness 
studies.311 With utilitarian calculations, focus is on the benefits on a population level. 
Utility maximization is an important criterion for guiding decision-making in public 
health. However, utility can sometimes be difficult to measure. For instance, when 
treatment options are chosen for PC, a man’s age is taken into account; many elderly 
men are more unlikely to die from the disease and more likely to suffer from co-
morbidities that can serve as contra indications to curative treatment. However, a man’s 
chronological age of, for instance, 80 years may correspond to a biological age of 70. 
Similarly, a symptom such as impotence may be regarded as less severe (though still 
severe to some) compared to pain, nausea and anxiety in the palliative stage of PC.9 
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2.1.3. Communitarianism 
Communitarian viewpoints are found among the Greek philosophers Plato and 
Aristotle. Communitarianism emerged as a response to John Rawls A theory of justice 
(liberalism). It criticized the ‚atomic‛ picture of the human being as ‚a dimensionless 
dot in no context who knows what is right or wrong‛. Michael Sandel (1953- ) who at 
that time was a student of Rawls at Harvard University, counter argued that the human 
being becomes an individual through response to values and beliefs in a society312. 
While the view of liberalism is that all individuals should stand back and personally 
assess what is right, the communitarian response is that this is impossible, because the 
self is ‚encumbered‛ or embedded in a community.313 From a relative communitarian 
perspective, an individual is shaped in the context that he or she lives in, and formed by 
the moral values that are defined by that particular community. Because the individual 
‚selves‛ are encumbered in the community they are not always capable of making the 
best decisions. Therefore, various degrees of paternalism, responsive to the values in the 
community, may be advocated applying this ethical framework as opposed to the liberal 
view, which has little tolerance for paternalism but expects the state to be neutral. 
Communitarians do not prioritize individual rights and self determination, but rather 
define what is good based on community values, thus allowing the state to take a 
position on what is right and wrong. Decision-making should be based on the norms 
that exist in that community, and will thus consequently have contextually-dependent 
outcomes. In contrast to utilitarianism, communtarianism does not rely on cost-
effectiveness analyses or hedonic calculations in terms of the total burden/benefit for 
this particular community. Assuming a relative communitarian view, whether to screen 
or not, would depend on what values and norms are believed to increase well-being and 
what is regarded as ‚good‛ in the community. Paternalism can act in both directions. 
  
2.1.4. Conclusions from ethical considerations 
In conclusion, a synthesis of the ‚four-principle approach‛ and the three philosophical 
views of liberalism, utilitarianism and communitarianism cannot yield a definite answer 
for public health policy decision-makers on PC screening, on the evidence available 
today, 2010, but they can perhaps provide an arsenal for a structured ethical analysis in 
the future. The ethical analysis can, at present, act in both directions. Utilitarian 
calculations are under way. A public health advisory committee, government or similar 
has a moral obligation to serve the public welfare by increasing overall public health, in 
a way that is also fair and equitable. The concept of autonomy indicates that information 
should be provided to men about the benefits and limitations of testing so that an 
informed decision about it can be made with the clinician’s assistance.  
 One compromise, and possibly the most ethical choice from an autonomy point-of-
view, between completely voluntary screening and mandatory screening (here: strongly 
recommended/encouraged), would be to opt for mandatory information and offering.314 
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3. AIMS OF THE THESIS 
 
Background to the studies forming the thesis 
This thesis reports on the main outcomes of the Göteborg randomized population-based 
prostate cancer screening trial. This study is registered as an International Standard 
Randomised Controlled Trial (http://www.controlled-trials.com number 
ISRCTN54449243). The thesis attempts to answer the following questions: Does PSA 
screening reduce PC mortality and what are the potential negative consequences for 
men undergoing such screening? 
     In 2009, a 20% disease-specific mortality reduction at 9 years of follow-up was 
reported for men in the core-age group in the ERSPC study39. This report was important 
as it contributed the first ‚level 1 evidence‛ that PSA-based PC screening can reduce PC 
mortality. However, the simultaneously released report from the U.S. PLCO trial found 
no difference in PC mortality between men randomized to screening and those in the 
control group at 11.5 years’ follow-up.40 In an editorial comment, Barry argued that 
longer follow-up was needed before any definitive conclusions could be made.315  
     Whether the benefit would increase with longer follow-up is now being investigated. 
The Göteborg randomized population-based prostate cancer screening trial now has 14 
years to report in answering this key question. The study design allows for an analysis 
of both how a screening program will be received by the population and also its 
effectiveness in terms of PC mortality reduction on a population level. It allows for the 
calculations of the number needed to screen and treat to prevent one PC death. 
One objection to population screening in general, has been the assumption that 
invitation to and participation in screening examinations for cancer cause psychological 
distress316,317-318. This thesis therefore deals with the psychological effects of the screening 
procedures, especially among men with elevated PSA, repeatedly examined for PC. 
 Due to the low specificity of PSA, PC screening will unavoidably involve a large 
number of prostate biopsies. Despite being an invasive and sometimes uncomfortable 
procedure, prostate biopsy is regarded as safe and acceptable254, 319 with a low rate of 
major complications but with frequent minor complications320. Although rarely 
encountered, a few cases of fatal outcome after prostate biopsy have been described in 
the literature319, 321-329. The majority of cases have been due to septicemia; either anaerobic 
(bacteria) or due to Escherichia coli (bacteria). A few cases (mainly case-reports) of 
profuse potentially life-threatening rectal hemorrhage have been reported; some have 
required different types of interventions, but, to the best of our knowledge, there are no 
reported fatalities from rectal bleeding.330-339 Although direct causes such as sepsis and 
rectal hemorrhage seem to be very rare causes of deaths after prostate biopsy, these 
complications might increase the risk for death from other causes. Many men who are 
referred to prostate biopsy are elderly and often have co-morbid diseases such as 
cardiovascular disease. Whether the prostate biopsy may elevate their risk of death from 
existing co-morbidity (excess mortality) has not been well studied. As prostate biopsies 
are numerous in PC screening, attention must be paid to the potential hazards of this 
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common procedure. The aim of the second study was therefore to assess possible excess 
mortality and, in particular, deaths from sepsis and hemorrhage in men who undergo 
prostate biopsy within the ERSPC. 
This thesis further explores the most common curative treatment option for early 
localized PC in Sweden340, radical prostatectomy, and its associated potential side-effects 
and risks. The operation was introduced in Sweden in the 1980’s, but until the mid 
1990’s only a few hundred cases were operated on each year. Since then, the operation 
has become common and today radical prostatectomy is performed at almost all 
hospitals in Sweden (to a lesser extent at minor hospitals). In 2006, more than 2,000 
radical prostatectomies were performed in Sweden.219 In previously published papers, 
radical prostatectomy has been associated with very low perioperative mortality, 
varying from 0.1 to 0.5%, but many of these series represent high-volume centers and/or 
centers with a long experience of the operation341-346. The aim of the fourth study was to 
assess the risk of the worst possible side-effect, i.e. mortality due to the operation, 
measured as the 30-day mortality rate, in a nationwide survey in Sweden. 
     Moreover, screening programs for PC pose a potential risk for adverse side-effects 
following treatment with curative intent for early detected tumors. Despite the 
reduction in disease-specific mortality achieved with screening, there is a need for 
ethical considerations to ensure that the benefits outweigh the harms if general PC 
screening were to be introduced on a population level. Most cancers detected in an 
organized screening program are early stage tumors that are suitable for treatments 
with curative intent. In the literature, the incidence of post-prostatectomy potency rates 
varies widely between 11% and 87%236-237 and post-prostatectomy incontinence between 
0% and 87%236-240. In order to get a balanced picture of screening for PC, there is an 
urgent need to evaluate the potentially negative side-effects following treatment in the 
screening trials. The final study therefore investigated the main side-effects of radical 
prostatectomy, impotence and incontinence translated into population-induced risks. As 
the study is truly population-based with up-front randomization, it should be possible 
to calculate reliable estimates on how much more surgically-induced morbidity 
screening will cause on a population level if a screening program were to be introduced. 
 
The studies outlined in this thesis were intended to address the following questions: 
I.     Does PSA screening impact disease-specific mortality at 14 years of follow-up and 
what are the potential negative consequences? 
II.     Is screening associated with anxiety, especially among men with an elevated PSA? 
III. Is the diagnostic procedure, prostate biopsy, associated with excess mortality? 
IV. Radical prostatectomy is the most common treatment with curative intent in a PC 
screening program. What is the 30-day mortality after this surgery in a nationwide 
setting? 
V.     What would be the population-induced risk of impotence and incontinence after 
radical prostatectomy if PSA screening were to be introduced? 
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4. STUDY POPULATION 
 
As of December 31, 1994 the Population Register documented 32,298 men born between 
January 1, 1930 and December 31, 1944 (ages 50-64, median 56 years) living in the city of 
Göteborg, Sweden (440,000 inhabitants in total). Of these, 20,000 men were randomly 
allocated (without prior information) in a 1:1 ratio to either a screening group invited for 
biennial PSA testing, or to a control group not invited. Subsequent to randomization, we 
excluded 56 men with a prior diagnosis of PC, 34 men who had died, and 6 men who 
had emigrated before the randomization date (these latter individuals were not yet 
removed from the Population Register at the time of randomization). The Ethical 
Review Committee at the University of Göteborg approved this study. The study began 
to invite men in January 1995, and in 1996 the study was associated to the European 
Randomized Study of Screening for Prostate Cancer (ERSPC), without any changes in 
the protocol.  Figure 7 depicts the study design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Consolidated Standards Of Reporting Trials (CONSORT) diagram showing the screening algorithm of the 
Göteborg randomized population-based prostate cancer screening study between 1995-2008.  
PSA indicates prostate-specific antigen. 
 
Excluded: 
(n = 48) 
 Deceased or emigrated before  
 randomization date: (n = 19) 
 Men with prevalent prostate 
cancer: (n = 29) 
Excluded: 
(n = 48) 
 Deceased or emigrated before  
 randomization date: (n = 21) 
 Men with prevalent prostate 
cancer: (n = 27) 
Total male population in Göteborg on 
December 31, 1994, aged 50-64 yrs  
n =32 298  
Control group 
not invited 
n = 9952 
Screening group (invited biennially 
for PSA testing 1995-2008)  
n = 9952 
Randomized in a 1:1 ratio 
n = 20 000 
Non-attendees 
n = 2374 
Attendees 
n = 7578 
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The Göteborg randomized population-based prostate cancer screening study constitutes 
the basis for this thesis in all its papers except for paper IV.  
 
 
In paper I, 9,952 men randomized to biennial invitation for PSA testing 1995-2008 were 
compared with 9,952 men randomized to no such testing (regular care) with respect to 
PC incidence and mortality. 
 
 
In paper II, 1,781 men with a positive screening test (PSA >3 ng/mL) referred to further 
clinical investigation with prostate biopsies were studied with respect to anxiety levels.  
 
 
In paper III we studied short-term overall (here: other cause than PC) mortality for a 
cohort of 12,959 first-time screening-positive men (i.e. with biopsy indication) and a 
cohort of 37,235 first-time screening-negative men. This is a multi-center study within 
the ERSPC in which Finland, The Netherlands and Sweden participated. 
 
 
Paper IV, is a nationwide (Sweden) population-based study assessing 30-day mortality 
after radical prostatectomy. In this, all men diagnosed with localized PC (≤70 years, 
clinical stage T1-2, PSA <20 ng/ml) who underwent radical prostatectomy in Sweden 
between 1997 and 2002 were identified through the National Prostate Cancer Register 
(NPCR), n=3,700 men. From linkage with the Inpatient Register and the National 
Population Register during the same period, there were 4,457 radical prostatectomies 
performed (this covered all men who underwent radical prostatectomy because of PC 
regardless of age, PSA level or clinical stage). 
 
 
After 14 years, 1,856 men were detected with PC; 1,849 when excluding seven cases, 
detected at autopsy in the control group. Of these, 1,047 received treatment with 
curative intent. Open radical prostatectomy was performed in 829 cases (562 screened, 
267 controls). In paper V, 294 of these men participated in a sub-study (205 screened, 89 
controls). These men underwent radical prostatectomy at Sahlgrenska University 
Hospital between 2001–2008 and were registered in a quality assurance database in 
which side-effects from treatment were recorded. 
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5. METHODS & STATISTICS 
 
 In paper I and paper V, the analysis was made according to the intention-to-screen 
principle, i.e. comparing men randomized to the screening group (attendees and 
non-attendees) with men randomized to the control group. 
 In paper I-III, and paper V, data have been prospectively collected, and 
longitudinally analyzed statistically in paper II and in paper V.  
 Paper III is a prospective cohort study following men with and without a biopsy 
indication.  
 Paper IV is a registry linkage study. 
 
Paper I 
Methods 
The aim of paper I was to evaluate the effects of PSA screening on PC incidence and PC 
mortality after 14 years. Men allocated to the screening arm were invited every second 
year for PSA testing, until they reached the upper age limit of 70 years (mean 69 years, 
range 67-71).347 Men with PSA below the threshold were not further evaluated, but were 
invited again after two years. Only men with PSA at or above the threshold were invited 
for further urological work-up including digital rectal examination, trans-rectal 
ultrasound examination, and at least laterally directed sextant biopsies. For men 
diagnosed with PC, the protocol did not specify any particular treatment; further 
evaluation and treatment was at the discretion of their physicians. Men with a benign 
biopsy were re-invited for screening after two years. Men with persistently elevated PSA 
were recommended a new prostate biopsy at each visit PSA was elevated. Seven 
screening rounds were completed by the end of 2008. Minor changes in the PSA-cut-off 
and in the screening algorithm were made during the study period.348 
     In both arms of the study, the incidence of PC was checked by linking with the West-
Swedish Regional Cancer Registry every third month since the study started.  For every 
man with PC, all available medical documentation was retrieved for establishing tumor 
stage, treatment, and disease course. In addition, for all deceased men we obtained a 
copy of the cause of death (COD) certificate. Causes of death for men diagnosed with PC 
were determined by an independent COD committee. The committee performed a 
blinded review of all cases diagnosed with PC (including all medical records, pathology 
reports, autopsy protocols) according to a standard algorithm used in the ERSPC.349 The 
COD certificates were not available to the COD committee. Deaths classified as 
definitive PC deaths, intervention-related deaths (i.e. deaths from diagnostic procedures 
or treatment), or probable PC deaths were regarded as being caused by PC, while other 
classifications were regarded as non–PC deaths. 
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Statistics 
The main outcome measures were absolute and relative risk reduction in cumulative PC 
mortality between study arms. Secondary measures were the cumulative PC incidence 
and the proportion of screening attendees. A pre-study power calculation (two-sided 
test, p<0.05 and 80% power) was performed on the assumption of a 70% participation 
rate. A 40% mortality difference between the study arms was calculated to become 
significant 15 years after the study start (at the end of 2009). A new power calculation in 
2009 incorporated the observed 76% participation rate in the Swedish branch in the 
published ERSPC results.39 The new calculation implied significant power to analyze the 
data through 2008. 
     Cumulative incidences of PC in screening and control groups were plotted as 1 – the 
Kaplan-Meier estimator. The corresponding hazard ratio for the incidence of PC 
between the groups was estimated by Cox regression. The proportional hazard 
assumption was tested with Schoenfeld residuals350. A time-dependent covariate 
approach was used to estimate the hazard ratio at different time periods after the start of 
screening to avoid violence to the proportional hazard assumption. The Nelson-Aalen 
method was used to calculate the cumulative hazard for PC mortality.351 Poisson 
regression analysis was used to estimate the rate ratio of mortality in the screening 
group to the mortality in the control group. All p-values were two-sided. The number 
needed to screen (NNS) was calculated as (1/absolute reduction in PC mortality). As this 
study is an intention-to-screen analysis, we refer to NNS as number needed to invite for 
screening. The number needed to treat (NNT) was calculated as ((1/absolute reduction 
in PC mortality)*excess PC incidence). This measure was also rephrased to number 
needed to diagnose, because many patients actually were not treated.  
 
Paper II 
Methods 
The aim of paper II was to evaluate the degree of anxiety among men who turned out to 
be screen-positive, i.e. those who had elevated PSA values (>3 ng/mL) within the 
screening trial. Men with a positive screening test (elevated PSA) referred to biopsy 
were requested in the waiting-room to answer a study-specific self-administered 
questionnaire on anxiety awaiting the PSA test result and anxiety associated with the 
invitation to further clinical work-up (including prostate biopsies). A secondary 
objective was to study the possible influences of age, PSA level, heredity, lower urinary 
tract symptoms, biopsy finding and round of examination on levels of anxiety. Men 
with elevated PSA were informed of their PSA result through a standardized letter. In 
the same letter these men were invited to a clinical examination and they were informed 
that they had about a 15% risk of PC. Men with elevated PSA and benign biopsy 
findings were re-invited for biennial measurement of PSA. In this study, five screening 
rounds were completed and analyzed (1995-2005).  
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Statistics 
Descriptive statistics were calculated using conventional methods. A multinomial 
logistics model for repeated measurements of individuals was performed to analyze the 
impact of the covariates age, PSA level, heredity, symptoms of urinary outflow 
obstruction, irritative urinary symptoms, biopsy finding and round of examination on 
anxiety. To avoid selection bias, only men with repeated measures (longitudinal data) 
were incorporated into the multinomial logistics model. We assumed that the data 
followed a proportional odds model when analyzing the impact of these covariates 
(which were dichotomized). The intensity of lower urinary tract symptoms was 
analyzed statistically as ‘No symptoms’ or ‘Symptoms’ (including minor or major 
symptoms). Odds ratios (ORs) and confidence intervals (CIs, 95%) for all covariates 
were calculated. The relative risk (RR) was calculated using conventional methods when 
analyzing the probability of reporting high levels of anxiety at repeated screening. The 
Chi-square-test was used for testing the level of significance. The possible relationship 
between non-participation rate and degree of self-reported anxiety was also analyzed by 
means of the Chi-square-test. P values <0.05 were considered significant.  
 
Paper III 
Methods 
The ERSPC was initiated in the early 1990’s352. Screening protocols, practices and referral 
criteria for further examination with prostate biopsies differ between the centers within 
the ERSPC. Biopsy indication for the absolute majority of screens was based on a PSA 
level of ≥ 3 or initially 4 ng/mL in some centers, but some additional criteria were also 
initially included such as digital rectal examination findings, trans-rectal ultrasound 
findings and the ratio of free to total PSA (for definition per center, see website)103. 
Strategies of antibiotic treatment, use of local anesthetic agents as well as pre-biopsy 
regimens with respect to rectal cleansing enemas differ somewhat. All three centers in 
the present study (Finland, The Netherlands and Sweden) prescribe screen-positive men 
laterally directed, sextant (at least), trans-rectal biopsies of the prostate. In most cases, 
men with a biopsy indication underwent clinical examination by an experienced 
urologist, including medical history, digital rectal examination (DRE) and trans-rectal 
ultrasound. The study protocols prescribe all men with a biopsy indication to undergo 
biopsies, but the urologist responsible has the final decision to refrain from biopsy in 
cases with (severe) co-morbidities. 
In the present study, 50,194 screened men with at least one eligible screen were 
identified and were prospectively followed with overall mortality (other cause than PC 
mortality) as major outcome. A positive screen was defined as an eligible screen 
resulting in biopsy indication and was found in 12,959 men, while 37,235 men had only 
negative screening tests. The median PSA for screening-positive men was 4.5 ng/mL 
(quartiles Q1 3.5; Q3 6.0) and for screening-negative men 0.9 ng/mL (Q1 0.6; Q3 1.4). The 
age at screening ranged between 50.2 and 78.4 years. The mean age at screening was 64.8 
(SD 5.0) years in the screening-positive group and 61.2 (SD 5.2) years in the screening-
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negative group. Of the group of screening-positive men, 11,721 (90.4%) actually 
underwent biopsy (mean age 64.7 years, SD 5.0) and 1,238 (9.6%) did, for various 
reasons, not undergo a biopsy (mean age 65.8 years, SD 5.2). Of the latter, 73.8% were 
non-responders to the clinical examination and 26.2% underwent examination but were 
not biopsied. Of those with a positive screening test, 59.4% underwent biopsy within the 
first month after screening and 94.0% within 3 months. 
 
Statistics 
Mortality rates were calculated within 30, 60, 90, 120 and 365 days after the screening 
test and was compared between the two groups. Cumulative mortality at 120-days and 
one year was calculated by the Kaplan-Meier method, with statistical significance 
evaluated using the log-rank test. Incidence rate ratios and statistical significance were 
evaluated using Poisson regression analyses (taking the follow-up time into account), 
adjusting for age and total-PSA level (continuous variables), screening centre and 
whether a biopsy indication was present, or whether a biopsy was actually performed or 
not, respectively. A p-value < 0.05 was considered statistically significant. Furthermore, 
the cause of death was collected in screening-positive men who had undergone biopsy 
and who died within 120 days of the screening test. Men who died from PC within the 
study period (1 year) were censored at the time of PC death (n = 6). 
      
Paper IV 
Methods 
The incidence of PC in Sweden is increasing rapidly, as is treatment with curative intent. 
Radical prostatectomy is currently commonly performed, either within or outside large 
high-volume centers. The aim of the study for paper IV was therefore to assess the 30-
day mortality rate after radical prostatectomy in Sweden. In this nationwide population-
based study, all men diagnosed with localized PC (< 70 years, clinical stage T1-2, 
prostate-specific antigen < 20 ng/ml) who underwent radical prostatectomy in Sweden 
between 1997-2002 were identified through the National Prostate Cancer Register 
(NPCR). Mortality within 30 days was analyzed through linkage between the follow-up 
study of the NPCR and the Regional Population Registers. The cause of death in death 
certificates was compared with data from the hospitals. A letter with a questionnaire on 
the cause of death and co-morbidity was sent to the hospital concerned regarding any 
possible relation to the operation, and at the same time assessing patient co-morbidity. 
The death certificates for these men were requested and were compared with the 
questionnaires retrieved from the hospitals. To validate the results, a record linkage 
between the Inpatient Register and the National Population Register was also 
performed. The total number of radical prostatectomies per hospital during the period 
was calculated and the definition of high-volume hospitals by Begg et al. was used (an 
annual average of at least 28 operations)353. 
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Paper V 
Methods  
In paper V, the frequencies of side-effects in a subset of men detected between 1995-2008 
and treated with radical prostatectomy between 2001-2008 in the Göteborg randomized 
population-based prostate cancer screening trial were extrapolated to the whole study. 
     Beginning in January 1, 2001 all men operated upon with radical prostatectomy at the 
Sahlgrenska University Hospital were entered into a quality assurance database 
including pre-operative and 18-month postoperative evaluation of erectile and urinary 
function. Men belonging to the screening study (screened men and controls) and 
operated upon between 2001 and 2008 formed the study population.  Erectile function 
was assessed using the validated and internationally well-established International 
Index of Erectile Function (IIEF)-5 questionnaire as described by Rosen et al.354 Men who 
reported use of alprostadil were incorporated into the impotency group, regardless of 
which IIEF-5-score they reported with this use, whereas use of PDE-5 inhibitors was not 
taken into account. Hospital records were reviewed for all men who underwent surgery 
after 2001 and who were sent questionnaires preoperatively and at 18 months, but for 
whom one or both questionnaires were missing (non-responders). A questionnaire 
regarding urinary incontinence was also included. The answers were measured on a five 
point scale ranging from 0-4, where a score ≥ 2 was supportive of urinary incontinence. 
This questionnaire has previously been used when measuring postoperative urinary 
continence after robot-assisted laparoscopic radical prostatectomy355. 
 
Statistics 
Analyses were made according to intention to screen and compared screened men with 
controls (i.e. standard clinical care). Data was extrapolated from our results (patients 
operated upon from 2001-2008) to the full screening setting with 14 years of follow-up. 
Extrapolated numbers of pre-operatively partially or fully potent and sexually active 
men were derived from the proportion of men with an IIEF-5-score of 12-25 and of 
these, the numbers of post-operatively impotent or sexually active men were derived 
from the proportion of impotent men or men who reported no sexual activity at 18 
months. Extrapolated numbers of post-operatively incontinent men, among all the men 
who underwent surgery, were derived from the proportions of men reporting urinary 
incontinence grade 2-4 at 18 months of follow-up.  
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Figure 9 depicts the study design.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              (‡ excluding 7 cases detected at autopsy) 
 
 
Figure 9. Study design 
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6. RESULTS AND COMMENTS 
 
Paper I 
This paper reported the first planned report on cumulative PC incidence and mortality 
calculated up to December 31, 2008, i.e. a median follow-up of 14 years. Screening and 
control groups each consisted of 9,952 evaluable men. In the screening group, 76% 
participated in at least one screening round (attendees). In 2,469 men (33%), PSA was 
elevated above the threshold at least once. Among these men with elevated PSA, 2,298 
men (93%) underwent prostate biopsy at least once.  
PC was diagnosed in 1,138 men in the screening group and 718 in the control group. 
The cumulative incidence of PC at 14 years was 12.7% in the screening group versus 
8.2% in the control group, corresponding to a hazard ratio of 1.64 (95% confidence 
interval [CI] 1.50-1.80, p<0.0001). (Figure 10)  
 
 
 
 
 
Figure 10. Cumulative incidence  
of prostate cancer in the study 
 
 
 
 
 
 
The majority of PCs diagnosed in the screening group were early-stage disease. The 
number of men with advanced PC (metastases or PSA >100 ng/ml at diagnosis) was 
lower in the screening arm: 46 men compared to 87 in the control arm (p=0.0003). 
Among the non-attendees in the screening group, a higher proportion of cancer cases 
were advanced at diagnosis than among attendees. 
The difference in stage distribution was mirrored by treatments, with more hormonal 
therapy in the control arm and more surveillance, or treatment with curative intent in 
the screening arm. However, among men with low and moderate-risk tumors, the 
proportion receiving curative treatment was similar between trial arms: 476/967 (49%) in 
the screening arm and 228/448 (51%) in the control arm. Among the men diagnosed with 
PC, the median follow-up after diagnosis was 6.7 years in the screening group and 4.3 
years in the control group. In evaluating whether deaths were attributable to PC, the 
COD committee and COD certificates were highly concordant.  According to the COD 
committee review, 78 men in the control group died from PC (77 according to death 
certificates) compared to 44 (45 according to death certificates) in the screening group. 
Within the screening group, 27 prostate-cancer–specific deaths were registered among 
7,578 attendees versus 17 among 2,374 non-attendees. Among attendees who died from 
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PC, 13 were diagnosed with PC at their first screening visit (prevalence screen), and the 
youngest of these men was 59 years at diagnosis. Of men born 1930-34, i.e. older than 60 
years at study entry, the number of PC deaths was 19 among attendees versus 35 among 
controls. These attendees seemed to be at higher risk of PC death relative to attendees of 
younger age at the study start. Of the younger men born 1935-44, only 8 PC deaths 
occurred among attendees as compared to 43 among controls.  
     The main outcome analysis performed on intention-to-screen showed that the RR of 
dying from PC was 0.56 (95% confidence interval, CI, 0.39-0.82, p=0.002) in the screening 
compared to the control group. The absolute cumulative risk reduction (Kaplan-Meier 
estimates) of death from PC at 14 years was 0.40% (95% CI 0.17-0.64%), from 0.90% in 
the control group to 0.50% in the screening group (Figure 11). The RR of dying from PC 
among attendees compared to the control group was 0.44 (95% CI 0.28-0.68, p=0.0002) 
and the RR between non-attendees and the control group was 1.05 (CI 0.62-1.78 p=0.84). 
 
 
 
 
 
Figure 11. Cumulative prostate cancer mortality 
 in the study 
 
 
 
 
 
 
The number of men needed to invite for screening (NNS) to prevent one PC death was 
calculated as 293, while the number needed to diagnose (NNT) was calculated as 12. If 
the calculations were restricted to attendees, the respective numbers were 234 and 15. 
These figures compare favorably with breast cancer and colorectal cancer screening. 
 The conclusions of paper I is thus that PSA screening is well accepted by the general 
population and may result in a relevant reduction (by half) in cancer mortality greater 
than what has been seen in screening for breast or colorectal cancer. A disadvantage of 
PSA screening is the long and varying lead time, resulting in a risk of over-diagnosis 
that is substantial although still of largely unknown magnitude. 
 
Paper II 
This paper focused on the aspects of men’s reported anxiety related to the screening 
procedures. The aim of the study was to evaluate the degree of anxiety only among men 
who turned out to be screen-positive, i.e. those who had elevated PSA values (>3 
ng/mL). The study specifically focused on anxiety associated with waiting for the results 
of PSA measurement and anxiety concerning the invitation to attend clinical 
examination (including prostate biopsies). Another aim was to study the possible 
influences of age, PSA level, heredity, lower urinary tract symptoms, biopsy finding and 
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round of examination. Participation rates were high (> 90%). The number of men with 
PSA elevation who also accepted clinical examination was high. 
Levels of anxiety were assessed through self-reported questionnaires completed by 
1,781 screen-positive men. During the first visit (clinical examination, including 
biopsies), no anxiety whilst awaiting the PSA test results was reported by 66% and 2% 
reported high levels of anxiety (Figure 12). Anxiety while awaiting the PSA was only 
influenced (increased) by the existence of previously elevated PSA tests (p < 0.0001).  
Figure 12. Anxiety awaiting the results of PSA measurement related to the number of examinations. 
Results are given as a percentage for every round of examination. *** p < 0.0001 
 
No anxiety associated with biopsy was reported by 45%, while 6% experienced high 
levels of anxiety (Figure 13). Levels of anxiety decreased significantly with subsequent 
rounds of examinations (p < 0.0001) and with increasing age (p = 0.0016). The level of 
anxiety reported at first examination had a significant influence on the level of anxiety 
reported at subsequent examinations.  
Figure 13. Anxiety associated with further clinical examination related to the number of examinations. 
Results are given as a percentage for every round of examination. *** p < 0.0001 
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From these results, we have reason to believe that the randomized sample of men in this 
study is most likely to resemble those who would participate if PC screening were to be 
introduced into routine practice. Considering a general, population-based screening for 
PC, this study indicates that the majority of men would be likely to accept an invitation. 
Attending a screening program for PC is seldom associated with severe negative 
psychological distress, even for men with persistently elevated PSA levels.  
 
Paper III 
This paper explored the risk of possible excess mortality associated with prostate biopsy 
in men undergoing PSA screening in the ERSPC. A group of screening-positive men was 
compared with a group of screening-negative men. The results show that there was no 
statistically significant difference in 120-day mortality between the two groups: 0.24% 
(95% CI 0.17 – 0.34) for screening-positive men versus 0.24% (95% CI 0.20 – 0.30) for 
screening-negative men, p=0.96 (figure 14). This implied no excess mortality for 
screening-positive men. As seen in figure 15, the cumulative 120-day mortality (%) was 
highest for screening-positive men who were not biopsied, in comparison with men 
who were biopsied and screening-negative men. These screen-positive men who were 
not biopsied had a more than four-fold risk of other cause of death during the first 120 
days whereas men who were biopsied had half the risk.  
 
Figure 14. Cumulative 120-day mortality (%) for 
screening-positive men (i.e. with biopsy indication) and 
screening-negative men (no biopsy indication)  
 
 
 
 
 
 
 
 
 
 
Figure 15. Cumulative 120-day mortality (%) for 
screening-positive men (i.e. with biopsy indication) with 
and without biopsy as well as for screening-negative men 
(no biopsy indication) 
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Our findings suggest firstly, a ‚healthy screenee effect‛ among screen-positive men who 
attend clinical examination and secondly, a ‚healthy selection‛ of those who actually 
undergo biopsies while attending clinical examination. Of those screening-positive who 
died within 120-days, 14/31 (45.2%) were in fact biopsied and in none of these cases, was 
death an obvious complication to the biopsy. Paper III is the largest study, in a 
screening-setting, that has evaluated biopsy-specific mortality rates as well as excess 
mortality after prostate biopsy in almost 12,000 biopsied men. Our findings confirm that 
biopsy-related death is infrequent and thus not a valid reason per se not to consider 
population-based PC screening programs. 
 
Paper IV 
This paper is a registry-linkage study that assessed the 30-day mortality rate after 
radical prostatectomy in Sweden. The results show that the number of radical 
prostatectomies performed increased over time, both for open and laparoscopic surgery 
(Figure 16). Among 3,700 radical prostatectomies performed, four deaths occurred 
during the first 30 days, yielding a 0.11% 30-day mortality rate. From the linkage with 
the Inpatient Register and the National Population Register during the same period, the 
corresponding figure was that six men were registered as dead within 30 days after 
radical prostatectomy of 4,457 performed yielding a 30-day mortality rate of 0.13%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Number of radical prostatectomies performed in Sweden between 1997 –  2002 
 
The four deaths in the follow-up study of the NPCR occurred at three different types of 
hospital (community, county and university hospital) and were all somehow most 
probably related to the radical prostatectomy. No evidence was found for a higher 
mortality in smaller hospitals; however, the few events in this study did not permit any 
comparison between different categories of hospitals. 
Paper IV thus provides further evidence that radical prostatectomy is a procedure 
with very low perioperative mortality even when performed outside high-volume 
centers.  
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Paper V 
This study aimed at assessing the excess burden of side-effects from PSA screening, and 
more explicitly to focus on incontinence and impotence induced by radical 
prostatectomy. We compared men with screen-detected PC and men with PC in the 
control group. In both groups, men were operated upon and men unavoidably suffered 
from side-effects. Paper V aimed at quantifying how many more side-effects screening 
induced in the population. 
Of preoperatively potent men (and of those with mild ED), 79.1% of screened and 
90.7% of controls reported either no sexual activity, or an ED score ≤ 11 at 18 months 
after surgery. Applying the patient selection as used by Parsons et al.356 (age ≤ 60 years, 
preoperative IIEF-5-score ≥ 21 and who had a bilateral nerve-sparing procedure) yielded 
only 10/294 (3.4%) patients of our study population. In this small subgroup, 7/10 (70.0%) 
were potent (IIEF-5-score ≥ 16) at 18 months according to the criteria suggested by 
Parsons et al. 
 As regards urinary incontinence, at 18 months, 24 men (14.3%) in the screening group 
and 18 men (20.5%) in the control group reported some degree of incontinence (any use 
of pads).  
Extrapolating these data in the full screening setting yielded that, with 14 years of 
organized PSA screening, the frequency of post-prostatectomy impotence and sexual 
inactivity is increased by 120/10,000 men for men subjected to screening as compared to 
the control population (representing the current clinical practice in Sweden). The 
corresponding figure for post-prostatectomy urinary incontinence (defined as use of any 
pad) is an increase of 25/10,000 screened men. (Figure 17)  
The results of paper I showed a 44% relative PC mortality reduction in favor of 
screening, which corresponded to an absolute number of 34 PC deaths averted/10,000 
screened men. In the light of paper I, we can now interpret paper V as implying that for 
each PC death averted with screening (34/10,000), the surgically-induced morbidity due 
to screen-detected PC will render four (120/34) men impotent or sexually inactive and 
less than one (25/34) man incontinent. 
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* Indicates extrapolated numbers            (‡ excluding 7 cases detected at autopsy) 
 
 
Figure 17. Flow chart, 14 years of screening 
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7. DISCUSSION 
 
Discussion 
Paper I 
The first paper in this thesis reports the longest follow-up and the largest benefit seen, 
this far, from a prospective, population-based randomized PC screening trial. With 
randomization before consent and a 76% participation rate, this program decreased PC 
mortality by 44% and by 56% for screening attendees, over 14 years’ follow-up. 
Furthermore, screening induced a stage migration that reduced the risk of metastatic 
disease and the need for hormonal treatment.  
If our screening program is regarded as successful, we suggest that the favorable 
characteristics of this program suggest a starting point of 50 years, a PSA threshold of 3 
ng/ml or less, a not too extended screening interval and a protocol for follow-up of 
positive screening results with a high biopsy rate. A long follow-up time seems to be 
one of the most important factors for evaluating the effectiveness of screening. 
The disadvantage of the program is an increased risk (RR 1.6) of low and moderate 
risk PC diagnosis in the screening arm. At 14 years of follow-up, the number who need 
to be invited to screening (corresponding to NNS) to prevent one PC death was 293, and 
the number who needed to be diagnosed (corresponding to NNT) was 12. These figures, 
and the RR of 0.56, can be compared with those of the commonly recommended 
practices of screening for breast and colon cancer. For mammography, a 2009 meta-
analysis of randomized trials yielded a number needed to invite to screening of 377 
(credible interval 230–1,050) for women aged 60-69 and 1,339 (credible interval 322–
7,455) for women aged 50-59, and RR’s of 0.68 and 0.86 respectively, at 11-20 years of 
follow-up.275 Separate or other mammography studies have yielded similar numbers.269, 
280-287 In a separate 2009 Cochrane review, the NNT for mammography was 10 
throughout 10 years.269 For colorectal cancer screening by fecal occult blood test, the RR’s 
have varied between 0.67 and 0.87 among four randomized trials289-292 and was 16% 
overall in both a 2008 Cochrane review293 (after 11.7–18.4 years) and a meta-analysis by 
Towler et al. (after 7.8–13 years).294 In the latter, the NNS after 10 years was estimated as 
1,173 (95% CI 741–2807). A recent multicentre study presents a RR of 0.69 for colorectal-
cancer mortality with flexible sigmoidoscopy screening for colorectal cancer and a lower 
NNS of 489 at a median follow-up of 11.2 years357. As screening for colorectal cancer is 
associated with a reduced colorectal cancer incidence, NNT is not possible to calculate 
for comparison.  
The NNT in our study is substantially lower compared to the ERSPC publication 
from 200939. The NNT is very much dependent on the length of follow-up and it is not 
easy to predict when and at which level NNT will stabilize. Furthermore, as NNT in PC 
screening mainly reflects the risk of over-diagnosis it is not easy at this point to make 
estimates of this risk but it is probably not so high as some have feared358, at least if 
screening is restricted to the age groups included in this study.  NNT in PC screening 
would be better rephrased as ‚number needed to diagnose‛ as many men were not 
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treated. As many as 314 (30%) of screen attendees were on surveillance at last follow-up 
in this study. This strategy will at least lower the risk of over-treatment and the risk 
associated seems low359.   
Screening with PSA leads to the diagnosis of PC at an earlier stage as compared to the 
clinical situation (‘stage migration’).106,360 This was shown in the ERSPC trial, which 
revealed that 72.2% of screened men with PC had a Gleason score 6 or less.39 In most 
cases, screen-detected PCs are organ-confined without extra capsular spread and are 
therefore completely curable.108,252 PSA screening is thought to advance PC diagnosis by 
5 to 13 years.360,120  
Most of the PCs diagnosed in the screening group of our trial were early stage 
disease. This was also mirrored in the treatment differences. There was a great 
difference between the arms in the number of men needing endocrine treatment – 182 
(1·8%) in the control group versus 103 (1.0%) in the screening group, which may be 
regarded as an important advantage of screening. 
Although the RR of 0.56 after 14 years is considerable, the absolute risk reduction is 
somewhat modest (0.40%), which reflects the young age at study start and the shorter 
follow-up of men after PC diagnosis (6.7 years in the screening group vs. 4.3 years in the 
control group). As it takes a long time to achieve the benefit of PC screening, with only 
marginal benefit during the first 10 years from starting PC screening, one should be 
cautious to recommend screening all elderly men. As the risk of over-diagnosis and 
over-treatment are still the major concerns it seems questionable to invite all men over 
the age of 70 for PSA screening. The oldest men in our study were born in 1930, hence 64 
years old at study entry in 1995. They were invited for two rounds before they 
terminated screening because of age. Whether continued screening for these men would 
have been beneficial or disadvantageous is not known. 
In an earlier study, Grenabo Bergdahl et al. have shown that the majority of those 
men who were classified as attendees to screening and died of PC either had their 
disease detected at the time of the first screening round (prevalent cases), or were 
noncompliant with the screening algorithm/biopsy recommendations. Of 10,000 men 
randomized to screening, after 13 years, 18 men had died from PC, of which 12 tumors 
were detected in the first screening round (prevalent cases).347 
  Much of the criticism of the ERSPC can be applied also to the Göteborg trial. There 
could be criticism as to whether PC-specific mortality not should be the correct 
endpoint, but overall mortality is more relevant. However, one should not confuse a 
randomized screening trial with a randomized controlled treatment trial, in the latter of 
which overall mortality is indeed the relevant endpoint. As PC constitutes ‚only‛ a 
modest proportion of the total mortality for Swedish men, even a big difference in PC 
mortality (HR 0.56 in the present study) will only have a small impact on overall 
mortality (the number of overall deaths after 14 years was 1,981 men in the screening 
group and 1,982 men in the control group in our study). In the ERSPC trial, there was no 
difference in overall survival (RR 0.99; 95% CI 0.97 – 1.02, p=0.50). However the risk 
reduction seen in the present study is still clinically relevant. 
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How do we know that the mortality benefit was not due to more aggressive treatment 
in the screened group instead of the screening per se? Questions have been raised as to 
whether the mortality result seen in the ERSPC was confounded by treatment 
differences, i.e. that men in the screening arm were treated with curative intent at 
university hospitals whereas men in the control arm received other treatments or 
curative treatment with poorer outcomes outside the big cities. A public media debate 
arose when paper I was published online in Lancet Oncology on June 30, 2010361. In a blog 
on the American Cancer Society’s official webpage (http://acspressroom. 
wordpress.com/2010/07/01/digging-deeper-into-prostate-screening-study/) the society’s 
chief medical officer Dr. Otis W. Brawley said: ‚It is important to recognize that this was 
not only a trial of screening alone; it was a trial of screening and superior treatment. 
Men in the screening group received treatment at a few centers that specialized in 
treatment of PC. The men in the control group received standard care in their 
community. That is likely to account for some and possibly all of the survival benefit.‛ 
However, this statement is not true, as this was certainly not the case in our study. All 
men randomized were at least at time of randomization living in the city of Göteborg 
and almost all patients operated on or radiated were treated at the Sahlgrenska 
University Hospital, so there was no difference between the groups in this respect.  
There has also been a fear that patients belonging to the screening group would be 
treated more aggressively. From paper I, it may appear to some that there was a higher 
rate of radical prostatectomy in the screening group that could have had an impact on 
the cancer-specific survival outcome. More men were, indeed, treated with radical 
prostatectomy in the screening group in absolute numbers. As screening aims to detect 
cancer earlier we had more cases with early PC in the screening group compared to the 
control group. The fact that screening resulted in a lower PC rate was because men were 
diagnosed early enough to be cured by treatment. However, in paper I, there is no data 
supporting the theory fully. Rather, the treatments seemed to be very equally 
distributed between the two arms. In men with low and moderate-risk tumors, the 
proportion receiving curative treatment was similar between groups: 476 (49.2%) of 967 
in the screening group and 228 (50.8%) of 448 in the control group, implying that the 
mortality difference resulted from screening and not from different treatments. To put it 
quite clearly, the rate of curative treatment was not higher in the screening group in 
those men in which curative treatment is an option, mainly the low and moderate risk 
groups. Therefore, one cannot include all the men with advanced and metastasized 
disease in the calculation of the rate of curative treatment as most of these men are never 
candidates for curative treatment. The important issue when evaluating the effect of 
screening is that men in the screening and control group receive the same types of 
treatments group by group. However, one can indeed say that paper I is to some extent 
a study of ‚superior treatment‛ or that ‚early invasive treatment for PC works‛, but that 
is because screening detects more tumors at a curable stage. 
In the supplementary appendix to the ERSPC trial39, the ‚overall‛ proportion 
receiving curative treatment was higher in the screening arm. However, these results 
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were not adjusted to stage and grade, but a ‚crude overall‛ measure. Since screening 
introduced both a stage and grade shift, it is not surprising that these differences were 
seen. The difference in treatments was in concordance with the stage distribution. In a 
separate analysis, the study arm had statistically significant associations with treatment 
with reference to the fact that especially high-risk men were more likely to receive 
hormonal therapy, radiotherapy of watchful waiting, but the study arm was far less 
important than other factors such as age, PSA level, T-stage or Gleason score. In low and 
intermediate-risk PC, no significantly predictive value was observed for the study arm. 
Therefore, no systematic discrepancy in treatment selection between arms could be 
shown and a mortality reduction solely caused by a treatment effect is very unlikely.362  
 
Discussion 
Paper II 
Studies of adverse psychological effects from attending different screening modalities 
for PC have shown disparate outcomes. As many as 64% of men experiencing anxiety 
before prostate biopsy have been reported363 and as many as 49% of men with a benign 
prostate biopsy have been reported as having thought about PC either "a lot" or "some of 
the time".318 However, in a review on the psychosocial implications of PC screening, 
Hewitson et al. concluded that PC screening can be associated with some anxiety-raising 
reactions, although not sufficient to cause any deleterious effects in men.364  
     Paper II focused on anxiety related to men with an elevated PSA >3 ng/mL and 
anxiety related to the invitation to attend further clinical work-up including TRUS-
guided prostate biopsies. Among a total of 1,781 screen-positive men included in our 
study, few men reported high levels of anxiety while awaiting the results of PSA 
measurement. Furthermore, very few men experienced high levels of anxiety regarding 
the invitation to attend clinical examination, despite elevated PSA levels.  
     These findings concur entirely with Brindle et al. who found that the receipt of an 
abnormal PSA test and attendance for further clinical investigation did not appear to 
have an impact on psychological health among men screened for PC within the ProtecT 
study (Prostate testing for cancer and Treatment) in the U.K.365 Recently, Macefield et al., 
working also for the ProtecT group, added further strength to our findings in paper II in 
a study using the validated Hospital Anxiety and Depression Scale (HADS) 
questionnaire. In the article, the authors write (under Discussion, p.4): ‚The limited 
published research on anxiety levels of those at higher risk by age and family history 
generally examined anxiety levels at PSA test, whereas here we focus on these risk 
groups at a further stage in the testing process. The results of this analysis build upon 
findings of the Swedish cohort of the European randomised study of screening for 
prostate cancer (ERSPC)<‛366 
     In their prospective cohort of 4,198 men aged 50-69 with a PSA >3 ng/mL, age, 
heredity or having a higher PSA level had no detrimental effect on men’s anxiety level 
when proceeding to biopsy. With older men, anxiety levels overall were lower than 
those reported by younger men.366 These results are all in complete conjunction with our 
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findings in paper II. The results by both Macefield et al. and ourselves in paper II 
suggest that the screening process for PC affects men’s anxiety very little (or moderately 
in some); even at the biopsy testing stage, and for those men who are aware that they are 
at greater risk of a positive result.  
     However, we do take note from paper II that the proportions of men experiencing 
‚moderate anxiety‛ were substantial (approximately between 30-40% in all five 
screening rounds for both the PSA test and the clinical examination). On the other hand, 
in all cases but the first screening round prior to the first clinical examination, the 
majority of men reported ‚no anxiety‛. It should also be noted that the term for 
‚anxiety‛ used in the Swedish version of our questionnaire (sv. ‚ångestfyllt‛) 
corresponds more to ‚worry‛ or ‚distress‛ than to real ‚anxiety‛, which is more of a 
psychiatric rather than an item of normal psychological terminology. The psychological, 
mental or medical impact of ‚moderate anxiety‛ should be interpreted carefully.  
     In paper II, we observed a subgroup of men who experienced ‚severe anxiety‛ 
throughout several screening visits. The relative risk of continuing to reporting high 
levels of anxiety was substantially higher in men reporting a high level in the first 
screening round. This may reflect the hypothesis that there is a small sub-group of 
susceptible men with a predisposition to high anxiety levels. The findings are in 
accordance with those reported from the Rotterdam arm of the ERSPC317 in which initial 
high anxiety levels were maintained during testing. For this subgroup of men, baseline 
psychological factors may have underlain anxiety and distress levels during the whole 
screening period. These results are also supported by Brindle et al., who found that men 
who had higher levels of anxiety before PSA testing also had higher scores at biopsy,365 
as well as by Macefield et al. in 2009, showing that psychological mood at PSA testing 
was predictive of anxiety and distress at later stages of the testing process. Hence, 
similar to our findings in paper II, anxiety seems to be related to the individual. That 
anxiety seems to affect a sub-group of susceptible individuals has also been reported in 
breast cancer screening.367-369  
     The finding that there is a subgroup of men who while being investigated for PC may 
experience anxiety, may not be clinically significant for the individual man. However 
this information may, firstly, have significance for primary care or preventive medicine 
physicians or urologists who discuss risk information with men who are making 
decisions whether to consent to PSA testing (which may lead to a prostate biopsy, which 
may lead to a diagnosis of PC, which may lead to<and so on). Secondly, this 
information could be important to include when assessing the potential side-effects from 
a PC screening program in cost-benefit calculations.  
     In paper II, the PSA level did not influence anxiety levels; neither anxiety levels while 
awaiting the PSA test result, nor anxiety levels when receiving an invitation to attend 
clinical examination with prostate biopsies were affected. Thus, in harmony with Roth et 
al., the PSA level itself does not seem to be a predictor of anxiety, while changing 
patterns do seem to be. This ‚PSA-change-anxiety‛ was indicated in paper II, in which 
we observed that more men reported anxiety while waiting for PSA at repeated 
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screening as compared to the first screening round (a significant finding in the 
multinomial logistic regression model, with an OR of 1.49 at repeat screening compared 
to the first screening round, p < 0.0001). We interpreted this as that many men attend 
screening for reassurance i.e. a man prior to his first invitation assumes his PSA to be 
normal. When the PSA instead turns out to be abnormal, the awareness of a possible 
cancer disease becomes evident and affects the level of anxiety in subsequent screening, 
when a man continues to have elevated PSA levels. This was true for some men, but 
overall, the majority of men still continued to report ‚no anxiety‛ while waiting for PSA, 
even those with several abnormal PSAs previously.  
     On the other hand, anxiety associated with biopsy was lower at subsequent screening 
in paper II. The explanation for this is not obvious, but one possible explanation could 
be that these men had confidence in the care process. On a biennial basis they met a 
limited number of nurses and urologists. Whether these results would be the same in 
men with a different cultural background, or with a different screening organization 
remains unanswered. 
In a recent longitudinal report from the ProtecT screening study, anxiety levels 
throughout the testing process were measured for men with PSA ≥ 3 ng/mL – a design 
very similar to paper II.370 The study finding is reassuring, as most men coped well with 
the testing process, although a minority experienced elevated distress at the time of 
biopsy and after a negative result. As seen in paper II, psychological state at the time of 
PSA testing predicted high levels of distress and anxiety at subsequent time-points. 
     Instruments used to measure short-term outcomes of PC screening have been 
established in a review and include: State–Trait Anxiety Inventory (STAI), Impact of 
event scale (IES), Mental Health Inventory, Short Form Health Survey SF-36 or SF-12, 
and questionnaires developed for the study.371 Other suggested questionnaires include 
the Hospital Anxiety and Depression Scale when measuring screening related anxiety365, 
372 and the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) to identify PC-related 
anxiety.373 However, these questionnaires may be too general and not the most sensitive 
measures for mentally healthy, non-patients to assess fluctuating mood changes in a 
screening setting. In paper II, we used a study-specific/for-study-developed 
questionnaire consisting of three levels of anxiety: ‚no‛, ‚intermediate‛ and ‚high‛. 
Although it is not a validated psychometric questionnaire, we used the same identical 
questionnaire throughout the 10 years; it was easy for the screened men to respond to, 
the response rates were consistently high (~ 90%) and we believe that it assessed what 
we intended to measure.      
     The number of men with PSA elevation who accepted clinical examination and 
responded to the questionnaires was consistently high in paper II. There was no 
relationship between the non-participation rate at the subsequent screening round and 
the degree of self-reported anxiety at the first round. However, it ought to be mentioned 
that we do not have information on non-participants who did not attend the first 
screening round. Did men who refused the first PSA testing, or who did not accept 
clinical examination, do so because of psychological distress (i.e. there may be a risk of 
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selection bias)? Essink-Bot challenged the hypothesis of psychological self-selection.317 
They hypothesized that men with a predisposition to anxiety would be more likely not 
to respond to a screening invitation. However, they found no difference between 
attendants and non-attendants, i.e. non-attendants did not have significantly higher 
levels of anxiety. From the ProtecT study Avery et al. investigated acceptance and 
decision-making in men accepting, not-responding, or refusing PSA testing and or 
biopsy374-375. They found that men accepting a biopsy had similar scores on the HADS 
and the SF-12 to those refusing biopsy. Depressed or anxious mood, co-morbidity and 
LUTS were not associated with the decision to respond to invitations for a PSA test.375 
     This suggests that in the majority of cases non-attendance is not explained by 
psychological distress. The high participation rates among men with persistently 
elevated PSA at repeated screening rounds in the present study might support this. 
Screening for PC may have a reassurance value, as was reported by Cantor et al.304 
Seeking peace-of mind has been reported to be the most important reason for a man to 
attend PC screening events.376-378 
     In paper II, there was no significant correlation between the level of anxiety and 
family history of PC, a finding consistent with the following previous studies. Taylor et 
al. reported an increased level of psychological distress prior to PC screening only 
among men who were also considered to have an elevated perceived risk of the disease, 
compared to those without a family history.379 Sweetman et al. reported that first-degree 
relatives attending familial PSA screening do not experience high levels of psychological 
morbidity.380 Similar results were reported by Bratt et al., who concluded that men with 
a high hereditary risk of PC do not experience severe negative psychological effects 
from attendance for screening.381 It thus seems that most men with a family history of PC 
do not experience more anxiety associated with PC screening compared to other men. 
     The results of paper II revealed that levels of anxiety associated with clinical 
examination were inversely related to age, a finding consistent with screening not only 
for PC. The adverse psychological impact of screening in relation to younger age has 
been reported by Brett et al. for mammography screening273 and by Hughson et al. 
among women awaiting breast biopsy.382 The same inverse association between age and 
anxiety has also been observed in women with abnormal cervical smear test results.383 
Suggesting that screening provides reassurance, Taylor et al. showed that PC-related 
distress, particularly among young men, decreased following receipt of a negative 
result.379 Among screened men with elevated PSA recalled for biopsy, Brindle et al. 
found, contrary to the present study, no association between anxiety and age, but found 
that older men were less anxious than younger men when before the PSA test.365 
     In paper II, there was no correlation between urinary-tract symptoms and anxiety in 
a multinomial analysis, contrary to the findings of Steginga et al., who reported that 
men with urologic symptoms at the time of PSA testing were more worried about PC.384 
The presence of lower urinary-tract symptoms is common in this age group of men and 
it seems plausible that symptoms from the urinary tract would be associated with an 
elevated level of anxiety for PC. As paper II comprises as many as 1,781 participating 
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men one may at least conclude that if such a relationship exists it is weak and is 
probably not clinically significant.  
In paper II, we studied the possible influences of age, PSA level, heredity, lower 
urinary tract symptoms, round of examination, but also biopsy finding. The latter may 
seem a not intuitively important covariate. However, one might hypothesize that either 
anxiety levels can affect cancer risk, or alternatively, that men with cancer might be 
subconsciously anxious. We found no association between biopsy finding and anxiety 
levels. This finding was confirmed in a recent study from the ProtecT group by Turner 
et al., where no associations between anxiety and cancer diagnosis were observed. 
However, as measured by the HADS questionnaire, ‘possible’ clinical depression was 
associated with an increased risk of PC, after controlling for urinary symptoms (OR = 
1.23; 95% CI=1.01–1.49; p=0.04)385. These findings, the authors stressed, highlight the 
need for further investigations into the possible role of depressed mental state at the 
onset of PC and research examining the biological basis for these relationships.   
     The most stressful aspect of PC screening seems to be waiting for the biopsy result. 
This has been reported by several authors316-317,363,372,386. In 1995, Gustafsson et al. elegantly 
explored this longitudinally by measuring serum cortisol as a biological marker for 
stress at various points during the investigation of men undergoing screening. When 
compared to a control group of Swedish men during normal daily activity, cortisol 
levels at the screening examination were higher for screened men, indication that 
screening per se can create emotional stress. However, two weeks after screening, levels 
were normal again. Gustafsson et al. further found that the highest levels were found in 
men who had undergone a prostate biopsy, but were not informed of the result. After 
they had been informed, cortisol levels fell, regardless of the results of the biopsy. 316 
These findings were confirmed in a structured review by Dale et al. in 2005, in which 
anxiety appeared to fluctuate over the clinical timeline in response to stressors and 
uncertainty (such as at the time of screening and/or biopsy), rising before these times 
and falling afterward.377 These findings imply that the interval between a test and 
informing the subject of the results should be minimized to decrease the duration of the 
increased emotional stress. 
     From paper II and the relevant literature, we may conclude that if a PC screening 
program is introduced, there seems to be no apparent need to introduce special anxiety 
reducing interventions. We believe that anxiety is not the main barrier to PC screening. 
However, that high levels of distress may be encountered by some men, should be 
included in the information presented to men before they consent to undergo a PSA-test. 
 
Discussion 
Paper III 
This study investigated excess mortality and cause-specific mortality in men undergoing 
a prostate biopsy among screening participants of the ERSPC. We found no excess 
mortality during the first year after screening and no deaths directly caused by the 
biopsy.  This low mortality has been confirmed by others.254, 320, 329, 387 
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To study potential excess mortality, men who have undergone a prostate biopsy need 
to be compared with men who have not. However, in doing so there is a risk of a 
selection bias; men who are actually biopsied already constitute a selected group as men 
who do not undergo biopsy commonly have contraindications to the procedure 
implying an increased risk of complications, such as bleeding or infection (and 
potentially death from these complications, or death from co-morbidity or high age). 
This is the reason why we included not only biopsied men but all men who had a biopsy 
indication (i.e. screening-positive men).  
 We found that men who were screen-positive but not biopsied had an increased risk 
of other-cause mortality up to one year as compared to screen-positive and biopsied 
men. Our findings therefore suggest, firstly, a ‚healthy screenee effect‛ among screen-
positive men who attend clinical examination and secondly, a ‚healthy selection‛ (by 
the urologist responsible performing the biopsy) of those who actually undergo biopsies 
while attending clinical examination. 
     Our findings are interesting from several aspects, if they are compared with another 
large-scale population-based biopsy mortality study with similar design, conducted in 
Canada between 1989 and 2000 by Gallina et al.388 The authors suggested that prostate 
biopsy might predispose to a higher mortality rate whereas we found that biopsied 
cases actually had a lower mortality than unexposed men (both screen-positive and 
screen-negative men). Gallina et al. showed a high overall 120-day mortality after biopsy 
of 1.3% for 22,175 biopsied men (age range 36 to 101, Md 69 years) as compared to 0.3% 
for a control group of 1,778 men (aged 65 to 85 years, Md 69.5 years) who did not 
undergo biopsy. These figures should be compared with 0.24% for our screening-
negative group and 0.12% for our screening-positive group who actually underwent 
biopsy at the same follow-up time. The reasons our result differ can have several 
explanations. The Canadian population may differ from the European and the settings 
were different. The Canadian population was included in the Quebec Health plan 
(clinical data) and patients were in general approximately 5 years older and some very 
old (up to 101 years), as compared to the present study which emerged from a 
population-based screening population in which men were younger (range 50.2 – 78.4 
years; median 64.8 years for the screening-positive men and 61.2 years for the screening-
negative group). In the ERSPC, very few screened men were diagnosed with advanced 
disease, while the number of men diagnosed with advanced disease in the Canadian 
study is not presented. Men diagnosed with advanced cancer have an increased 
mortality rate while men with early disease have not389. To study the association with 
biopsy it is thus important to include mainly men with non-metastatic disease. 
 In the paper by Gallina et al., increasing age and co-morbidity were significant 
predictors of 120-day mortality in multivariate analysis.388  We corroborated the impact 
of age on mortality, but co-morbidity status was not available in our present screening 
population. Those who did not undergo a biopsy despite the indication either had co-
morbidities or had personal reasons for not wanting to be biopsied. Some men did not 
show up at all to biopsy and for some men no reason was stated in the biopsy protocol. 
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However, our findings indicate that men with co-morbidities are less likely to become 
biopsied in a screening setting, while the selection of men who were actually biopsied in 
the study by Gallina et al. is not obvious. Whether the rather small control group fully 
compensates for possible selection of men who were biopsied could be questioned even 
if co-morbidity status was present in that study (but not among the controls).  
 However, even though we found no excess mortality associated with prostate biopsy, 
the procedure is still associated with anxiety for some men, since there may be frequent 
minor side-effects such as hematospermia and macrohematuria (bleeding from 
urethra/urinary bladder)85 and costs. A recent Canadian study has shown that the 
hospital admission rates for complications following TRUS-guided prostate biopsy has 
risen from 1.0% to 4.1% over the last ten years, primarily due to an increasing rate of 
infection-related complications390. There is therefore a risk, albeit low, of serious 
complications, although non-fatal. Much research is now being conducted on new 
markers and nomograms or algorithms for PC screening programs which aim to avoid 
unnecessary biopsies. 
 
Discussion 
Paper IV 
This paper is a nationwide population-based record-linkage study showed that the 30-
day mortality after radical prostatectomy within the follow-up study in the NPCR and 
in the linkage with the inpatient register, was low, 0.11% vs. 0.13%, a finding consistent 
with previous studies based on modern series. A low perioperative mortality is 
confirmed by others.182, 342, 344-345, 391-394 In 2007, the National Board of Health and Welfare 
regarded this measure as one important quality indicator for PC.9 Our study is the first 
nationwide study from Sweden. The low 30-day mortality found in our study (0.11-
0.13%) can be compared with the ethical problem associated with, for example 
screening, for aortic aneurysms where the peri-operative mortality is estimated at 4-7% 
(6% after elective surgery in the MASS-study395). In a large randomized trial in the U.K., 
endovascular repair of abdominal aortic aneurysm was recently reported to be 
associated with a lower 30-day operative mortality (1.8%) as compared to open surgical 
repair (4.3%) (however, with up to 8 years of follow-up, no differences were seen in total 
mortality or aneurysm-related mortality, and endovascular repair was also associated 
with increased rates of complications and re-interventions).396 
Due to increasing diagnostic activity for PC, the numbers of radical prostatectomies 
performed have increased with time. Concomitantly, the perioperative mortality has 
decreased. This reduction can probably be explained mainly by improved patient 
selection, i.e. surgery is more often performed on men who have no co-morbidities. 
Other explanations attributing to this could be improvements and refinement in surgical 
technique, anesthesia and perioperative and supportive care. 
It has been shown that men selected for radical prostatectomy have a lower mortality 
than the age-matched background population340. In Sweden, it is not very common for 
men aged over 70 years to undergo radical prostatectomy219. Several authors have 
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reported that co-morbidity353 and increasing age are the two most important factors 
associated with higher risk of perioperative death343-344,397. In one study on radical 
prostatectomies performed between 1984 and 1990, 30-day mortality for men older than 
75 was almost 2%397. However, in 2006, Alibhai et al. called for a rethinking of 30-day 
mortality with reference to age when reporting that men aged 70-79 years did not have 
an excess relative risk of 30-day mortality after radical prostatectomy compared with 
younger men398. In 2004, the same authors had shown that older men were treated with 
radical prostatectomy less often than younger men with the same remaining life 
expectancy, even after controlling for co-morbidity. Thus, it has been suggested that 
there is an age bias in treatment of localized PC, and that this could be questionable, 
since the relation between age and co-morbidity may be uncertain and fears of treating 
older men with radical prostatectomy are claimed to be unfounded by some399. Otto et 
al. explored the risk of cardiovascular mortality in PC patients in the Rotterdam section 
of the ERSPC. They found that cardiovascular disease was the most common co-
morbidity among PC patients. However, compared with all men in the study population 
with PC, those who underwent radical prostatectomy had the lowest occurrence of 
cardiovascular disease and were also, on average, younger. This further suggests that 
there is a selection of healthier patients for surgery400. 
According to the questionnaires retrieved from the hospitals, the interpretation of the 
four case presentations is that the deaths were all, somehow, related to the surgical 
procedure. Three out of the four deaths occurred as a result of acute myocardial 
infarction. As shown by others, ischemic heart disease seems to be a major risk of death 
associated with this surgery. 401, 402, 341 In previous publications, pulmonary embolism has 
been a common cause of postoperative death,401, 403-405 while in the present study there 
was no such death, at least within 30 days. A more general use of anticoagulants may 
explain this. However, there is a possibility that thromboembolic complications could 
still occur after 30 days. 
     All RPs performed for localized PC at all types of hospital were included in the 
nationwide study of paper IV. The four deaths were considered to be too few to perform 
an analysis stratified for hospital volume. They occurred at one community hospital, 
two county hospitals and one university hospital. One death occurred at one of the five 
high-volume hospitals, which, in total, performed 35% of all radical prostatectomies. 
Begg et al. found that neither hospital volume nor surgeon volume was significantly 
associated with surgery-related death (within 30 days). Their overall death rate was 
0.5% and was identical for all hospitals353. Analyzing in-hospital mortality after radical 
prostatectomy in England, between 1997 and 2004, Judge et al. found that hospitals with 
the lowest volume of radical prostatectomies had the highest 30-day in-hospital 
mortality (0.76% for low-volume hospitals compared with 0.30% for high-volume 
hospitals); however, the finding was based on only 59 deaths, and was further, in 
multivariate analysis, somewhat attenuated391. 
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Discussion 
Paper V 
The present report focuses on the self-reported side-effects of the most commonly used 
curative therapy for men with localized PC – radical prostatectomy – and a comparison 
between men randomized to screening and the control group. It should be noted that 
already, before surgery, the prevalence of erectile dysfunction was high for both 
screened and controls in this population as emerges from a randomized sample from the 
population. This has been confirmed by others.406, 407 In both arms, the majority were 
sexually inactive or impotent at 18 months postoperatively.  
The main limitation of the present study is the relatively small number of evaluable 
men, and that not all men operated upon provided full and complete answers to all 
questionnaires. The present study only included men who provided complete answers 
at both pre and post-treatment assessments. However, we have no reason to believe that 
this has resulted in a skewed sample of men, thus introducing a potential bias in the 
results presented. According to a review of the hospital records, non-responders to the 
questionnaires did not report more unfavorable outcomes. This is further supported by 
the fact that the actual complications reported by the patients are well in line with the 
published literature. If anything, the rate of side-effects in the present study was higher 
than that reported in many other studies. 
The not-so encouraging ED outcomes relate in part to the method of presenting data. 
We calculated impotency not only among men preoperatively potent but also the 
decrease in function also of men with mild ED preoperatively. Furthermore, presenting 
frequencies for men reporting several ‚X‛ on the IIEF-5 score as ‚No sexual activity / 
Did not attempt intercourse‛, instead of calculating a total IIEF-5 score where an ‚X‛ 
contributes with 0, is an accurate way of presenting data, since it is not possible to judge 
whether a man did not attempt intercourse because of erectile dysfunction or any other 
cause, such as physical distress due to cancer diagnosis, co-existing urinary leakage, or 
having no partner, et cetera. Using these presumptions, results in lower potency figures 
compared to what could be the case, if these men are excluded from analysis. Another 
explanation to the low reported potency rates is the fact that only half of the men in the 
screening group and less than one third in the control group had a bilateral nerve 
sparing procedure. Nor was any patient excluded from analysis due to second-line 
treatment with radiation and/or hormone therapy. Only 3% of men in this population-
based study fit into the patient selection published by Parsons et al. in which they 
reported a 71% postoperative potency after 12 months356. However, in this small 
subgroup a very much higher potency rate was recorded, in complete harmony with 
Parsons, 70%. The low postoperative potency rate is in line with other studies on 
unselected patients found in the literature235, 408-412.  
Furthermore, it is worth pointing out that in the present study, erectile function was 
evaluated at 18 months postoperatively. However, it has been shown that the sexual 
function can continue to improve even beyond two years postoperatively.413-414 
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 For continence, 14.3% of screened men and 20.5% of controls reported some degree of 
daily urinary incontinence at 18 months post prostatectomy. Most of these men 
belonged to group ‚2‛ which mean they use pads daytime but not necessarily wet. The 
difference observed between the groups in this study could probably be explained by 
the difference in the frequency of nerve-sparing operations and stage difference. It has 
been reported that men who undergo a non-nerve-sparing procedure have a lower 
chance415 of regaining, or at least need longer time to regain continence. More severe 
incontinence (group ‚4‛) was more uncommon but still reported by 2.5 % in the 
screening group and 2.3 % in the control group. 
     To the best of our knowledge, study V provides the first data available that has 
attempted to quantify the side-effects of screening based on a truly population-based 
randomized controlled trial. With 14 years of follow-up, screening reduced PC mortality 
by 44%, which corresponded to an absolute number of 34/10,000 PC deaths averted. We 
extrapolated the increased frequency of impotence or sexual inactivity as 120/10,000 
men invited and for incontinence 25/10,000 men with screening as compared to no 
screening. This could thus be interpreted as that for each PC death averted with 
screening (34/10,000), the surgically induced morbidity because of screen-detected PC 
will render four (120/34) men impotent or sexually inactive and less than one (25/34) 
man incontinent. When presented in this way, the number of men with permanent side-
effects after radical prostatectomy was low, if related to the number of men saved from 
PC death. 
 The present study provides one of the first reports of how an organized, population-
based prostate screening program will affect the number of men that will have to live 
with complications if such a program is introduced. These data can be used when the 
benefits and harms of PC screening are to be calculated. A limitation is, however, that 
we have not adjusted for the number of years the men will have to live with these side-
effects relative to life-years gained for each PC death averted.  
 However, we are aware of the fact that these side-effects are not the total population-
induced effect of screening, but stem from the most common active treatment option 
used (80% of cases in the present study). The absolute number of men who received 
radiation therapy was only slightly higher in the screening compared to the control 
group in the whole study population (127 versus 82). Radiation therapy in this study 
will therefore only marginally contribute to the increased burden of long-term side-
effects associated with screening. On the other hand there were significantly more men 
in the control group who received primary endocrine treatment (162 controls versus 80 
screened) which will act in the opposite direction, i.e. increase long-term side-effects in 
the control group.    
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8. CONCLUSIONS 
 
 
    PSA screening significantly, and substantially, reduces PC mortality at 14 years 
of follow-up. Nevertheless, PSA screening is associated with a long and varying 
lead time, resulting in a risk of over-diagnosis that is substantial but still of a 
largely unknown magnitude. 
 
 
    Attending a screening program for PC is seldom associated with severe negative 
psychological distress, even for men with persistently elevated PSA levels 
resulting in repeated examinations with prostate biopsies. 
 
 
   The risk of fatal complications after biopsy of the prostate is low in a population-
based screening setting. 
 
  
    Radical prostatectomy is a procedure with very low perioperative mortality 
throughout the whole of Sweden (even when performed outside high-volume 
centers).  
 
 
    With 14 years of screening, for each PC death averted, the surgically-induced 
morbidity due to screen-detected PC will render four men impotent or sexually 
inactive and less than one man incontinent as compared to men who are 
diagnosed in the clinical setting. 
 
 
In conclusion, PSA screening significantly, and substantially, reduces PC mortality. This 
benefit compares favorably to other cancer screening programs. The potential negative 
consequences of such screening may be acceptable in the light of a disease-specific 
mortality reduction. The risks of severe consequences from the screening procedures 
and radical prostatectomy seem minor, but the risk of negatively influencing sexual 
performance may be substantial. The outcome on a population level may differ from the 
benefit for the individual. 
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9. FUTURE PERSPECTIVES 
 
There will never be one study that teaches us everything about the complexities of PSA 
screening, but the present thesis have given us some clues. We have shown that PSA 
screening reduces PC mortality by 44% over 14 years, and that the potential negative 
aspects arising from screening attendance may be acceptable in relation to this disease-
specific survival benefit on a population level. The accumulating evidence to date 
suggests that PSA screening produces a beneficial grade and stage shift, a reduction in 
advanced disease as well as affording the opportunity to reduce PC mortality.  
     The 20% PC mortality reduction in favor of screening seen in the ERSPC39, together 
with the corresponding figure of 44% seen in paper I therefore adds some information 
on what to tell Swedish men who are considering PSA screening. The ERSPC study it 
was showed, for the first time, that a screening benefit exists. As was already indicated 
in the Nelson-Aalen curve over cumulative risk of PC death in the ERSPC study (see 
p.1352, Figure 2 in Schröder et al. NEJM 2009;360:1320-8)39, paper I in the present thesis 
now shows us that this benefit increases with longer follow-up. The PLCO trial40 could 
not demonstrate any difference in PC mortality between the trial arms after 7 to 10 years 
of follow-up (see p. 1314, Figure 1. Panel B in Andriole et al. NEJM 2009;360:1310-1319). 
 
Summary of evidence? 
Recently, and after the publication of paper I, Djulbegovic and colleagues performed a 
systematic review and meta-analysis of randomized controlled PC screening trials (PSA-
based trials, with/without DRE) that was published up to July 2010. Six trials met 
inclusion criteria, encompassing nearly 400,000 men.416 The forest plot in figure 18 shows 
the result of the meta-analysis on effects of screening on death from PC. The authors 
concluded and signaled to the world media that screening for PC is not supported by 
evidence as their analysis showed no significant impact on PC mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Effects of screening on death from prostate cancer. [Djulbegovic et al. BMJ 2010; 341: c4543] 
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Based on the large study by Djulbegovic et al. should we now reject screening? 
     Well, let us take a closer look at the figure again. Whether the variability in study 
results go beyond chance is called heterogeneity. When statistically tested, the p-value 
was 0.06 and the I2 was 55%. I2 values > 50% indicate a moderate to severe level of 
inconsistency and the results of such an analysis should be interpreted with caution. 
     However, the Quebec study and the Norrköping study were again included, when in 
a previous Cochrane review96 it was already concluded that these studies had 
substantial methodological weaknesses. The Norrköping study was primarily designed 
as a feasibility trial, which is different from studying the clinical outcome mortality.99 In 
the Quebec study, only 23.6% of participants actually complied with the randomization 
and were screened.97 The problem was similar in the PLCO; 30% of men were already 
pre-screened before the study, and 52% were screened in the control arm by the sixth 
year.40 Therefore, the meta-analysis by Djulbegovic included studies that would not 
have met eligibility criteria for inclusion had they been predefined. Instead, one could 
regard this analysis as flawed because of a selection bias when including studies of 
inadequate quality. To answer the question above: refuting PC screening should not rely 
on a limited meta-analysis with misleading results, but on evidence from high quality 
randomized controlled trials together with cost-benefit- and cost-effectiveness analyses.  
 
Preventing the harms of screening 
The main harms of PSA screening seem to be over-diagnosis and over-treatment. Future 
research should be aimed at addressing these issues. Paper I in the present thesis 
informs us that the number needed to be diagnosed in order to prevent one PC death is 
not as many as previously believed. While it has previously been argued that the 
balance of benefit against harm for early treatment of PC is not as substantial as it is for 
other common malignancies, such as breast and colorectal cancer, our results in paper I, 
challenge this. We have shown that the number needed to treat in order to prevent one 
PC-related death in PC screening is comparable to other screening programs. 
Furthermore, the numbers may be even fewer, as the identification of PC through PSA-
based screening does not have to imply active intervention, but rather management. 
Kantoff summarized this very well when the ERSPC and PLCO reports were published 
in 2009: ‚I do think that there is going to turn out to be a reduction in mortality 
associated with PSA-based screening, but I also firmly believe that not everybody 
diagnosed with PC needs to be pigeonholed into a treatment paradigm. And we need to 
individualize, because clearly there are many patients who are diagnosed with PC that 
do not need to be treated, who can be observed safely, and will not die of their cancer.‛ 
In paper I, as many as 28.8% of screening attendees were managed expectantly at last 
follow-up. The concept of active surveillance seems promising for some PCs. 
 
Quality of life and natural history 
Any effective screening program, requires more than just effectiveness. More studies are 
needed on the negative aspects of a screening program, as discussed in this thesis. More 
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studies are needed on quality of life and cost-effectiveness. While it is accepted that PC 
is an important public health problem, there is still some paucity of evidence on the 
natural history of screen-detected disease. More knowledge is needed from modern 
long-term data for screen-detected tumors from randomized trials, comparing curative 
treatment options with radical prostatectomy or radiotherapy with the newer active 
surveillance. Studies on quality of life issues with these different treatment strategies are 
especially needed.  
 
Aspects on age 
Although it was a post-randomization analysis, a recent sub-study of men with no or 
minimal co-morbidity in the PLCO trial showed a similar decrease in PC-mortality in 
favor of screening after 10 years of follow-up as that found after 14 years in paper I; 
adjusted hazard ratio 0.56 (95% CI 0.33 – 0.95, p = 0.03). The NNT to prevent one PC 
death was calculated as 5. Men with no or minimal co-morbidity represented more than 
1/3 of the study cohort and were younger (median 61 vs. 63 years). The results indicate 
that selectively screening younger men in good health may reduce the risk of death from 
PC with a small risk of over-diagnosis and over-treatment.417  
     In paper I, the median age at study entry was 56 years (range 50-64 years). We 
noticed that attendees who were older than 60 years at study entry seemed to have a 
higher risk of dying from PC compared with younger men. Still we are not certain about 
what age to start and what age to stop screening. Screening should, most probably, be 
restricted to men <70 years and definitely to men <75 years, who seem to have a very 
low risk of dying from PC because of co-morbidity and competing risks (and who may 
only be at increased risk of suffering from serious adverse effects from treatments). As 
discussed (see above), a single PSA taken in middle age may predict PC up to 25 years 
subsequently.68 It has been suggested by Lilja et al. that if the PSA level taken once at 
around 40-45 years of age is above the median (corresponding to ≥0.65 ng/mL), further 
PSA testing should be considered with a frequency (annual/biennial/every fourth year) 
depending on the baseline PSA. For men with levels below the median and no other risk 
factors, they can consider re-screening at age 55-60.67 The PSA test can therefore be used 
not only to help predict the risk of developing PC, but also to predict the chance of 
avoiding the disease. Until the time when better markers become available, PSA can be 
regarded as an appropriate screening tool for PC at a population level. 
 
Screening strategies 
A better screening tool more specific for significant tumors is needed. A higher 
specificity can perhaps be achieved through models that combine the PSA value, the % 
free to total PSA (F/T PSA), PSA doubling time and previous biopsy outcomes.  
     For impalpable, silent PC, a blood test can signal cancer, but the diagnosis is made by 
means of prostate biopsies. In a clinical setting, the decision to proceed to prostate 
biopsy is mainly based on the PSA level and the DRE finding but also takes into account 
multiple factors, including F/T PSA, patient age, PSA velocity, PSA density, family 
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history, ethnicity, prior biopsy history, co-morbidities and absence of contra indications 
to the biopsy procedure (anticoagulant use, rectal diseases, co-morbidities et cetera). 
Roobol et al., from the Netherlands section of the ERSPC have shown that using a more 
individualized approach when deciding to perform prostate biopsies can help reduce 
potential negative consequences such as unnecessary biopsies (reduced by 1/3 with a 
PSA cut off level of 3 ng/mL) and detection of indolent disease (reducing PC diagnosis 
by 13% of which 70-80% were considered as indolent). Very few important PC cases 
were missed. An individual risk assessment of the screening algorithm was perfomed by 
applying a logistic regression model that, in addition to the PSA value, included the 
transrectal ultrasound picutre, the ultrasound volume and DRE.118 It can be discussed 
whether an individualized approach should be used or whether in a screening 
algorithm, the indication for biopsy can be simple, such as only a specific PSA cut-off. 
Perhaps the PSA level needs to be lowered below 3 ng/ml? The optimal indicator/cut-off 
PSA level for biopsy and the optimal screening interval needs to be established. A 
screening interval of 8 years might be enough in men with initial PSA levels ≤1 ng/ml418.  
    There is a need for new sophisticated methods that can predict prognosis (which 
cancers will most likely be slow-growing as opposed to those will become aggressive). 
The prognosis can to some extent be calculated from a combination of pre-diagnosis 
measurements and post-biopsy measurements (histopathology). Nomograms for 
evaluating the probability of harboring a PC that will show indolent behavior have been 
developed, including for example PSA levels, ultrasound prostate volume, clinical stage, 
prostate biopsy Gleason grade, and total length of cancer and noncancer tissue in biopsy 
cores.124, 419 The future will aim at reducing the detection of indolent PC and unnecessary 
biopsies with more selective strategies. 
 
Shared decision-making 
PSA screening emphazises the importance of informed consent. Shared decision-making 
is crucial. The decision to proceed with screening should always be discussed with the 
individual, including the benefits and risks of screening, biopsies and treatments. It is 
essential that the discussion takes place before the screening stage. This may help men 
considering PSA screening to make quality-decisions. Screening should only be 
undertaken if a man wishes to proceed. A recent study has indicated that cancer 
screening decisions reported by patients who discussed screening with their health care 
providers failed, to a large extent, to meet the criteria for being informed.420 Finding a PC 
early by means of a screening program, can allow the opportunity for an informed 
discussion with the patient on the pros and cons of therapy that may otherwised be 
missed in the absence of routine screening. 
     There is evidence that treatment for screen-detected PC can cause moderate to 
substantial harms, especially in those men who would never have developed symptoms 
during their lifetime. However, the extent to which this is true, should perhaps be left to 
the individual men to judge? Men have different preferences and values regarding PSA 
screening. The outcomes of screening, whatever they might be, might not always be in 
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an individual man’s best interest. If a man’s goal in life is do to everything possible to 
minimize the potential risk that a PC will ever harm him, then he should perhaps take 
the PSA test and either obtain comfort in the knowledge that the test is normal or be 
treated aggressively in the case of PC that needs treatment (if his remaining life 
expectancy exceeds > 10 years). However, if a man believes that there are potentially 
more harm than good to come from screening, he should avoid being tested.  
 For men with PC, the diagnosis itself, the clinical effects of the disease and its 
treatment and uncertainties about the future can all take their toll on mental and 
physical well-being. PC affects not only on the patient, but also his family members and 
spouse or partner, who may also experience significantly greater psychological 
distress421, but who may consider the eradication of the cancer more important than the 
QoL effect of treatment side-effects.358  
 
The future 
It should be noted, that this far, we have studied only the early effects of PC screening. 
In study I, PC mortality was lowered from 0.90% in the control group to 0.50% in the 
screening group after 14 years. Of 1,982 deaths in the control group, 78 were due to PC. 
The lifetime risk for a Swedish man of dying from the disease is 5-6% today. Whether 
the benefit from screening continues to increase with longer follow-up will be 
interesting to see and also whether there will be a different balance between the benefits 
and harms within the upcoming ten to fifteen years. An estimation of the future is 
difficult to make. Competing morbidity/mortality need to be taken into consideration. 
 With more extensive observation, we now see that the NNS and NNT have 
decreased. However, what numbers justify the application of screening on a population 
basis? The present thesis has described the benefits and the potential negative 
consequences of PC screening with PSA. But whether the benefits will, at a certain point, 
outweigh the harms is more of a political and ethical question than a medical one. The 
limited health-care resources need to be carefully weighed to judge how these should be 
best spent. Furthermore, the outcome on a population level may differ from the benefit 
for the individual. There are still uncertainties about the risks of PSA screening, 
especially the risk of over-diagnosis, over-treatment, and how many years a man needs 
to live with possible side-effects from treatment before he gains the benefits of screening. 
One might regard screening as an investment in future health, but as with all 
investments, there are costs.  
The challenges for the future will be to translate the long-term results of the findings 
of paper I, the ERSPC and the PLCO into nationwide population settings. To believe 
that we will be able to define the precise magnitude of the benefit and a precise schedule 
for screening is a very high ambition. Breast cancer screening studies have shown that 
the effect depends on several factors such as age, background mortality and more. What 
paper I has shown is that the benefit from PSA screening could be substantial and much 
greater than previously believed. This is an important piece of new knowledge but we 
need more studies in the future to understand all aspects of these complex questions.     
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Conclusions – where do we go from here? 
 
At the current time point, the results from PC screening studies are promising with 
regard to the ability to prevent PC death in the male population. However, the step to 
recommend a general screening in Sweden is not ready to be taken yet. The main 
reasons for this are: 
 
 A longer follow-up time is still needed to see if the favourable outcome will 
persist when many men have stopped screening (i.e. too few events in the study 
at this time point). 
 
 The harms of screening does not always apply to those who benefit from the 
program which causes an ethical dilemma. 
 
 There are uncertainties regarding the capacity of current health care resources 
regarding the ability to handle a population-based screening program. 
 
 
 
With these points in mind, one could expect a scenario for the next coming years where 
the new knowledge about PC screening is incorporated in everyday clinical practice in 
the following way: 
 
 Well informed men, in actual age groups, and without severe co-morbidity 
should have access to PSA-testing upon request. For men with a confirmed 
elevated PSA, a referral for urological work-up is recommended. 
 
 Health care providers are recommended to test various models for how a 
population-based screening program should be organised in the future. This 
should preferably include some different models including testing via a family 
doctor or special screening clinics. Pilot projects are ongoing or under way. 
 
 Patient information about the harms and benefits and other consequences of PSA 
screening needs to be refined and made more accessible to all men, before they 
make a decision about taking their PSA. This is true irrespective of whether we 
have the current situation or whether a formal screening program is introduced.  
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Epilogue 
 
The words of the famous American-born poet and Nobel prize laureate T.S. Eliot (1888 – 
1965) will conclude this thesis: 
 
 
 
Where is the wisdom we have lost in knowledge? 
Where is the knowledge we have lost in information? 
 
 
 
(Choruses from The Rock, 1934) 
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10. Swedish summary (Sammanfattning på svenska) 
 
10.1. Sammanfattning 
Denna avhandling utvärderar förhållandet mellan nytta och skada av regelbunden, 
populationsbaserad screening (=massundersökning) för prostatacancer med blodprovet 
Prostata-Specifikt Antigen (PSA). Avhandlingen är sprungen ur en prospektiv, 
populationsbaserad, randomiserad kontrollerad screening studie utgående från 
Göteborg. År 1995 randomiserades (=lottades) 10,000 män (50-70 år) till PSA screening 
vart annat år och 10,000 män till kontroller. I avhandlingen ingår fem delarbeten som 
syftade till att besvara följande frågeställningar: 
 
I. Kan screening med PSA påverka dödligheten i prostatacancer? Hur stor är risken för 
överdiagnostik i förhållande till en vinst mätt som sänkt prostatacancerdödlighet? 
II. Upplevs det som ångestfullt när man får besked om förhöjt PSA värde och kallas för 
vidare undersökning (ultraljud och biopsi) i en screeningsituation? 
III. Diagnosen prostatacancer kan bara ställas med hjälp av vävnadsprovtagning (biopsi) 
ifrån prostatakörteln vilket sker under vägledning av ultraljud och via ändtarmen. Detta 
är en invasiv undersökning med viss risk för komplikationer inklusive blodförgiftning. 
Kan prostatabiopsier vara associerat med en ökad dödlighet?  
IV. Radikal prostatektomi (borttagande av hela prostatan) är den vanligaste 
behandlingsformen för screeningupptäckt prostatacancer. Hur hög är risken att avlida 
av operationen? 
V. Radikal prostatektomi är förenat med en tämligen stor risk för impotens och en 
mindre risk för besvärande urinläckage (inkontinens). I en situation med screening 
kommer fler män att opereras men samtidigt kan man möjligen operera med 
skonsammare teknik vid tidigt upptäckta tumörer. Hur många fler män skulle bli 
inkontinenta och impotenta om screening skulle införas och kan dessa antal sättas i 
relation till antalet räddade liv i sjukdomen? 
 
 
Metoder 
I delarbete I analyserades skillnaden i prostatacancerdödlighet efter 14 års screening, 
absoluta och relativa risker beräknades.  I delarbete II utvärderades frågeformulär från 
män med förhöjt PSA med avseende på ångest. Delarbete III är en multi-center studie 
där även data från screeningstudierna i Holland och Finland ingår och där det 
studerades om det förelåg någon överdödlighet hos män som genomgick prostatabiopsi 
(eller hade indikation för detta) jämfört mot dem som inte gjorde det. Delarbete IV är en 
nationell studie (hela Sverige) där alla män diagnostiserade med lokaliserad 
prostatacancer och som genomgick prostataoperation (radikal prostatektomi) mellan 
1997-2002 identifierades via det Nationella Prostata Cancer Registret (NPCR). 
Information om 30-dagars-dödlighet efter operation erhölls genom länkning med 
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populationsregistren. Dödsbevis och frågeformulär från sjukhusen rekvirerades. En 
validering gjordes via Slutenvårdsregistret. I delarbete V studerades specifikt de som 
opererades med radikal prostatektomi på Sahlgrenska Universitetssjukhuset och som 
ingick i en kvalitetssäkringsdatabas. Frekvenserna av impotens före och efter radikal 
prostatektomi studerades genom ett validerat frågeformulär (IIEF-5) och inkontinens 
genom ett strukturerat frågeformulär. För män som saknade frågeformulär studerades 
journaler. Data extrapolerades till hela screening-populationen med 14 års screening.  
 
Resultat 
I: Med medellång uppföljning (14 år) så är det en klar skillnad (44%) i prostatacancer-
specifik dödlighet till fördel för screening; en effekt som är bättre än för bröstcancer-
screening med mammografi och screening för kolorektalcancer. I absoluta tal är 
minskning emellertid liten, 0,40%, vilket motsvarade att 293 män PSA-testades i 14 år för 
att ett dödsfall i prostatacancer skulle undvikas. För varje förebyggt dödsfall hade också 
12 fler cancerfall diagnosticerats i den screenade gruppen jämfört med kontrollgruppen.  
II: 1781 män med förhöjda PSA svarade på frågeformuläret i första omgångens 
screening. Av dessa rapporterade 66% ingen ångest av att vänta på PSA-provsvaret 
medan 2% rapporterade att det var mycket ångestfyllt. Ångestnivån ökade med 
upprepade undersökningar, även om majoriteten fortsatte att rapportera "inte 
ångestfyllt". Att bli kallad för vidare klinisk undersökning med biopsier var associerat 
med ingen ångest i 45%, medan 6% upplevde detta som mycket ångestfyllt. Med 
upprepade undersökningar samt med ökande ålder minskade ångestnivåerna.  
III: Ingen överdödlighet sågs till följd av prostatabiopsi hos mer än 12,000 biopserade 
män jämfört med män som inte biopserats. I världslitteraturen beskrevs ett fåtal 
ovanliga fall med dödlig utgång av biopsi till följd av svår infektion (blodförgiftning). 
IV: Av 3,700 utförda prostataoperationer (radikala prostatektomier) ingående i 
uppföljningsstudien i NPCR var 30-dagars-dödligheten 0.11%. I samtliga fyra fall, som 
förekom på tre olika typer av sjukhus, var dödligheten sannolikt relaterad till 
operationen. Av samtliga 4,457 män opererade enligt slutenvårdsregistret (oavsett ålder, 
tumörstadium, PSA etc.) under samma tidsperiod var motsvarande siffra 0.13%. 
V: Radikal prostatektomi var den vanligaste kurativt syftande terapin. Majoriteten var 
impotenta eller sexuellt inaktiva 18 månader efter operationen. Eftersom fler tumörer 
upptäcktes i screeninggruppen blev också fler män impotenta och inkontinenta i denna 
grupp, men relativt sett sågs en tendens till en lägre andel biverkningar i denna grupp. 
Screeningen förhindrade också död i sjukdomen. Satt i relation till denna vinst var 
antalet män med biverkningar få; för varje förhindrat dödsfall efter 14 år, hade fyra män 
blivit impotenta och mindre än en man blivit inkontinent (‛kostnaden per räddat liv‛).  
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10.2. Kortfattade slutsatser  
I: PSA screening ger en säkerställd minskning av dödligheten i prostatacancer och 
effekten verkar större än den man ser vid mammografi, men priset är överdiagnostik. 
II: PSA screening är sällan associerad med upplevelse av svår ångest, även för män med 
förhöjda PSA-nivåer resulterande i flera kliniska undersökningar med prostatabiopsier. 
III: Risken för fatal utgång efter prostatabiopsi är mycket låg i populationsbaserad PSA 
screening. 
IV: Radikal prostatektomi är en säker operation med mycket låg operationsrelaterad 
dödlighet i hela Sverige (även utanför sjukhus med högst operationsvolym). 
V: Satt i relation till varje förhindrat dödsfall i sjukdomen efter 14 års screening, är 
frekvenserna av impotens och inkontinens förhållandevis låga för män med screening-
upptäckt prostatacancer jämfört med kliniskt upptäckta cancrar. För den enskilde 
mannen kan dock biverkningarna vara betydande. 
      
Sammanfattningsvis har denna avhandling visat att masstestning med blodprovet PSA 
kan halvera dödligheten i prostatacancer. Denna fördel är jämförbart bättre än vad man 
sett i andra cancerscreening-program. De potentiellt negativa konsekvenserna av sådan 
screening kan vara acceptabla i ljuset av den sänkta dödligheten i sjukdomen. Allvarliga 
komplikationer av screening-procedurerna samt av prostataoperationer (radikala 
prostatektomier) är ovanliga, men risken att negativt påverka den sexuella förmågan är 
betydande. Utfallet för en hel population kan också skilja sig från vinsterna för den 
enskilde mannen. 
 
Framtiden? 
     Vid denna tidpunkt är resultaten av screeningstudier lovande vad gäller att förhindra 
prostatacancerdöd i den manliga befolkningen. Ännu är dock tiden inte mogen att 
rekommendera allmän PSA-testning då kunskaperna om skada visavi nytta ännu inte är 
tillräckliga. De män som erfar biverkningar av screening har inte nödvändigtvis 
samtidigt nytta av densamma, vilket innebär ett etiskt dilemma. Vi behöver fortfarande 
längre uppföljningstid och mer kunskaper. Vi vet ännu inte säkert om det finns resurser 
inom svensk hälso- och sjukvård att hantera följderna av en allmän PSA-testning. 
Sjukvårdshuvudmän rekommenderas därför att pröva olika modeller för att studera hur 
information och inbjudan till screening accepteras samt hur screening kan organiseras i 
primärvård och/eller via speciella screeningkliniker. För män med förhöjt PSA-värde 
rekommenderas uppföljning hos urolog. Patientinformationen bör revideras/uppdateras 
och göras tillgänglig till alla män innan de beslutar sig för att ta sitt PSA, så att såväl 
risker (nackdelar) som möjliga vinster (fördelar) lyfts fram. Välinformerade män i den 
aktuella åldersgruppen och utan samsjuklighet bör inte nekas PSA-testning. 
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13. APPENDICES 
 
13.1. Original screening questionnaire (in Swedish) 
 
© Copyright Professor Jonas Hugosson, Dept. or Urology, Sahlgrenska University Hospital, 1994 
 
 
 
Tacksam om Du kunde fylla i nedanstående uppgifter. Alla Dina svar kommer att behandlas 
konfidentiellt och när alla svar är inkomna, kommer resultatet att avidentifieras.  
Ringa in lämpligt alternativ. 
 
 
Har Du några allvarliga sjukdomar som Du behandlas av läkare för? I så fall, vilka? 
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<. 
 
 
Har Du behandlats för någon tumörsjukdom? I så fall vilken? 
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<. 
 
 
Har Du tidigare undersökt Dig avseende prostatacancer? 
1. Ja 
2. Nej 
3. Vet ej 
 
 
Har Du några släktingar med prostatacancer? 
1. Ja, i så fall vem? <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< 
2. Nej 
3. Vet ej 
 
 
Har Du haft problem med vattenkastningen i form av dåligt flöde eller svårt att tömma blåsan? 
1. Inte alls 
2. Lätta besvär 
3. Avsevärda besvär                        
 
 
Har Du problem med vattenkastningen i form av täta trängningar? 
1. Inte alls 
2. Lätta besvär 
3. Avsevärda problem   
     Forts. 
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Har du upplevt problem med minskad sexuell lust? 
1. Inte alls 
2. Lite problem 
3. Avsevärda problem 
 
 
Har Du upplevt besvär med minskad sexuell förmåga? 
1. Inte alls 
2. Lite problem 
3. Avsevärda problem 
 
 
Hur upplever Du möjligheten att deltaga i den aktuella studien avseende prostatacancer?  
Ringa in mest lämpliga svar.  
1. Som en förmån 
2. Brukar ställa upp i olika undersökningar och därför var det naturligt. 
3. Blev rekommenderad av någon annan att deltaga 
4. Deltager mot min vilja, men vågar ej låta bli. 
5. Annan orsak, var god ange vad  
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< 
 
 
Upplever Du det ångestfyllt att vänta på svaret efter blodprovet? 
1. Inte alls 
2. Lite ångestfyllt 
3. Mycket ångestfyllt 
 
 
Hur upplever Du det att få kallelse för läkarundersökning? 
1. Inget särskilt 
2. Lite ångestfyllt 
3. Mycket ångestfyllt 
 
 
 
TACK FÖR DIN MEDVERKAN! 
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13.2.1. The International Index of Erectile Function-5 questionnaire  
 
 
 
354 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13.2.2. IIEF-5, modified from Rosen et al. (as used in paper V) 
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13.2.3. Frågeformulär sexuell funktion, ”ED-score” (In Swedish) 
 
Varje fråga har 5 svarsalternativ. Dessutom finns i de flesta fall ytterligare en kolumn med ett kryss (X) som Du ringar in om 
frågan inte är relevant för Dig. Ringa in det svar som bäst beskriver Din situation. Ringa endast in ett svarsalternativ per fråga. 
 
EREKTION 
 Mycket svag 
eller ingen alls 
Svag Måttlig Stark Mycket stark 
1. Hur uppskattar Du 
att Din tilltro till att 
kunna få och behålla 
en erektion varit de 
senaste 3 månaderna? 
 
 
- 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
2. Hur ofta efter 
sexuell stimulering har 
Din erektion, under de 
senaste 3 månaderna, 
blivit tillräckligt styv 
för att kunna tränga in 
i Din partner? 
Ingen sexuell 
aktivitet har 
förekommit 
Nästan aldrig 
eller aldrig 
Några få 
gånger (mycket 
färre än hälften 
av gångerna) 
Ibland (ungefär 
hälften av 
gångerna) 
De flesta 
gångerna 
(mycket mer än 
hälften av 
gångerna) 
Nästan alltid 
eller alltid 
 
X 
 
1 
 
2 
 
3 
 
4 
 
5 
3. Hur ofta har Du, 
under samlag, kunnat 
behålla erektionen 
sedan Du trängt in i 
Din partner de senaste 
3 månaderna? 
 
Inga försök till 
samlag har 
förekommit 
Nästan aldrig 
eller aldrig 
Några få 
gånger (mycket 
färre än hälften 
av gångerna) 
Ibland (ungefär 
hälften av 
gångerna) 
De flesta 
gångerna 
(mycket mer än 
hälften av 
gångerna) 
Nästan alltid 
eller alltid 
 
X 
 
1 
 
2 
 
3 
 
4 
 
5 
4. Hur svårt hade Du 
att behålla erektionen 
ända till slutet av 
samlaget de senaste 3 
månaderna? 
 
Inga försök till 
samlag har 
förekommit 
Mycket stora 
svårigheter 
Stora 
svårigheter 
Svårigheter Vissa 
svårigheter 
Inga 
svårigheter 
 
X 
 
1 
 
2 
 
3 
 
4 
 
5 
 
TILLFREDS- 
STÄLLELSE 
Inga försök till 
samlag har 
förekommit 
Nästan aldrig 
eller aldrig 
Några få 
gånger (mycket 
färre än hälften 
av gångerna) 
Ibland (ungefär 
hälften av 
gångerna) 
De flesta 
gångerna 
(mycket mer än 
hälften av 
gångerna) 
Nästan alltid 
eller alltid 
5. När Du de senaste 3 
månaderna försökt 
genomföra samlag, 
hur ofta har Du 
upplevt dem som 
tillfredsställande? 
 
 
X 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
                        Total ED-poäng (fr 1-25): __________ 
6. Är Du  Gift/sambo     
   Ensamboende men med fast relation     
   Ensamboende   
 
7. Om Du angett att Du är sexuellt aktiv – hur ofta upplever Du orgasm? 
   Aldrig     
   Någon enstaka gång    
   Ungefär hälften av gångerna 
   Mer än hälften av gångerna 
   Alltid eller nästan alltid 
 
8. Använder Du något potenshjälpmedel (läkemedel eller annat hjälpmedel)? 
   Aldrig   Ibland   Oftast  Alltid    
                       I så fall, vilket?………………………………… 
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13.3. Questionnaire assessing urinary incontinence (as used in paper V) 
Värdering av vattenkastning 
 
 
Har Du urinläckage?  
Aldrig 
 
 
 
 
 
 
 
 
 
 
0 
 
Läcker ibland 
vid hosta, nys-
ning eller an-
vänder dropp-
skydd vid spe-
ciell fysisk 
ansträngning, 
t ex sportaktivi-
tet, trädgårds-
arbete 
 
1 
 
Droppskydd 
hela tiden (utom 
möjligtvis nat-
tetid) men de är 
inte alltid våta 
 
 
 
 
 
 
2 
 
Droppskydd 
hela tiden som 
måstes bytas 
pga. att de är 
våta 
 
 
 
 
 
 
3 
 
Läcker 
kontinuerligt 
och behöver 
blöjor som 
kontinuerligt 
bytes 
 
 
 
 
 
4 
 
 
Do you have urinary leakage? 
 
 
Never 
 
 
 
 
 
 
 
 
 
 
 
0 
 
Sometimes 
urinary leakage 
when coughing 
or sneezing / 
sporadic use of 
pads associated 
with physical 
exertion such as 
sports, 
gardening et 
cetera 
 
1 
 
Regular use of 
pads (except 
sometimes at 
night), but they 
are not always 
wet 
 
 
 
 
 
 
2 
 
Regular use of 
pads that need to 
be changed 
because they are 
wet 
 
 
 
 
 
 
 
3 
 
Constant 
urinary 
leakage that 
requires 
diapers to be 
changed 
continuously 
 
 
 
 
 
4 
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